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Abstract 
Limb Girdle Muscular Dystrophy 2I (LGMD2I) is caused by mutations in the fukutin 
related protein gene (FKRP). It is an important and frequent cause of LGMD, 
particularly in Northern Europe, and can range from a severe muscular dystrophy in 
childhood, very similar to Duchenne muscular dystrophy, to a much milder adult 
disease. Respiratory involvement and cardiomyopathy are common. 
This thesis aims to assess the natural history of a particular subset of this rare condition 
across four main European centres. Thirty eight ambulant LGMD2I patients from 
Newcastle, London, Paris and Copenhagen were recruited. The age range was 18-64 
years and disease duration, 0-49 years.  
Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS) have 
both been performed. T1-weighted images were used to assess fat infiltration patterns 
using a qualitative radiological score and a quantitative 3-point Dixon technique, 
applied over two time points, and was performed to track the progression of fat 
infiltration. MRI fat infiltration has been correlated with muscle strength and function 
longitudinally.  
In the Newcastle upon Tyne cohort, cardiac MRI was also studied assessing the cardiac 
involvement in this condition. 
Chapter 1 presents an overview of muscular dystrophy and the current knowledge in 
LGMD2I and chapter 2 includes a literature review of both skeletal muscle and cardiac 
imaging. Chapter 3 focuses on the methodology of the study, including the patient 
demographics, physical assessment tools and MRI and MRS specifics. Chapters 4 -9 
contain the results section; including physical and functional assessments, both cross-
sectional and longitudinal, the cross sectional and longitudinal MRI results, skeletal 
MRS, cardiac MRI data and  the FKRP registry respectively. Discussion of the results is 
found at the end of each chapter. Chapter 10 concludes with areas for future research. 
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Chapter 1 – Introduction 
Limb Girdle muscular dystrophy 2I (LGMD2I) is an autosomal recessive disease caused 
by mutations in the fukutin related protein gene (FKRP). Its rate of progression is 
variable in different individuals and it is associated with cardiomyopathy and 
respiratory failure. Currently there is no treatment for this rare disease and its natural 
history is not fully understood.  
In this first chapter I will provide an overview of the muscular dystrophies as a whole. I 
will describe how muscle structure and function is affected in these disorders and will 
specifically focus on the pathogenesis of LGMD2I. This will include a clinical 
description of patients with LGMD2I, highlighting their cardiac, respiratory and skeletal 
muscle phenotype. I will then progress to explain the underlying genetic defect of this 
condition and will summarize our current knowledge of the role FKRP in LGMD2I 
based on work in animal models.  
In order to provide appropriate care to patients with LGMD2I, it is imperative that the 
natural history of the condition is fully understood. This knowledge will therefore assist 
in developing clinical guidelines and standards of care that can be used to manage these 
patients clinically in a timely fashion. In preparing for clinical trials, objective, reliable 
and sensitive outcome measures are necessary. Many clinical trials use subjective 
measures as outcome measures, such as the six minute walk distance (6MWD) 
(McDonald et al. 2010). Magnetic Resonance Imaging (MRI) is an objective measure 
and has been used in the past for delineating patterns of muscle involvements in 
muscular dystrophy patients. Most of these studies have used T1weighted (T1w) images 
and a visual scoring technique (Mercuri et al. 2002a).  
In order to learn more about the muscle pathology in patients with LGMD2I I 
coordinated a multicentre study with a focus on clinical assessment, muscle MRI and 
MRS and cardiac MRI in a subset of ambulatory adult patients with LGMD2I. I have 
analysed the MRI images both qualitatively (T1w) and quantitatively using the 3 point 
Dixon technique (Dixon, 1984) in a large cohort (n=38) of patients with LGMD2I. The 
purpose of the study was to firstly compare the historical qualitative scoring with the 
quantitative MRI fat fraction, and secondly assess whether quantitative MRI was a 
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sensitive enough tool to detect changes in the fat fraction longitudinally, over a 12 
month period. These results were then compared to the clinical and functional state of 
the patient.  
Two of the centres were able to perform Magnetic Resonance Spectroscopy (MRS) and 
this was performed in just over half of the cohort (n=20) of the patients in order to 
assess whether there was any metabolic abnormalities detected in these patients 
muscles. In particular I wanted to assess whether any change detected predated the 
appearance on the MRI images and clinically, which could then potentially highlight 
MRS as an early biomarker.  
One centre also performed cardiac MRI on the patients (n=10). It has been reported that 
cardiac MRI is more sensitive than conventional measures (Gaul et al. 2006), such as 
echocardiograms that are commonly used as a screening tool for cardiomyopathy in 
LGMD2I. These results were compared against the echocardiograms available. 
The standard of care for patients with LGMD2I tends to be variable around the world, 
and little is known about the natural history of this condition. Part of my work on this 
project has been to address this issue by designing and launching the international 
FKRP patient registry (Appendix F), which will be discussed further in Chapter 9. This 
registry will enable the natural history and progression of this disorder to be studied in a 
large cohort internationally. As well as the development of appropriate standards of care 
and treatment guidelines, the registry will also provide an important resource for 
developing well designed trials and defining sensitive outcome measures and 
biomarkers. 
One of the main objectives of my study was to contribute to the “trial readiness” of 
LGMD2I patients. With further knowledge on the natural history of the condition that 
can be obtained from the registry and longitudinal studies, care standards can be created 
and implemented internationally. With these in place, clinical audit can be undertaken 
and comparisons made. The knowledge of how ambulant patients with LGMD2I 
perform on standardised physical testing and the relevance of the tests for this group of 
patients, contributes to the further preparation of designing a good clinical trial. Whilst 
the physical and functional tests are subjective, MRI is objective. As with any outcome 
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measure, it not only has to be objective but clinically meaningful and sensitive to 
change. Thus studying the MRI data both cross sectional and longitudinal and 
comparing this to the physical and functional tests is important in order to address this.  
As one prepares for “trial readiness”, it is important to realise that there is however no 
„one‟ test that can fully assess this complicated and heterogeneous group of patients. A 
combination of functional assessments, strength measurements and MRI need to be 
considered. 
1.1 – Background and overview of the research project 
In this section I will be covering an overview of the muscular dystrophies as a whole. I 
will describe how muscle structure and function is affected in these disorders and will 
specifically focus on the pathogenesis of LGMD2I. This will include a clinical 
description of patients with LGMD2I, highlighting their cardiac, respiratory and skeletal 
muscle phenotype. 
1.1.1 - Overview of muscular dystrophy 
The disorders known as the muscular dystrophies (MDs) are a group of hereditary 
conditions that is characterised by progressive weakness and degeneration of skeletal 
muscle. The pattern of these abnormalities shows a variation in both distribution and 
severity. The diseases can be subdivided into several disease types. These subdivisions 
are largely based upon the age of the patient and the distribution and pattern of 
weakness (figure 1.1) (Emery, 2002). They include the dystrophinopathies, Duchenne 
muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), Emery-Dreifuss 
muscular dystrophy, distal muscular dystrophy, congenital muscular dystrophy (CMD), 
facioscapulohumeral dystrophy (FSHD), myotonic dystrophy, oculopharyngeal 
muscular dystrophy, and limb girdle muscular dystrophy (LGMD). LGMD represent the 
most heterogeneous group. 
MDs are caused by a wide range of gene mutations, ranging from genes encoding 
structural proteins such as dystrophin in DMD, to sarcomeric proteins such as 
telethonin, and membrane regulators such as dysferlin.  
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Function of normal muscle 
Skeletal muscles are essentially collections of muscle units bound by connective tissue. 
During development, undifferentiated myoblasts fuse to form long, cylindrical 
multinucleated cells which make up the muscle fibre. The muscle fibre is made up of 
bundles of myofibrils, and the myofibrils in turn consist of bundles of myofilaments. 
These myofilaments are primarily made up of the two proteins, actin and myosin (Engel 
and Franzini-Armstrong, 2004). 
When viewed under the microscope, a distinctive banding pattern is evident within the 
muscle due to the arrangement of the cytoskeletal elements in the muscle cytoplasm, 
also called sarcoplasm. Actin and myosin also referred to as „thin‟ and „thick‟ filaments 
respectively are arranged in a repeated unit, called the sarcomere. Surrounding each 
myofibril is the sarcoplasmic reticulum, which holds a reserve of calcium ions required 
for muscle contraction. The interaction of actin and myosin in the myofilaments and the 
release of calcium, signalled by the action potential, are responsible for muscle 
contractions (Saladin, 2010).  
Skeletal muscle is required to withstand repeated cycles of contraction and relaxation 
throughout a lifetime. In order to maintain stability a highly specialised system of 
Figure 1.1: Distribution of predominant muscle 
weakness in different types of dystrophy.  
A; DMD and BMD type, B; Emery-Dreifuss, C; LGMD, D; 
facioscapulohumeral, E; distal, F; oculopharyngeal. Shaded = affected 
areas (Emery, 2002). 
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linkages between the subsarcolemmal cytoskeleton and the components of the 
extracellular matrix are required. Many muscular dystrophies are caused by either a 
disruption at some point in the link between the extracellular matrix and the 
cytoskeleton or by abnormalities in the specific matrix components themselves 
(Campbell, 1995). A patient with MD does not have normal muscle function and 
stability. 
  
 6 
(a)  
 
(b)  
 
 
 
 
 
 
 
Figure 1.2: Diagram of skeletal muscle. (a) Skeletal muscle surrounded 
by epimysium and composed of fascicles made up of myofibres. Each 
muscle fibre is surrounded by endomysium. (b) A enlargement of a 
myofibril, which is a cylindrical bundle of contractile proteins found 
within the muscle cell. Myofibrils are composed of individual contractile 
proteins called myofilaments. These myofilaments are generally divided 
into thick and thin myofilaments. It is the arrangement of the contractile 
proteins within the myofibril that cause the striated appearance of 
skeletal and cardiac muscle. 
http://faculty.etsu.edu/forsman/Histologyofmuscleforweb.htm 
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The Dystrophin Glycoprotein Complex (DGC)  
In skeletal muscle the dystrophin glycoprotein complex (DGC) works as a 
transmembrane linkage between the extracellular matrix and the cytoskeleton (figure 
1.3) and hence is important in normal muscle stability. Dystroglycan is a central 
component of the DGC and is made up of two types of protein, alpha-dystroglycan 
(ADG) and β-dystroglycan (BDG). The ADG is a peripheral membrane protein and the 
receptor for laminin-211 in the basement membrane. BDG is a transmembrane protein 
that binds to dystrophin (Campbell, 1995, Bushby 1999). 
Dystrophin is a large rod-like cytoskeleton protein, absent in DMD patients. Dystrophin 
binds to intracellular actin cables. In this way, the DGC, links the actin cytoskeleton of 
a muscle cell with extracellular ligands, such as laminin and provides structural integrity 
in muscle tissues. The DGC is also known to serve as an agrin receptor in muscle, 
where it may regulate agrin-induced acetylcholine receptor clustering at the 
neuromuscular junction. This illustrates how the function of individual components of 
this complex works synergistically to achieve muscle and membrane stability (Engel 
and Franzini-Armstrong, 2004).  
Integral to the stability of the DGC is the correct glycosylation of ADG. POMT1 
(protein-O- mannosyltransferase 1), POMT2 (protein-O- mannosyltransferase 2) and 
POMGnT1 (protein O-linked mannose beta1, 2-N-acetylglucosaminyltransferase) have 
been shown to catalyze specific steps of O-linked glycosylation of ADG and are known 
to cause CMD. The function of the proteins fukutin, FKRP (fukutin related protein) and 
LARGE have not been fully explained (Brown et al. 2005, Xiong et al. 2006, de Paula 
et al. 2003, Brockington et al. 2005). The function of FKRP will be covered in Chapter 
1.1.5 as it is a mutation in the FKRP gene that causes LGMD2I, our study cohort. 
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Limb Girdle Muscular Dystrophy 
The diagnostic entity of „Limb Girdle Muscular Dystrophy‟ (LGMD) was first assigned 
by Walton and Nattrass in 1954. Initially the diagnosis was controversial. The 
controversy was mainly due to a lack of clarity and definition. It was assigned to a 
heterogeneous group of patients who typically presented in the late first or second 
decade of life (Bushby et al. 2009a).  
The disease was described as presenting in either male or female patients genetically 
inherited usually in either an autosomal recessive (AR) way and less frequently 
autosomal dominant (AD). The pattern of muscle involvement was predominantly 
proximal muscle weakness with shoulder and hip girdle involvement and facial sparing. 
The disease had a progressive course with loss of ambulation after 20-30 years with 
elevated creatine kinase levels and dystrophic features on muscle biopsy.  
With the development of molecular genetics and improved diagnostic methods this 
group of disorders have been more clearly defined especially over the last 15-20 years. 
In 1995, this led to further categorisation of the LGMDs, with the AD groups assigned 
LGMD1 and the AR group assigned LGMD2.  
Figure 1.3: Current interaction 
model of the proteins in the 
Dystrophin Glycoprotein 
Complex (DGC). Proteins 
affected in muscular 
dystrophies are indicated. 
http://www.sanger.ac.uk/Teams/Tea
m31/muscle.shtml 
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As different genetic subtypes have been described, the group of LGMDs recognised has 
expanded and can now be distinguished by specialised diagnostic techniques. Currently 
at least 21 types of different genetically defined subtypes of LGMDs are recognised and 
can be seen in table 1.1 (Bushby et al. 2009a). 
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LGMD forms Chromosome Protein Important 
Complications 
Other diseases 
associated with this 
gene 
Autosomal Dominant 
LGMD1A 5q31 Myotilin Other forms of 
myofibrillar myopathies 
more associated with 
cardiac and respiratory 
complications 
Myofibrillar 
myopathies, spheroid 
body myopathy. 
LGMD1B 1q11-21 Lamin A/C High risk of arrhythmia 
with requirement for an 
implantable defibrillator, 
cardiomyopathy, 
respiratory failure. 
Many including AD 
Emery-Dreifuss MD 
and dilated 
cardiomyopathy 
LGMD1C 3p25 Caveolin 3  Rippling muscle 
disease, hyperCKaemia, 
myalgia, hypertrophic 
cardiomyopathy 
LGMD1D 7q ?   
LGMD1E 6q23 ?  Cardiomyopathy and 
conduction defect 
LGMD1F 7q32 ?   
LGMD1G 4p21 ?   
Autosomal Recessive 
LGMD2A 15q15.1 Calpain 3   
LGMD2B 2p13 Dysferlin  Miyoshi myopathy 
LGMD2C 13q12 γ- sarcoglycan Cardiomyopathy and 
respiratory impairment.  
 
LGMD2D 17q21 α- sarcoglycan Cardiomyopathy and 
respiratory impairment. 
 
LGMD2E 4q12 β- sarcoglycan Cardiomyopathy and 
respiratory impairment. 
 
LGMD2F 5q33 δ- sarcoglycan Cardiomyopathy and 
respiratory impairment. 
 
LGMD2G 17q12 Telethonin   
LGMD2H 7q31-q33 TRIM 32  Sarcotubular myopathy 
LGMD2I 19q FKRP Cardiomyopathy and 
respiratory impairment; 
diaphragmatic 
involvement may cause 
respiratory insufficiency 
whilst still ambulant. 
Congenital muscular 
dystrophy type 1C 
(MDC1C), Walker-
Warburg syndrome 
LGMD2J 2q24.2 Titin  Heterozygous mutations 
cause AD tibial MD 
LGMD2K 9q34 POMT1  Walker-Warburg 
syndrome 
LGMD2L 11p13-12? Anoctamin 5   
LGMD2M 9q31 Fukutin  Fukuyama muscular 
dystrophy 
LGMD2N 14q24 POMT2  Walker-Warburg 
syndrome 
CK, creatine kinase; LGMD, limb girdle muscular dystrophy; POMT, protein O-mannosyltransferase; MD, 
muscular dystrophy; AD, Autosomal dominant. 
 
  
Table 1.1: This table summarises the current limb girdle muscular dystrophy 
classification (Bushby et al. 2009a) 
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The overall prevalence of all the LGMDs has been estimated at 5-70 per million 
populations in several countries; however different populations have different 
frequencies of the various LGMDs. Norwood et al. (2009) studied the North of 
England‟s neuromuscular population and found out of 1105 patients registered, 68 were 
classified as having LGMD, representing a population prevalence of 2.27/100,000.  
The autosomal recessive LGMDs are more common with only approximately 10% of 
the total accounted for by autosomal dominant LGMDs (Norwood et al. 2009). In all 
studies conducted, LGMD2A appears to be the commonest LGMD accounting for 
approximately 8-26% of all cases (van der Kooi et al. 2007, Balci et al. 2006), although 
this figure is 5-6 times lower in the ethnic Danes (Duno et al. 2008). LGMD2B accounts 
for 3-19%.  Sarcoglycanopathies (LGMD2C-F) as a group account for 3-18%, however 
individually they are relatively rare. Within the sarcoglycanopathy group, LGMD2D (α-
sarcoglycanopathy) is the commonest, and overall this type is twice as common as 
LGMD2C (γ-sarcoglycanopathy) and LGMD2E (β-sarcoglycanopathy) with LGMD2F 
(δ-sarcoglycanopathy) the rarest. These figures apply to Europe only. 
The prevalence of LGMD2I worldwide is 3-8% of LGMDs, however in certain parts of 
Northern Europe, including Denmark and parts of England, the prevalence of LGMD2I 
is higher. Sveen et al. (2006) showed a high population of 38% of LGMDs with 
LGMD2I, and in the North of England accounted for 19.1% of the LGMD group, a 
prevalence of 0.43/100,000 (Norwood et al. 2009). This reflects possible previous 
migration from Denmark to the Northern region of England. 
Overall morbidity and mortality rates depend upon associated features, such as 
respiratory or cardiac involvement. The earlier the onset of the disease, generally a more 
rapid and precipitous course is observed. This is in contrast to the late onset cases of 
LGMD where a more indolent course is seen. Variability is seen both within the LGMD 
subtype and within families with the same mutation. Some patients present in early 
childhood with an aggressive or congenital muscular dystrophy phenotype, whereas 
other family members may be asymptomatic with hyperCKaemia. 
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1.1.2 – The clinical phenotype of LGMD2I 
In this subchapter I will cover the clinical phenotype of LGMD2I and highlight the 
involvement seen in the skeletal muscles, cardiac muscles and respiratory system. 
 Skeletal muscle phenotype 
Whilst the limb girdle muscular dystrophy phenotypes present with a high degree of 
overlap, a definitive diagnosis can be made in the majority of cases. This is based on a 
combination of clinical signs and symptoms, immunohistochemistry on the muscle 
biopsy, genetic testing and more recently imaging. With all these modalities a more 
defined differential diagnosis can be achieved, eventually leading to a precise diagnosis 
and hence correct management and prognosis (Bushby, 2009a). 
LGMD2I is a heterogeneous condition with age of presentation varying between early 
childhood and mid adulthood (Poppe et al. 2003). These patients can present with either 
an early onset DMD like phenotype with rapid deterioration and loss of ambulation in 
their teens or present later in adulthood with a less severe phenotype (Poppe et al. 
2004). In the study by Poppe et al. (2004) approximately 1/3 of the cohort reported 
symptoms in childhood, although only one had actual delayed motor milestones (mild), 
the others reported that they were poor at sport, unable to run fast or were toe walkers. 
The majority of the cohort had their onset of symptoms during the 2
nd
 to the 4
th
 decade.  
The difficulties experienced were mainly related to proximal muscle weakness and 
included; walking, particularly up slopes, stair climbing and a waddling gait. Patients 
generally reported an indolent period from between 5-45 years followed by a more 
noticeable deterioration over 5 to 10 years.   
The pattern of skeletal involvement is similar to the other LGMDs with proximal 
weakness in both the pelvic and shoulder girdle, however distinctions can be made. 
Early onset DMD phenotypes can present with greater degrees of weakness in their 
shoulder girdle compared to other early onset LGMDs, as in the sarcoglycanopathies 
(Mercuri et al. 2003). The weakness tends to be limited to the proximal muscles with 
clinically sparing of the distal muscles, and good strength in the hands and also the 
ankles in plantarflexion, dorsiflexion, inversion and eversion. There tends to be 
demonstrable asymmetry but not to a large extent. Facial weakness is not generally 
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recognised, however tongue hypertrophy and dysphagia has been reported (Mercuri et 
al. 2003). Generally there is no scapular winging or neck weakness, but if present it is 
usually mild (grade 4 out of 5 on the MRC (Medical Research Council) scale). Poppe et 
al. (2003) reported that in patients with LGMD2I the quadriceps muscles are generally 
weaker than the hamstrings and this is reflected in hip flexion which is very weak as is 
hip adduction and abduction, more so than hip extension.  
In the upper limbs there is no distal weakness and in general the biceps muscles are 
stronger than the triceps and shoulder abduction was stronger than adduction (Poppe et 
al. 2003). 
Contractures are not commonly seen in this group of patients, but some early onset 
DMD like phenotypes can have tendon Achilles tightness and contractures (Poppe et al. 
2003, Mercuri et al. 2003).Whilst most patients have a lumbar lordosis, scoliosis or 
rigid spine is variable. In Poppe‟s study (2003), only one patient had a scoliosis, 
compared to Mercuri‟s study (2003), where nine of the cohort had a scoliosis. Although 
the study numbers were similar, 16 and 18, respectively, 13 out of the 16 studied by 
Poppe et al. were homozygous for the common mutation (C826A/Leu279Ile) compared 
to only 1 out of the 18 studied by Mercuri et al. (2003). The majority of patients tend to 
have calf hypertrophy and can have hypertrophy of other muscles including the 
quadriceps and more unusually the tongue (Poppe et al. 2003, Mercuri et al. 2003). 
Respiratory phenotype 
Patients with LGMD2I are prone to early respiratory involvement. This tends to be 
independent of their skeletal or cardiac muscle involvement. These patients can still be 
ambulant and require nocturnal non-invasive ventilation (NIV) with the earliest sign of 
involvement being diaphragmatic, with a drop in their lying forced vital capacity (FVC) 
compared to their sitting. This has been illustrated in the study by Poppe et al. (2004), 
where 44.4% of the patients exhibited respiratory compromise, and 5 out of the 8 
patients ventilated were still ambulant. 
In a previous study, Poppe et al. (2003) demonstrated in a LGMD2I cohort that the FVC 
ranged from 19-102% (corrected for height) In 2/3 patients there was a drop in lying 
from 8-22% suggesting diaphragmatic involvement. Over time a gradual deterioration 
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was observed in 7 patients over 5 years. Respiratory failure was documented in 25% of 
the cohort and NIV instigated with relief of symptoms. Half of the patients on NIV were 
still ambulant.  
Cardiac phenotype 
The relationship between cardiac and skeletal phenotypes is complex. The association 
of cardiac disease, whether cardiac dysrhythmias or cardiomyopathy, is individual 
depending upon the gene mutation. Some muscular dystrophies tend to have a higher 
relative risk. This has important implications for management. Cardiac involvement in 
patients with LGMD2I has been reported as being between 10% (Walter et al. 2003) 
and 55% (Poppe et al. 2004).  Poppe and colleagues (2004) conducted a multicentre 
study with LGMD2I patients, who had an overall prevalence of 55.3% when assessed. 
The cardiac involvement was more frequent in men, with 83% affected compared to 
42.3% of women.  There was however a higher proportion of compound heterozygotes 
in the male group compared with the women who were predominantly homozygotes. 
Using the Kaplan-Meier analysis this suggests that 66% of heterozygotes would have 
cardiac involvement by the age of 20 years and 100% by 39 years, compared to the 
homozygotes where only 4.4% would have cardiac involvement by 20 years and 100% 
would have cardiac involvement by 58 years. At the time of the study 83% of the 
patients were still ambulant (Poppe et al. 2004).  
In a previous study by Poppe et al. (2003) it was shown that the incidence of cardiac 
involvement was 38%. This study had a small cohort of LGMD2I patients and the 
majority of patients were homozygous for the common mutation (L276I) and hence less 
phenotypically severe.  
Due to the high prevalence of cardiac involvement in LGMD2I, it is therefore important 
to assess the patients regularly and start treatment early as this may have a 
cardioprotective effect (Duboc et al. 2007). Cardiac involvement in LGMD2I is 
amenable to treatment with ACE (angiotensin-converting-enzyme) inhibitors. In a large 
study by SOLVD investigators in 1992, it was demonstrated that left ventricular 
dysfunction improved and stabilised with the use of ACE inhibitors. This study was on 
patients without muscular dystrophy. 
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1.1.3 - The genotype of LGMD2I 
More than 70 different FKRP mutations have been identified, of which approximately 
40 cause LGMD2I (Human Genome Mutation Database). The FKRP gene consists of 
four exons containing a 1,488 base pair (bp) open reading frame that encodes a 495 
amino acid protein. Mutations in the FKRP gene not only cause LGMD2I but more 
severe congenital muscular dystrophies such as congenital muscular dystrophy 1C 
(MDC1C), muscle eye brain disease (MEB) and Walker-Warburg syndrome (WWS) 
(de Paula et al. 2003). Whilst LGMD2I and MDC1C are allelic, they are clinically, 
pathologically and genetically diverse. Different types of mutations cause MDC1C, 
whereas the majority of LGMD2I are caused by the common C826A missense mutation 
in the FKRP gene (Mercuri et al. 2003, Wickland and Hilton-Jones 2003, Brown et al. 
2004).  
(i) The LGMD phenotype 
The c.826C>A/Leu276Ile mutation is the most frequent among LGMD2I patients in 
Northern Europe.  Patients homozygous for this common mutation tended to have a 
milder phenotype compared to those patients with a compound heterozygous mutation 
who presented with the earlier more severe DMD like phenotype (Mercuri et al. 2003, 
Sveen et al. 2006). In Northern Europe, LGMD2I appears to be one of the most 
common forms of LGMD (Poppe et al. 2003, Brockington et al. 2001a, Brockington et 
al. 2001b, Driss et al. 2003, Walter et al. 2004, Beltran Valero de Baernab et al. 2004, 
and Norwood et al. 2009). Sveen et al. (2006) identified FKRP mutations in 38 of 99 
Danish individuals with a clinical diagnosis of limb-girdle muscular dystrophy. Of the 
38 individuals, 27 were homozygous for the Leu276Ile mutation, and 11 were 
compound heterozygous for the Leu276Ile mutation and another pathogenic FKRP 
mutation. The homozygous patients had later onset, milder clinical progression, and less 
muscle weakness compared to compound heterozygous patients, all of whom were 
wheelchair-bound by their mid-twenties. Cardiac and respiratory involvement was 
found in both groups. Nine were homozygous for the Leu276Ile mutation, but no 
compound heterozygous, patients had initial symptoms of exertional myoglobinuria. 
The Leu276Ile variant was identified in 1 of 200 control alleles. 
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In Norway, 87 live patients were identified with FKRP mutations in 2008 (Stensland et 
al. 2011). This corresponded to a minimum point prevalence of 1/54,000 and a carrier 
rate of 1/116. The allele frequency for c.826C>A has previously been reported as 1/200 
for Denmark and the UK (Beltran Valero de Baernabe et al. 2004, Brockington et al. 
2001b) and 1/600 for Germany (Walter et al. 2004). 
In Southern Europe higher frequencies of other FKRP mutations have been found (de 
Paula et al. 2003, Boito et al. 2005, Harel et al. 2004). In 16 patients with LGMD from 
13 Brazilian families, de Paula et al. (2003) identified 10 distinct mutations, including 9 
novel mutations, in the FKRP gene. The most common mutation, Leu276Ile, was 
identified in 9 of 26 alleles. Like those patients who carry the c.826C>A mutation, there 
was substantial variability seen those that carry the same genotype (Harel et al. 2004), 
and mildly affected patients other than those homozygous for the c.826C>A mutation 
have been described (de Paula et al 2003, Harel et al. 2004). 
(ii)The CMD phenotype 
Mutations in the FKRP gene can cause the more severe phenotypes, MEB and WWS. 
Beltran-Valero de Bernabe et al. (2004) identified homozygous mutations in the FKRP 
gene in 2 unrelated patients with muscle-eye-brain disease and Walker-Warburg 
syndrome, respectively. Both disorders are characterized by severe disruption of brain 
and eye structure in addition to muscular dystrophy. Mercuri et al. (2009) identified 
FKRP mutations in 7 (9%) of 81 Italian patients with a dystroglycanopathy. Three had 
MEB and 4 had a less severe congenital muscular dystrophy. Three patients had normal 
brain MRI. The findings expanded the phenotypic spectrum of disorders associated with 
mutation in the FKRP gene. 
In a retrospective review of brain MRI in patients with FKRP mutations, Mercuri et al. 
(2006) found a range of various patterns. Five of 13 patients had normal imaging results 
and normal neurologic function. Three patients had isolated cerebellar cysts and mental 
retardation without other abnormal brain structure. Of the 5 remaining patients, 2 had 
features of MEB disease, one had features of WWS, and 2 had cerebellar cysts with 
nodular heterotopia and cerebellar dysplasia, respectively. Topaloglu et al. (2003) also 
demonstrated cerebellar cyts and mental retardation in patients with CMD and FKRP 
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mutations. There was no correlation with severity of the neurologic involvement and 
FKRP mutation. Mercuri et al. (2006) postulated that the variability may be related to 
the severity of disruption of alpha-dystroglycan glycosylation.  
1.1.4 – Care standards in LGMD2I 
The ideal model of care for patients with neuromuscular disease is a holistic one, based 
on medical, social and psychological elements. These patients require a 
multidisciplinary approach and the level of care and treatment given should be 
universal. As severe LGMD2I patients have a phenotype similar to BMD and DMD, the 
standards of care, recently published (Bushby et al. 2010) for DMD, should be adhered 
to as these have led to improved care and outcomes in terms of morbidity and survival 
in these patients. The care guidelines direct clinicians towards a more proactive 
management of complications rather than a reactive one. As in DMD and BMD, 
LGMD2I patients are at risk of both cardiomyopathy and type II respiratory failure, this 
therefore needs to be monitored and treated early to prevent further morbidity. 
As part of the initial assessment of these patients, a structured history and family history 
should be taken and a physical examination conducted by a physician who is 
experienced in neuromuscular disorders, with the focus on the strength, motor function 
and any resultant functional impairment.  Regular assessments should be obtained at 
each visit, monitoring the disease progression, such as strength, range of motion, timed 
tests and gait. Functional assessments should also be applied to assess the level of 
ability to cope with activities of daily living and psychological adjustments to any loss 
of function. 
The suggested range of neuromuscular assessments for patients with DMD could be 
applied to the LGMD2I patient as described in table 1.2; 
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 Method Aim of testing Ambulatory Non-ambulatory 
Strength 
testing 
Manual 
muscle testing 
(MRC scale) 
Quantitative 
myometry 
(beneficial if 
muscle 
strength 3-5 
on MRC 
scale) 
Serial assessment; to identify 
outliers from expected clinical 
course; to monitor disease 
progression and predict 
functional losses; to assess 
response to treatment; and to 
monitor muscle imbalance. 
Test lower extremity 
strength by manual 
muscle testing every 6 
months. 
Early stages; Test 
upper and lower 
extremity strength by 
manual muscle 
testing every 6 
months. 
 
Later stages; value of 
testing is less certain. 
Range of 
motion 
Goniometry Baseline: to identify emerging 
muscle hypo-extensibility and 
joint contractures that might 
contribute and lead to 
functional deterioration or 
musculoskeletal or 
integumentary problems. To 
identify need for additional or 
altered therapeutic/surgical 
intervention (ie orthoses, 
splinting, use of standers, 
iliotibial band lengthening)   
Lower extremities; hip, 
knee, ankle joints, 
iliotibial band, 
hamstrings, 
gastrocnemius. 
Lower extremities; 
hip, knee, ankle 
joints, iliotibial band, 
hamstrings, 
gastrocnemius.  
 
Upper extremities; 
elbow, wrist, long 
finger flexors. 
Timed 
testing 
Standardised 
use of timed 
function tests 
Easy and relevant measure of 
daily functional status; 
responsive to change. 
Timed 10m walk, timed 
Gowers‟ manoeuvre, 
time to climb 4 stairs, 
time to rise from a 
chair, 6 minute walk 
distance. Time to put on 
a shirt maybe relevant 
in late ambulatory 
phase. 
Time to put on a shirt 
maybe relevant in 
early non-ambulatory 
phase. Timed tests 
not applicable in the 
late non-ambulatory 
phase. 
Activities 
of daily 
living 
Assessment of 
impairment in 
daily activities 
in the home, 
school and 
community 
settings. 
Highly relevant to targeted 
input with aids, adaptations and 
access to environmental 
controls 
Frequency of falls, step 
activity monitoring, 
self-care skills, writing, 
computer use. 
Functioning in school 
and community setting. 
Self-care skills, 
writing, computer 
use, control of 
manual and electric 
wheelchair. 
Functioning in school 
and community 
setting. 
Motor 
function 
scales 
Assessment of 
motor 
function in 
specific 
domains to 
give a 
composite 
score 
Allows monitoring of 
progression and response to 
therapy 
Vignos lower extremity 
scale, North Star 
ambulatory assessment, 
motor function measure. 
Brooke upper 
extremity scale, Egen 
Klassification 
functional 
assessment, 
Hammersmith motor 
scales, motor 
function measure. 
Routine clinic appointments should be every 6 months, unless otherwise specified. Specialist physical and 
occupational therapy assessments are recommended every 4 months. MRC UK Medical Research Council. Although 
the panel found these tests to be appropriate assessment tools they are used more typically in research than in clinical 
settings. 
Table 1.2: Suggested neuromuscular assessments for patients with DMD. 
(Bushby et al. 2009) 
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Although not all these tests will be possible in a busy clinic setting, it is important that 
the assessments that are used are appropriate for the patient and completed. These 
assessments should ideally be done consistently and over time to delineate the 
progression of the disease. I will now describe some of these assessments in more detail 
with relevance to LGMD2I. 
(i) Mobility and strength;  
Stretching and Positioning Effective stretching of the musculotendinous unit requires 
a number of interventions including passive stretching, active stretching, active-assisted 
stretching as well as the use of splints and orthoses to achieve a prolonged stretch of the 
unit to prevent contractures.  Whilst contractures are not usually a marked feature in 
LGMD2I daily stretching, active, passive and active-assisted is advised on at least 4-6 
days per week. Stretching of the hips, knees and ankles are essential to aid ambulation 
and when non-ambulant to prevent contractures and ultimately difficult positioning in 
the wheelchair.  
Orthoses are used to prevent or minimise contractures. These are particularly useful in 
the non-ambulant phase when a custom-moulded AFO (Ankle Foot Orthoses) can be 
fashioned and fabricated for comfort and optimum foot and ankle alignment.  
Exercise Regular gentle exercise, such as swimming, is recommended and the evidence 
suggesting exercise as a treatment is just beginning to be recognised. Aerobic exercise 
is safe and beneficial in a number of neuromuscular diseases (van der Kooi et al. 2005). 
Sveen et al. (2007) found that over 12 weeks of low intensity aerobic exercise, patients 
with LGMD2I increased their level of fitness with documented increased endurance, leg 
strength and walking distances. There was no evidence of muscle damage and no 
increase in CK levels. Capillary densities increased with training by 18%. The capillary 
density prior to the exercise regime had been 55% lower than healthy controls. This 
phenomenon has previously been described by Olsen et al. (2003). The disease process 
or deconditioning may be the reason that the difference in capillary densities is seen and 
the lower capillary density is associated with a 43% higher fibre type area. 
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Endurance training is also advised by the cardiologists (Stolen et al. 2003) and therefore 
would be of benefit to patients with LGMD2I as they develop cardiomyopathy as part 
of the condition.  
(ii) Cardiac health;  
LGMD2I patients should have regular cardiac evaluations as part of their annual review 
to detect early signs of cardiomyopathy. Cardiomyopathy can develop independently to 
their walking ability and skeletal muscle strength (Sveen et al. 2008). Early treatment 
with beta blockers and ACE inhibitors is well recognised to improve cardiac function in 
established cardiomyopathy (SOLVD investigators, 1992). Further research is required 
into whether treatment with these cardio-protective drugs before the onset of 
cardiomyopathy in muscular dystrophy should be commenced.  Further research is also 
needed into more sensitive markers, such as cardiac MRI, and whether this should be 
employed if a normal echocardiogram (ECHO) is obtained.  
The current clinical practice in the care of patients with LGMD2I is the same as 
employed in the treatment of Duchenne and Becker muscular dystrophy (DMD/BMD) 
patients (Bushby et al. 2010)  At diagnosis all patients should have a cardiological 
workup including an ECHO and electrocardiogram (ECG). This should be followed up 
by annual assessments depending on investigational findings and clinical symptoms. 
Patients should be treated with angiotensin-converting enzyme (ACE) inhibitors 
initially in the presence of progressive abnormalities (Ishikawa et al. 1999). 
Subsequently the addition of beta blockers should be considered (MacMahon et al. 
1997). 
(iii) Respiratory health;  
LGMD2I are at risk of type II respiratory failure due to diaphragmatic weakness. As a 
consequence patients should be assessed on a yearly basis with at least a sitting and 
lying Forced Vital Capacity (FVC). If a postural drop is observed and/or symptoms of 
nocturnal hypoventilation are observed, then a sleep study should be requested and early 
referral to a respiratory physician with experience in non-invasive ventilation (NIV) 
made.  
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(iv) Steroid treatment;  
In LGMD2I, there is a small amount of data concerning therapeutic steroid use. Darin et 
al. (2007) reported two patients, both with a DMD phenotype and compound 
heterozygotes. In both patients they commenced on steroids at a lower dose of 
0.35mg/kg/day as per the Swedish study (Backman et al.1995), rather than the higher 
usual dose of 0.75mg/kg/day used in DMD (Manzur et al. 2004). Both patients, treated 
in their teens, made dramatic improvements in motor function and even on relatively 
small doses maintained motor function. In one the steroid was withdrawn as he was 
only on 0.07mg/kg/day, however he rapidly deteriorated but regained his previous 
motor function on restarting at the same dose (Darin et al.2007). 
1.1.5 – The FKRP gene and its protein product  
Since the discovery of the FKRP gene in 2001 by Brockington and colleagues, there has 
been much debate as to the function of FKRP and its role in LGMD2I and MDC1C. In 
this subchapter I will describe the process of glycosylation, which affects the stability of 
the DGC and hence the muscle in patients with LGMD2I and the role of FKRP in this 
process. 
 (i) Glycosylation 
Glycosylation, the enzymatic addition of carbohydrates to lipids or proteins, is the most 
common and most complex post translational modification (Wopereis et al. 2006). 
Approximately 1% of human genes are required for this process (Lowe and Marth, 
2003) and it is estimated that almost half of all proteins are glycosylated (Apweiler et al. 
1999). Glycosylation can be divided into three main groups, N-linked, O-linked and C-
linked glycosylation (Lowe and Marth, 2003). 
Glycans possess the potential for huge structural diversity, they have many branches 
and can form glycosidic linkages with sugar residues in α or β configuration.  O-linked 
glycans are classified by the first sugar attached to a Ser, Thr or Lys residue in a protein.   
There are 7 O-glycans identified in humans and O-Mannosyl glycans represent the least 
common type, of which ADG is one (Wopereis et al. 2006)  
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The biosynthesis of complex O-linked and N-linked glycans is located in the secretory 
pathway (Wells and Hart, 2003). Proteins are made by the ribosomes and then directed 
to the rough endoplasmic reticulum (ER) following which protein folding occurs and 
then transportation by the transport vesicle to the Golgi apparatus (Matlack et al. 1998, 
Rapoport et al. 1996)  
The O-linked glycans are found to have functions involving protein structure and 
stability, immunity, receptor mediated signalling, non-specific protein interactions and 
protein expression and processing (Wopereis et al. 2006). The sialylated O-mannosyl 
glycans of ADG serves as binding sites for laminin in both muscle and brain (Endo, 
2004).  
(ii) Glycosylation defects of dystroglycan. 
Recently there has been recognition that a number of congenital muscular dystrophies 
and LGMDs have been associated with abnormal glycosylation of the DGC (Muntoni et 
al. 2002, Muntoni et al. 2004, Martin 2007, Barresi and Campbell 2006). As stated 
earlier the DGC is a large protein complex, derived from post translational cleavage of a 
precursor polypeptide encoded by the DAG1 gene (Henry and Campbell 1999, Winder 
2001, Ervasti and Campbell 1993), that is integral to maintaining the stability of the 
sarcolemma by connecting components of the extracellular matrix to the internal 
cytoskeleton of the muscle fibre (figure 1.3).  
In congenital muscular dystrophy mutations in six genes have so far been identified. 
These include POMT1, POMT2, POMGnT1, LARGE, fukutin and FKRP (Brockington 
et al. 2001a, Beltran-Valero de Bernabe et al. 2002, van Reeuwijk et al. 2005, Yoshida 
et al.2001, Kabayshi et al. 1998, Longman et al. 2003). They cause a spectrum of 
diseases from severe congenital muscular dystrophies, usually associated with structural 
brain malformations and eye involvement to a variable extent. Fukuyama congenital 
muscular dystrophy (FCMD), muscle-eye–brain disease (MEB) and Walker-Warburg 
syndrome (WWS) represent the severe CMDs, (Muntoni et al 2004) whilst MDC1C is 
milder and does not have any associated brain involvement. As with the other CMDs, 
patients with MDC1C present early in life, usually before 6 months, with hypotonia and 
weakness, which is predominantly limb girdle in distribution and associated with severe 
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wasting in these muscle groups. Patients are unable to walk and also develop a severe 
restrictive respiratory defect progressing to failure in the second decade. 
Cardiomyopathy is also observed in some patients (Brockington et al. 2001a), however 
the brain is rarely involved, although severe mutations can lead to cerebellar changes 
(Topaloglu et al. 2003, Mercuri et al. 2006) or more extensive changes as seen in WWS 
and MEB (Longman et al. 2003). 
The LGMD type 2 variants include LGMD2I, LGMD2L and LGMD2N.  
 (iii) Functional properties of FKRP 
There has been much debate about the subcellular localisation of FKRP. Originally it 
was thought that both Fukutin and FKRP were Golgi resident proteins (Escapa et al. 
2002) required for post-translational modification of dystroglycan and that 
mislocalisation of the mutant protein may underlie MDC1C.  Later it was thought that 
FKRP localised to the rough ER (Escapa et al. 2005, Torelli et al. 2005) and that protein 
mislocalisation was not a common mechanism of disease in MDC1C and LGMD2I 
(Dolatshad et al. 2005, Torelli et al. 2005). More recently it has been hypothesised that 
FKRP is present at the cell surface, associates with the DGC and has a unique role in 
the ADG processing pathway (Beedle et al. 2007).  
The FKRP gene which encodes the FKRP is thought to be a tissue specific 
glycosyltransferase involved in the O-mannosylation of ADG (Brockington et al. 
2001a). FKRP is expressed in many tissues including skeletal muscle, placenta and 
heart and less predominantly in the lung, liver, kidney, pancreas and brain (Wopereis et 
a.l 2006).  
FKRP has been shown to directly affect dystroglycan processing by altering the 
isoforms of ADG. A mutation in FKRP has been demonstrated in vitro and causes a 
decrease in molecular weight of the ADG (Esapa et al. 2002). This could be secondary 
to modification, possibly explained by the addition of terminating glycans therefore no 
further modification can occur, or by altering the stability of the dystroglycan rendering 
it more susceptible to endogenous proteases (Esapa et al. 2002). This is evident in 
patients; mutations in fukutin result in an absence of glycosylated ADG on muscle 
biopsies, whereas mutations in the FKRP gene cause a decrease but still detectable 
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levels of ADG, indicating a difference in dystroglycan processing (Brockington et al. 
2001a, Brockington et al. 2001b, Boito et al. 2007, Yamamoto et al. 2008). 
Dystroglycan glycosylation is important for binding to laminin and agrin in the basal 
lamina (Ervasti and Campbell, 1993, Gee et al. 1994, Sugiyama et al. 1994). 
Abnormalities in the basal lamina (BL) and reductions in laminin alpha 2 have been 
demonstrated in the muscle and brain of patients with FCMD. This may represent 
defects in the BL and extracellular matrix (ECM) that involve components of the DGC. 
In MDC1C, disruption of the BL due to reduced capacity to bind ADG to EC laminin 
may be present. MDC1C patients also have secondary laminin immunoreactivity 
(Brockington et al. 2001a). In LGMD2I there is evidence on ultra structural studies of a 
focally disorganised and thinner BL (Boito et al.2007).  
Esapa et al. (2005) showed that mutant FKRP is altered in the cells and ER retained, 
whilst wildtype FKRP and mutant L276I that causes the milder LGMD2I were 
predominantly found in the Golgi apparatus. Mutant FKRP and hypoglycosylated ADG 
may be misfolded in the cell and detrimental to it (Boito et al. 2007). Esapa et al. (2005) 
also demonstrated that the ER retained proteins had a shorted half-life than the wildtype 
FKRP plus calnexin, an ER chaperone molecule, bound preferentially to the ER 
retained mutant FKRP acting as a possible quality control pathway. 
Upregulation of several ER resident proteins then occurs to re-establish cell 
homeostasis, via a process of unfolded protein response (UPR), an intracellular 
signalling pathway from the ER to the nucleus after triggers from misfolded proteins 
(Ellgaard and Helenius, 2001). Upregulation of MHC class I molecules were also 
identified and this could signal UPR (Boito et al. 2007). Upregulation of class I MHC 
molecules may induce ER stress and lead to damage and dysfunction of the muscle fibre 
in a non-immune fashion. In the LGMD2I muscle biopsies it was observed that the 
rough ER had proliferated and modified (Boito et al. 2007). 
(v) Animal model studies 
At present there is no animal model for LGMD2I, however zebrafish have been used in 
the study of the pathogenesis of muscular dystrophies (Parsons et al. 2002a, Basset and 
Currie, 2003, Basset et al. 2003, Guyon et al. 2005, Nixon et al. 2005). There have been 
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various Zebrafish mutants studied involving an ADG binding protein, such as the 
candyfloss (caf) mutant associated with mutations in the laminin α-2 gene and a 
degenerative muscle phenotype (Hall et al. 2007). Other laminin mutants bashful (bal), 
sleepy (sly) and grumpy (gup) have all demonstrated phenotypes involving defects in 
notochord differentiation and eye development (Parsons et al. 2002b, Pollard et al. 
2006).   
Downregulation of FKRP in the zebrafish By Kawahava et al. (2010) using 2 different 
morpholinos resulted in a phenotypic spectrum, seen also in the human spectrum from 
the severe congenital muscular dystrophy and the milder limb girdle forms. The most 
affected mutant embryos would die within 24 hours post fertilization and those with a 
less severe phenotype demonstrated a range of morphological abnormalities including 
alterations in the somitic and sarcomeric integrity, as well as disruption to the muscle 
fibres and basement membrane (Kawahava et al. 2010).  
In the FKRP morphant embryos a reduction in the glycosylation of ADG was 
demonstrated and this correlated with the resultant phenotype. Laminin binding was 
also found to be defective, as in the human disorders, suggesting a similar disruption to 
the extracellular matrix binding of the internal cytoskeleton.  
(vi)  Conclusion 
In conclusion, the FKRP gene, encodes for a putative O-linked glycosyltranferase. 
Abnormalities in FKRP function result in hypoglycosylated ADG, which causes 
destabilisation of the DGC. In LGMD2I, this disruption appears less, compared to the 
more severe phenotypes seen in the congenital muscular dystrophy and this may be a 
result of variability in the glycosylation process. In LGMD2I there is evidence of a 
reduction in ADG on muscle biopsies, a focally disordered and thinner basal lamina as 
well as proliferated and modified rough ER. All these findings suggest that 
glycosylation has been affected and that modification of the ADG has been altered. 
The milder LGMD2I phenotype is caused predominantly by the L276I mutation in the 
FKRP gene and in this case the FKRP is located in the Golgi and results in 
hypoglycosylation and protein misfolding. In the FKRP mutations causing the more 
severe phenotypes, there was ER retention and an absence of ADG on muscle biopsies. 
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The phenotypes associated with mutations in the FKRP gene range from WWS, MEB, 
and MDC1C to the milder LGMD2I patients and asymptomatic cases. Within LGMD2I, 
the phenotypes vary depending on whether the patient is homozygous or compound 
heterozygous for the common L276I mutation. The degree of glycosylation of ADG is 
crucial in the stability of the DGC and hence the integrity of the muscle. 
1.1.6 - Aims and Objectives 
LGMD2I represents a heterogeneous disorder caused in the majority of cases by the 
FKRP mutation. As it is one of the more frequently seen limb girdle muscular 
dystrophies in the Northern hemisphere, it highlighted a clinically relevant population to 
study in further detail. 
Clinical trials and studies in neuromuscular disorders are becoming increasingly evident 
as pharmaceutical companies develop more „orphan‟ drugs for these rare diseases.  
Feasibility studies using patient registries have proved invaluable for planning these 
studies and clinical trials. The feasibility studies establish disease population 
demographics and identify potential trial sites as well as numbers of patients potentially 
eligible to take part in such studies. Patient registries for rare diseases have become 
increasingly important in understanding these disorders, both within and outside the 
neuromuscular field.  
These patient registries have already proved useful to Industry in providing data on 
patients with Duchenne muscular dystrophy. The registry was able to identify patients 
who had a specific deletion of exon 51, therefore assisting with the design and trial site 
location for the antisense oligonucleotide therapeutic trials. With each study and trial 
alterations to the protocols and changes to end points and outcome measures have been 
made. Changes and recommendations to future therapeutic trials are made following the 
experience of previous trials, natural history studies and assessments. 
In order to define study parameters and outcome measures, it is essential that the 
population to be studied is well researched. In order to do this, natural history studies 
need to be undertaken, establishing the pattern of the disease. This includes the typical 
age of presentation and symptoms, as well as the features of progression and the rate at 
which this occurs. In neuromuscular conditions, and in particular, limb girdle muscular 
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dystrophies it is important to assess whether there is any respiratory or cardiac 
involvement, as well as the pattern of skeletal involvement. As referred to in chapter 
1.1, when the LGMDs were first defined there was no distinction as to which LGMD 
would present with cardiac or respiratory involvement, however with further genotype 
and phenotype definition it is now known for the currently defined LGMDs. Further 
classification of the LGMDs will continue as new genes are found.  
Skeletal muscle involvement and the particular patterns seen on muscle imaging is 
becoming more defined with further utilisation of this modality. The MRI studies that 
have been published however are still small in patient numbers and whist patterns are 
well established in some muscle conditions, others are less well defined. Historically the 
imaging modality widely used has provided a qualitative image using T1 weighted 
(T1w) images and grades assigned to the whole muscle as according to the Mercuri et al. 
(2002a) grading.  
The aims and objectives of this study were therefore; 
1) The first objective was threefold; firstly to define the muscle involvement on 
imaging using both the standardised method (T1w) as well as a quantitative 
method of MRI, secondly to assess these changes longitudinally and thirdly to 
assess whether any metabolic changes could be demonstrated on skeletal MRS. 
The initial aim was to complete this over a 12 month period and assess changes 
demonstrated by this method. As quantitative MRI is an objective measure, I 
was interested to determine whether this imaging modality would be sensitive 
enough to detect change. And if so, imaging could be another adjunct for use in 
clinical trials to monitor progression of the disease process or indeed any 
improvement in a therapeutic trial. Initially this project was planned to be a 
collaborative project between Newcastle upon Tyne and London, however 
during the development of the protocol it became evident that Paris, France and 
Copenhagen, Denmark would also be interested in collaborating and had 
previous experience in MRI studies. This therefore meant that careful planning 
and quality assurance was required from each centre to ensure reliable data and 
patient recruitment.   
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2) The second objective was to develop a standardised physical examination that 
was both meaningful in a clinical perspective as well as acceptable to an adult 
patient with LGMD. Recently scales, addressing function and strength have 
been rigorously developed for the DMD population as there are a number of 
therapeutic trials underway. These, however, are not entirely suitable or mirror 
the difficulties encountered by adults with LGMD2I. The aims were therefore 
twofold, to both assess the patients in order to correlate strength and functional 
ability with the MRI findings but also develop a robust set of assessments that 
could be applied to this population and hence useful in a clinical trial setting as 
outcome measures. These assessments, if appropriate to measure strength and 
function, may be appropriate for other adult LGMD patients and therefore useful 
in future natural history, multicentre studies.  
3) The third objective was developed during the course of the project as I was 
researching other MRI techniques and applications. The LGMD2I patients are 
known to develop cardiac complications in the form of a cardiomyopathy and 
this, as commented in chapter 1.3, these are conventionally screened for by an 
echocardiogram. In DMD there has been much debate about the use of cardio 
protective drugs before detection of any cardiomyopathy and certainly prompt 
treatment with cardio protective medication is recommended as soon as signs of 
a cardiomyopathy are detected. Gaul et al. (2006) demonstrated that cardiac 
MRI appeared more sensitive at picking up early changes not seen on 
conventional imaging and if this is the case then even earlier treatment could 
then be commenced. The objective therefore was to perform cardiac MRI on the 
Newcastle upon Tyne patient cohort and correlate this with their echocardiogram 
findings 
4) The fourth objective was to set up an international patient register with FKRP 
mutations; this register would be the first international neuromuscular registry, 
translated into a number of languages and designed to be patient initiated. It 
would aim to capture the data on all patients worldwide, to establish the 
presenting symptom and age of onset, the rate of progression and nature of the 
disease progression. The registry would also record on an annual basis the 
change in these patients, any concurrent diseases that may be an association and 
track the changes in their respiratory and cardiac function. Whilst patient 
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initiated it would also require medical input from professionals including the 
genetic confirmation, cardiac and respiratory parameters, and muscle strength 
testing including functional timed tests. This would therefore provide 
longitudinal, natural history data on a large number of patients with this 
condition as well as their demographics, which are essential if a feasibility study 
was required before a clinical trial. 
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Chapter 2 –Skeletal and cardiac muscle imaging and spectroscopy; 
literature review 
2.1 – Ultrasound imaging (US) 
2.1.1 - Ultrasound imaging; how it works 
Ultrasound imaging of the muscle was first introduced in the field of neuromuscular 
disorders (NMD) in 1980 (Heckmatt et al. 1980, Young et al. 1980). Muscle ultrasound 
has not been widely adopted in neuromuscular clinics or in diagnostic evaluation 
protocols, as many clinicians do not have adequate training in the use of and 
interpretation of US. It can be extremely useful in children as well as adults, as it is safe, 
painless, quick, and relatively cheap. It also has the great advantage of being portable.  
Sound waves and their echoes form the basis of ultrasound images. A transducer sends 
out pulses of high-frequency sound waves and receives their echoes. The temporal 
properties, the time taken to send and receive the pulse, and acoustic properties, the 
amplitude, determine the position and the brightness of the image produced 
respectively. Biological tissues are comprised of mainly fat and water, both of which are 
capable of transmitting sound and have only a small difference in acoustic impedance, 
the combination of sound velocity through and the density of the tissue. The echo 
intensity, and corresponding image, is determined by the quantity of returning echoes. 
Bone and air produce a strong reflection, at transition, and this results in a bright spot on 
the image. Hardly any sound can get through to the deeper layers either and hence no 
structures beneath that transition can be displayed. Muscle and fascia on the other hand, 
produce a partial reflection; however most of the sound waves can continue through to 
deeper structures, which then further reflect the sound waves producing varying echo 
intensities depending on the structure (Pillen et al. 2008). 
Normal muscle appears black on ultrasound images due to its low echo intensity. In the 
transverse plane muscle can appear speckled due to the echogenic sheets of perimysial 
connective tissue, which surrounds the muscle fibre bundles, and in the longitudinal 
plane this is visualised as hyperechoic lines. This means that muscle ultrasound images 
are distinct from surrounding structures and due to the echogenic nature of the 
 31 
epimysium (fascia), and the boundaries of the muscle are well demarcated.  All 
superficial muscles can be easily visualised, however deeper muscle can be more 
difficult due to the reflection or absorption of sound from more superficial tissue layers 
and individual small muscles can also prove difficult when multiple muscle groups 
overlap them (Pillen et al. 2008).  
When using US in a clinical setting, it is imperative that the normal values and 
appearances are known in order to detect disease states. The thickness of muscle alters 
both in childhood and depending on gender, and normal values for these have been 
established (Arts et al. 2007, Heckmatt et al. 1988, Reimers et al. 1998, Schmidt and 
Voit, 1993, Scholten et al. 2003). During childhood the muscle thickness increases 
rapidly, with the main determinant being the weight of the child (Scholten et al. 2003). 
Gender differences do not dominate until puberty (Arts et al. 2007, Kanehisa et al. 
1994, Kanehisa et al. 1995), when men start to develop thicker muscles than women. 
This trend continues and peaks between 25 and 50 years of age, after which a gradual 
decline is seen (Arts et al. 2007, Reimers et al. 1998, Kanehisa et al. 1994, Kanehisa et 
al. 1995, Doherty, 2003).  
As well as the thickness of the muscle, echo intensity can also be evaluated. As with the 
thickness of the muscle, echo intensity changes with age. The echo intensity increases 
due to an age related increase in fat and fibrous tissue. Due to the increased number of 
reflecting interfaces the muscle appears whiter. This also applies to the increase in fat 
and fibrous tissue in neuromuscular disorders. Heckmatt and colleagues (1982) 
developed a visual grading scale to classify this. Grade I is normal through to grade IV, 
which is severely increased muscle echo intensity with total loss of bone echo. The 
intensity can further be described depending on whether the muscle appears 
homogeneous or inhomogeneous.  Qualitative scales and visual grading are always 
subject to the experience of the observer and the settings of the machine. It has been 
demonstrated that visual assessment of muscle US has a low interobserver agreement (κ 
= 0.53), which is further lowered if an inexperienced observer interprets the images 
(Pillen et al. 2006a). If a quantitative gray-scale analysis is used the interobserver 
agreement improves (κ = 0.82)(Pillen et al. 2006a). Visual assessment still has a role, 
particularly in detecting focal changes and distribution of changes within a muscle, 
whether homogeneous or inhomogeneous.  
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In order for these measurements to be meaningful, adequate amounts of contact gel need 
to be applied to ensure optimal acoustic coupling as well as to remove the potential for 
pressure when scanning. If longitudinal measurements are being made then standard 
operating procedures need to be adopted and adhered to by individual operators. 
Contraction of the muscles will result in decreased echo intensity as well as an increased 
muscle diameter (Heckmatt et al. 1988a) and changes in the muscle fibres will alter the 
echo intensity, such as bending the knee when scanning the quadriceps (Heckmatt et al. 
1980, Zuberi et al. 1999).  
2.1.2 - Ultrasound imaging in neuromuscular disorders. 
There have been a small number of studies in NMD assessing the reliability of 
ultrasound. In adults with idiopathic inflammatory myopathies a robust correlation 
between the histologic and sonographic changes has been demonstrated (Walker et al. 
2004, Emery, 2002). Quantitative muscle ultrasound has been successfully used to 
differentiate between typical myopathies and neuropathies in adults (Mauritis et al. 
2003) and there also appears to be a robust correlation with the fibrous tissue content 
(Pillen et al. 2008). Whilst there has only been one prospective study in 28 adults there 
have been a few in children evaluating the role of muscle ultrasound. The study by 
Mauritis and colleagues in the adult population addressed the issue of quantitative 
muscle ultrasound, and whilst these quantitative techniques were able to distinguish 
between healthy and affected musculature, there was failure to determine distinct 
disease entities. Patients with dystrophic myopathies, inflammatory myopathies and 
motor neurone disease (ALS) were enrolled, however the study size was small at n=28 
and many parameters that have previously been used to diagnose these patients were not 
used, including the presence of fasciculation in ALS and oedema that can be 
demonstrated in inflammatory myopathies.  
In a paediatric study, by Pillen et al. (2007), a highly predictive value between 86- 91% 
was demonstrated in 150 children, from 1 week to 17.5 years, for the detection of any 
neuromuscular disorder. This was similar to the sensitivity of 78% and specificity of 
91% reported by Zuberi et al. (1999) in detecting any neuromuscular disorder, which 
increased to a sensitivity of 81% and a specificity of 96% in children over 3 years of 
age. These studies therefore demonstrate that muscle ultrasound as a suitable as a 
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screening tool for detecting a neuromuscular condition in children (Pillen et al. 2006a). 
In specific neuromuscular diseases these sensitivities are different, approaching 100% in 
clinically affected patients with DMD (Pillen et al. 2007), but only reaching 25-45% in 
mitochondrial myopathies (Pillen et al. 2006b). The diagnostic value in other specific 
neuromuscular diseases has not been studied, and only small series have been reported. 
In children under 3 years, the sensitivity decreases due to structural changes in the 
muscle are usually very minor at this early age, however if there is an abnormality 
detected the further more invasive tests would be required.  
The pattern of muscle involvement can also be described with ultrasound and this as 
with MRI and computerised tomography (CT) can help with the differential diagnosis. 
Muscle ultrasound can also detect suitable muscles to obtain muscle biopsies from, and 
hence prevent biopsies from too severely affected muscles which have pronounced 
fibrosis and atrophy and are uninterpretable (Lindequist et al. 1990).  
Muscle US changes in muscular dystrophies were first described in DMD (Heckmatt et 
al. 1980). Preclinical cases of DMD can have a normal US unlike the changes seen in 
MRI, but once the first clinical signs manifest, then muscle ultrasound is found to be 
abnormal in almost every patient. The proximal muscles have the highest echo 
intensities and the within the muscle there is a homogeneous, fine granular appearance 
(Heckmatt et al. 1982, Fisher et al. 1988). These findings were similar in patients with 
Becker Muscular dystrophy as well as LGMD, and the intensity increased with age and 
disease severity (Heckmatt et al. 1988b). This contrasted with the congenital muscular 
dystrophies (CMD) where all cases were severely affected with increased echo intensity 
but with no correlation with age (Heckmatt et al. 1982). In CMDs the clinical phenotype 
can often milder than the muscle biopsy results and imaging. In Bethlem myopathy, a 
collagen VI disorder, there is an abnormal peripheral signal with relative sparing of the 
central portion of the muscle, particularly seen in the vasti and the hamstrings. This also 
appears as a common finding on MRI in Bethlem myopathy (Mercuri et al. 2002, 
Mercuri et al. 2005a, Mercuri et al. 2005b). There is also a typical „central shadow sign‟ 
which can be detected, whereby the middle part of the rectus femoris appears echo 
dense in the anterior middle part of the muscle and this is also demonstrated on 
ultrasound images (Bonnemann et al. 2003). 
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Real-time ultrasound elastography (RTE) is an ultrasound based estimation of strain in 
living tissues. RTE is increased when the tissue is stiffer, with fibrous or dystrophic 
tissue, whereas it is reduced in areas of fat. In a case report of a patient with Bethlem 
myopathy, RTE was used to evaluate the elastic properties of the musculocutaneous 
tissue. This case report demonstrated that the patient‟s muscles on RTE correlated with 
the „central shadow‟ findings on MRI and ultrasound. This is the discrete rim of high 
signal intensity seen at the periphery, in this case, of the vastus lateralis and biceps 
femoris with central sparing. The RTE correlated with the above images, with increased 
stiffness detected in the periphery of these muscles. There was also an interesting 
finding that vastus medialis, not particularly affected on the MRI and ultrasound, 
demonstrated increased stiffness at the periphery. This finding was not seen on either 
the US or MRI. This may indicate that RTE may be more sensitive at detecting 
dystrophic change in this group of patients and therefore further work will be required 
to determine whether this is a sensitive predictor of early change (Drakonaki and Allen, 
2010).  
2.1.3 – Discussion 
US is therefore a useful imaging tools in experienced hands and has the advantage over 
MRI and CT as being relatively inexpensive, child friendly and portable. It‟s main 
disadvantage however is that it is a subjective measurement when used qualitatively and 
has poor visualisation of the deeper structures. In paediatric patients, it has high 
sensitivity and specificity in detecting a neuromuscular disorder from a normal muscle 
particularly in the older children, and can distinguish certain neuromuscular disorders. 
This however is not true for the adult population where affected musculature from 
healthy was discriminated, but distinct disease entities could not.  
2.2 - Computerised tomography (CT) 
2.2.1 – CT; how it works. 
Computerised tomography (CT) was invented by Sir Godfrey Hounsfield and was first 
installed and used in a patient in 1971 (Richmond, 2004). X-ray CT is a technique 
which produces two-dimensional and three-dimensional cross sectional images from flat 
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X-ray images taken around a single axis of rotation (Herman, 2009). Fundamentally CT 
imaging deals with constructing an image from projections, which are caused by x-ray 
attenuation. X-ray attenuation is the reduction of intensity of the x-ray beam as it 
traverses matter, such as muscle, bone and fat. The reduction may be caused by an 
absorption or deflection of protons from the beam and this can be affected by a number 
of different factors including, the beam intensity or physical characteristics of the 
tissues. The characteristics of the tissues being imaged include both the density of that 
tissue as well as its atomic number. The greater the atomic number or density of the 
tissue, the greater the attenuation, hence fat appears bright of CT, but not as bright as 
compact bone.  Projection reconstruction is then used to generate a three dimensional 
image. CT produces a volume of data that can be manipulated through a process known 
as “windowing”, in order to demonstrate various structures within the body by blocking 
the beam of the X-rays. Whilst historically this was performed in the axial or transverse 
plane, orthogonal to the long axis of this body, more modern scanners can now reformat 
the volume of data into various planes or as volumetric (3D) representations of 
structures (McKetty, 1998). 
The radiodensity of the image can be quantitatively graded using the „Hounsfield unit 
scale‟ (Richmond, 2004). 
2.2.2 - Clinical application 
CT has been used widely in the past to evaluate the presence and the degree of change 
seen within the skeletal muscles of patients with neuromuscular disorders. It was first 
used by O‟Doherty et al. in 1977 for imaging cases of DMD. With the increasing CT 
technology, speed splice count and image quality have improved therefore enabling 
assessment of the muscles with respect to shape and level of dystrophic change, in 
particular fatty infiltration. However it is not very sensitive at detecting oedema, the 
early inflammatory change that can be seen before overt dystrophic change in the 
muscle. This is due to the limited soft tissue contrast. CT imaging is relatively operator-
independent, unlike ultrasound, and in comparison is able to evaluate and image deeper 
muscles. The newer CT techniques have enabled spatial resolution and multi-planar 
reconstructions. The main disadvantage that CT has over US and MRI is the relatively 
high dose of ionising radiation; this means that imaging particularly in children using 
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this modality is difficult to justify ethically in the absence of treatment options. The 
radiation dose increases with coverage, meaning that whole body scans to delineate the 
pattern of muscle involvement in neuromuscular conditions are difficult to justify to 
research ethics boards (Wattjes et al. 2010).  
2.2.3 - CT use in neuromuscular disorders 
In DMD there have been a number of studies which assess the pattern of infiltration in 
the muscles of the lower limb in patients with mild, moderate and severe disability. 
Hawley et al. (1984) observed gross changes in the cases from mild to total disability 
and reported a sparing of the gracilis muscle and sartorius muscle. The selective 
involvement in „mid-stage‟ DMD were reported by Stern et al. (1984) and Kawai et al. 
(1985) and both reported the sparing of the gracilis muscle and sartorius muscle as well 
as the peroneus muscle and tibialis anterior and posterior muscles in the lower leg.  
In BMD, the same pattern of sparing was also observed (Termote, 1980, Bulcke, 1981). 
Arai et al (1995) studied the use of CT in early DMD patients, aged 6 months to 12 
years, who were reported to be preclinical with motor skills still continuing to develop. 
His group used Hounsfield units and correlated this with the age of the patient. The 
Hounsfield units refer to the density of the muscle seen on CT imaging. Other authors 
have used Hounsfield units to assess the degree of muscle involvement (Termote, 1980, 
Stern, 1984, Bulcke, 1981, Stern, 1985, Nordal, 1988); however unlike Arai et al 
(1995), they used a method that automatically generated Hounsfield units from an 
arbitrary region of interest (ROI) within the muscle, rather than the whole muscle as 
performed by Arai et al (1995). Whilst the other studies on DMD have assessed the 
muscle damage in the later stages of the disease, Arai et al has assessed the preclinical 
group and attempted to analyse the scans in an objective, quantitative manner rather 
than the visual, subjective and qualitative review that have previously been reported. 
Interestingly the group does show that there are changes in Hounsfield units of the CT 
in individual muscles and in particular those that visually do not appear to be affected. 
The Hounsfield units are less affected in the muscles that are generally well preserved, 
such as the anterior and posterior tibialis muscle, and a very slow and gradual regression 
rate was reported in the gracilis muscle reflecting the so-called selective pattern of 
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involvement seen in DMD even in the preclinical stage. This regression rate was 
analysed cross sectionally correlating the degree of disease severity seen in the boys 
clinically with the Hounsfield units obtained from the CT in the gracilis muscle.  Whilst 
this study was important from a quantitative perspective and identified that gross visual 
inspection alone is insufficient, there was no longitudinal data and no aged matched 
controls.  
In LGMD, Vlak et al. (2000) assessed 6 patients, 2 with sarcoglycanopathy (LGMD2D) 
and 4 with dysferlinopathy (LGMD2B). In these patients there was a possible 
relationship between those scoring low MRC grades (MRC 1-3) in their physical 
examination and the grades obtained on the CT images, however the numbers of 
patients assessed were small (n=6). Those with MRC grades 4 or above either had 
normal CT grades or severely affected, this was not qualified further in the paper. 
2.2.4 - Discussion 
CT is an imaging modality which is able to demonstrate the abnormal patterns of 
muscle involvement seen particularly in muscular dystrophy. It is a quick and relatively 
readily available imaging tool and has the advantage of being able to visualise deeper 
muscle structures compared to ultrasound. It is easy to use, non-invasive and can be 
analysed both qualitatively and quantitatively. It does however have the major 
disadvantage of ionising radiation, which in the context of research and with a lack of 
definitive treatment for LGMD2I at present, means that paediatric and longitudinal 
studies are not ethically justifiable.. The other disadvantage as stated earlier is the low 
level of soft tissue contrast, compared to MRI, and hence the lack of ability to detect 
early changes in muscles before the dystrophic process has become established.  
2.3 - Magnetic Resonance Imaging (MRI) 
In this subchapter I will describe the basics of MRI and how these can be applied to 
neuromuscular imaging and in particular the LGMDs. I will then conclude with a 
literature review of the MRI changes seen within this group of disorders, including the 
dystrophinopathies, the LGMDs and the congenital myopathies, and how the use of 
MRI can be applied both on a clinical basis and as a research tool. 
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2.3.1 - Magnetic Resonance imaging – how it works 
The initial concept for the medical application of nuclear magnetic resonance (NMR), 
originated in 1971, however due to the problems of low signal and high sensitivity to 
motion, body magnetic resonance (MR) was not widely practised until the 1990s 
(McRobbie, Moore et al. 2003).  
MRI is an imaging technique that uses the property of NMR to image nuclei of atoms 
inside the body. The essential requirement for MR is the magnet and the signals that 
produce the diagnostic information. These signals are produced from the patient‟s 
tissues in response to applied radiofrequency (r.f.) pulses which are generated and 
received by rf coils. These are usually built into the magnet (McRobbie, Moore et al. 
2003). Locally shaped coils, such as a knee coil, are only used as receivers and have 
better signal reception as they fit closer to the anatomy of interest and are therefore 
more sensitive (Elster and Burdette, 2001). The signals received are weak and therefore 
are sensitive to electrical interference. A special cage called the „Faraday cage‟, shields 
against interference from the surroundings and is built into the walls, ceiling, floor and 
door of the magnet room. 
The magnetic field strength is an important factor as it determines the maximum image 
resolution and scanning speed. Higher magnetic fields amplify the signal/noise ratio 
(the ratio of signal power to the noise power corrupting the signal; SNR) and hence 
higher resolution or faster scanning times are possible by comparison with lower field 
magnets. Higher magnetic field strengths require more expensive magnets. In this study 
we have used 3.0T  scanners. 
The homogeneity of the field is also important. This relates to the quality of uniformity 
of the magnets field. If poor this can lead to degradation and artefacts. The homogeneity 
of the field determines the maximum special resolution of the image (McRobbie, Moore 
et al. 2003). 
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The basic principles 
The basic principle underlying NMR and MRI is that all isolated nuclei or particles 
possess an intrinsic angular momentum known as spin, in addition to any angular 
momentum caused by rotation of the molecules. The component of the spin angular 
momentum, P, in the z direction, Pz is given by, 
Iz M
h
P
2
   
Where MI  is the spin quantum number related to I, the spin number of the nucleus in 
question. MI can take values of –I, -I+1…I-1, I. The hydrogen nucleus and the 
phosphorus nucleus have a spin number  1/2, meaning that the spin quantum number MI 
can only take the values -1/2 or +1/2 The magnetic moment of the nucleus, μ, is related 
to P by the following equation; 
μ = γ P 
where γ is the gyromagnetic ratio of the nucleus, and has a distinct value for each 
nucleus. Only nuclei that possess a magnetic moment can be detected and measured by 
NMR. When an external magnetic field is applied, B0, the two spin angular momentum 
states have different energies, the energy difference, ΔH between the two states are 
dependent upon the gyromagnetic ratio (γ) of the nucleus and the magnetic field 
strength (B0), thus, 
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Nuclei can be made to move between the two energy states by applying electromagnetic 
radiation of frequency v0 (in Hz) or ωo (in rad s
-1) with energy ΔH = hvo = hωo/2π which 
can be expressed in terms of the Larmor frequency or resonance frequency; 
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This means that for a 3.0T scanner, with γ= 42.6 MHz T-1, the gyromagnetic ratio for 
1H, the resonance frequency is 127.8MHz: for phosphorus with γ= 17.3 MHz T-1, the 
resonance frequency is 51.8MHz. A radiofrequency (r.f.) pulse therefore set at the 
relevant resonance frequency results in sinusoidal MR signals, which will be detected 
by the receiver coil at the same frequency. The proportionality of field and frequency 
underlies the process of image acquisition. After the excitation pulse, the r.f. pulse is 
discontinued and the r.f. coil is used to detect the signal from the sample as it loses 
energy and returns to the equilibrium state. The decay of these oscillatory signals is 
determined by relaxation processes which are the basis of the T1weighted scans and T2 
weighted scans which will be described below (McRobbie, Moore et al. 2003). 
In order to image objects, we must distinguish the spatial origin of spin signals. We can 
use magnetic field gradients to do this. Gradient coils produce an small additional 
gradient in the main magnetic field, such that the total magnetic field strength varies 
linearly by position along the applied axis. These gradients produce images from the 
localisation of the MR signals in the body, by creating short-term spatial alterations in 
magnetic field strength across the patient. A stronger gradient enables more detailed and 
specific anatomical characteristics to be visualised and allows faster scanning 
(McRobbie, Moore et al. 2003).  
2.3.2 - MRI – Basic scans 
T1 weighted (T1w) scans are one of the most common image types utilised and have 
been used in this study. They differentiate fat from water, using a gradient echo 
sequence with a short echo time (TE) to minimse T2 weighting (T2w) and a short 
repetition time (TR). After nuclei have been excited by an r.f. pulse, they have excess 
energy. As the system returns to equilibrium, with recovery of the longitudinal part of 
the magnetisation (Mz ,) this energy is redistributed to the surrounding environment, or 
„lattice‟, and this process is known as spin-lattice relaxation. Between each signal 
acquisition and the next excitation, there must be a delay (the recycle time, TR). When 
the recycle time is shorter, longitudinal magnetisation does not fully recover and 
therefore the signal becomes saturated. Therefore on T1w images the fat containing 
tissues appears bright, due to the short relaxation time whereas the fluid containing 
tissues are dark. Due to the short TR this scan can be run very fast and can collect high 
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resolution 3D datasets. It therefore can highlight fat deposition well (McRobbie, Moore 
et al. 2003). 
The other method of relaxation is spin-spin relaxation (T2 relaxation), where the phase 
coherence of the spins is lost across time. In T2w scans, fat again is differentiated from 
water, but in this case the water appears bright due to the long T2 relaxation time.  
Damaged tissue tends to initially develop oedema, the unbound fluid having a long T2 
relaxation time appears bright and therefore makes T2w scans  useful for identifying 
pathological tissue. T2 weighting is created with  long TE and avoiding T1 weighting 
with long TR. (McRobbie, Moore et al. 2003).  
2.3.3 - Quantitative MRI. 
Quantitative MRI methods such as T2 relaxation time, magnetic resonance spectroscopy 
(MRS), perfusion imaging and muscle fat quantification using the 3 point Dixon 
technique are all tools that can be used to analyse and quantify the degree of pathology 
in the striated muscle. The 3 point Dixon technique, used in this study on LGMD2I, is a 
powerful way to quantify the individual contributions of fat and water in each voxel of 
tissue, from which the fat fraction is calculated for detection of signal intensity from 
small numbers of fat protons (Dixon, 1984).  In this approach, the chemical shift 
difference between water and fat is encoded into images with different echo shifts           
(Kovanlikaya A et al. 2005a, Kovanlikaya A et al. 2005b). This technique, in part 
developed to overcome sensitivity to magnetic field inhomogeneity, has been found 
highly reproducible, accurate, and useful for in vivo quantification of fat in lean tissues, 
such as skeletal muscle (Kovanlikaya A et al. 2005a, Kovanlikaya A et al. 2005b). 
2.3.4 – Clinical application of MRI in neuromuscular disorders 
The interest in using MRI in neuromuscular conditions has been increasing over the last 
decade, however most studies in the literature have been limited by small numbers, are 
qualitatively scored and cross sectional rather than longitudinal. During this time 
substantial progress has also been made in the genetic diagnosis of many neuromuscular 
conditions, defining and redefining dystrophic and non dystrophic conditions of skeletal 
muscle. Imaging has also contributed to this process of diagnosis, providing images of 
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the lower limb muscles predominantly and defining the differential involvement of 
different muscle groups. This pattern of muscle involvement can help to distinguish 
between certain muscle disorders and if particular patterns are seen, such as the „central 
shadow‟ in Bethlem (Chapter 2.1.2) can be almost pathognomonic, hence narrowing the 
differential diagnosis (Mercuri et al. 2005a).  
Assessing skeletal muscle by MRI can provide information on  both the  shape and 
volume of the muscles and in particular whether a muscle is hypertrophied or atrophied, 
and also the architecture (Mercuri et al. 2005b, Mercuri et al. 2007). MRI is a relatively 
safe modality and attractive as an imaging method due to lack of ionising radiation, 
however in some circumstances, such as with very young patients, sedation may be 
required. MRIs are typically performed using a multi-sequence approach obtaining T1w 
and T2w images as well as fat suppressed images. The images are typically acquired in 
the axial plane and are approximately 5-7mm thick however other anatomical planes 
have been used, such as coronal or sagittal (Wattjes et al 2010).  
Using these approaches previous MRI studies have detected changes in dystrophic 
muscles and been able to identify patterns of involvement in certain conditions. These 
changes include initial inflammation and oedematous changes, picked up best on T2w 
fat suppressed images and fatty degeneration and atrophy on T1w images. As 
commented in the earlier chapter, chapter 2.2, MRI has been shown to have a higher 
degree of sensitivity and specificity than CT for detecting this early inflammatory stage. 
(Ozsarlak et al 2001, Schedel et al 1992). 
There is a number of rating scales used to access T1w images of muscle, with many 
assessments being made based on the scales derived by Mercuri et al (2002a/2002b), 
Kornblum et al (2006) and Fischer et al (2008). All these scales are based on a visual 
judgement on the degree of fat infiltration from normal-appearing muscle to severely 
affected, with only a fascial rim and neurovascular structures distinguishable (table 
2.1). 
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Grade Mercuri et al. 2002a/b Kornblum et al. 2006 Fischer et al. 2008 
0  Normal appearance Normal appearance 
1 Normal appearance Discrete moth-eaten appearance 
with sporadic T1 hyperintense areas. 
Mild: traces of increased 
signal intensity on the T1 
weighted MR sequences. 
2a/2 Mild involvement; Early moth-
eaten appearance with scattered 
small areas of increased signal or 
with numerous discrete areas of 
increased signal with beginning 
confluence, comprising less than 
30% of the volume of the 
individual muscle. 
Moderate moth-eaten appearance 
with numerous scattered T1 
hyperintense areas. 
Moderate: increased T1 
weighted signal intensity 
with beginning confluence 
in less than 50% of the 
muscle. 
2b  Late moth-eaten appearance with 
numerous confluent T1 hyperintense 
areas. 
 
3 Moderate involvement; Late 
moth-eaten appearance with 
numerous discrete areas of 
increased signal with beginning 
confluence, comprising 30-60% 
of the volume of the individual 
muscle. 
Complete fatty degeneration, 
replacement of muscle by 
connective tissue and fat. 
Severe: increased T1 
weighted signal intensity 
with  beginning 
confluence in more than 
50% of the muscle 
4 Severe involvement; Washed out 
appearance, fuzzy appearance due 
to confluent areas of increased 
signal or end stage appearance 
with muscle replaced by 
increased density connective 
tissue and fat, and only a rim of 
fascia and neurovascular 
structures distinguishable. 
 End stage appearance, 
entire muscle replaced by 
increased density of 
connective tissue and fat. 
 
Table 2.1: Summary of the three well established rating scales on MRI concerning the 
visual rating of dystrophic change in striated muscle. 
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2.3.5 - MRI imaging in neuromuscular disorders 
(i) The Dystrophinopathies  
The dystrophinopathies (DMD/BMD) are the most common muscular dystrophies 
worldwide, with DMD affecting one in 3,500 boys (Hoffman et al 1987). The patients 
present with progressive muscle weakness by the age of 5 years and if untreated will 
lose ambulation in their early teens, with death in their late teens/early twenties.  
Due to the progressive nature of DMD, there has been a need to develop an objective 
and non invasive measurement of disease progression. Muscle MRI allows evaluation 
of the muscle over time, and whilst standard T1w images may be normal in the early 
stages of the DMD, after six to seven years there is progressive involvement evident.  
The abnormal signals are initially confined to the gluteus maximus and adductor 
magnus, followed by involvement of the quadripceps, rectus femoris and biceps 
femoris. There is relative sparing of the sartorius, gracilis, semimembranosus and 
semitendinosus (Liu et al 1993). In the lower leg the gastrocnemius muscles are affected 
earlier than the other muscle groups, however on T2w and STIR images, oedematous 
changes and signs of inflammation can be seen in the muscles not thought to be affected 
on the standard T1w, where normal signal intensity is seen. These findings are 
interesting as they do suggest an inflammatory element, or phase of necrosis associated 
with oedema, pre-dating the fibrotic /dystrophic change seen later (Mercuri et al, 2007). 
Whilst there have been many studies assessing the pattern of fatty infiltration and 
temporal change, Wren et al (2008) demonstrated, by using the 3 point Dixon 
technique, that quantification of fat infiltration was possible. They correlated these 
findings with both histopathology results and functional testing. They demonstrated that 
whilst there was a strong correlation with disease progression, as indicated on the 
functional testing, manual muscle testing and myometry were not as strong. The 
limitation of this study was its small size, nine patients, and no control data. It did 
however demonstrate that quantitative MRI by 3 point Dixon is a useful non invasive 
tool, which correlates strongly with disease progression and in particular functional 
testing. It was not reliant on patient effort and in a paediatric condition this is vitally 
important. 
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(ii) Early onset Limb girdle muscular dystrophies 
Clinically the limb girdle muscular dystrophies (LGMD) represent a heterogeneous 
group of conditions and late onset BMD patients and manifesting female carriers of the 
DMD mutation may often fall into the differential diagnosis of LGMD. This overlap is 
particularly seen with LGMD2I as respiratory and cardiac involvement is common to 
both BMD and manifesting carriers of DMD, as well as LGMD2I.  
The MRI changes, however, are very different. With respect to the pattern of infiltration 
in the thigh, dystrophinopathies have pronounced signal changes in the anterior 
compartment rather than the posterior compartment, as seen in LGMD2I. 
In Northern European countries, LGMD2A, LGMD2I and LGMD2B are probably the 
most common LGMD forms. Previously a muscle biopsy has been required to 
distinguish between the different sub-types; however MRI can now help to direct the 
clinician towards the genetic analysis.  
As covered in  chapter 1.1.3, a novel gene encoding FKRP was described and 
discovered to be responsible for an early onset congenital muscular dystrophy 
(MDC1C) and also a less severe phenotype, LGMD2I (Mercuri et al 2003, Poppe et al 
2003). It has been reported that LGMD2I patients have a characteristic phenotype on 
muscle MRI, with involvement of the adductor muscles, and the posterior compartments 
of both the thigh and lower leg.  
In previous studies, specific temporal patterns have also been highlighted, with the 
initial stages of the disease associated with gluteus maximus muscle involvement more 
severely and earlier than the gluteus medius muscle in the pelvic region. In the thigh the 
adductor magnus muscle and biceps femoris muscle were often involved first, and with 
further progression of the disease it has been reported that the rest of the hamstrings 
become involved and eventually the anterior thigh muscles, vastus lateralis and vastus 
intermedius muscles. Vastus medialis muscle and rectus femoris muscle, to date, have 
only been involved in patients that are advanced in disease severity.  Sartorius and 
gracilis muscles are relatively spared and often hypertrophied (Fisher et al. 2005).  
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In the lower leg in LGMD2I it has been documented that again there is a posterior 
pattern of involvement and that the infiltration of the gastrocnemius muscles are diffuse 
and uniform. The anterior compartment of the lower leg was often spared until late on in 
the disease process. The tibialis anterior muscle was usually spared and often 
hypertrophied (Wattjes et al. 2010). 
In LGMD2A, Calpainopathy, caused by a mutation in the Calpain-3 gene, there appears 
to be very similar involvement on the muscle MRI in comparison with LGMD2I. There 
are however a few differences in the MRI which allows some distinction. In the thigh 
there is the similar pattern of posterior involvement, with infiltration of the gluteus 
muscles, biceps femoris muscle, adductor muscles and the semimembranosus muscle 
with relative sparing of the vastus lateralis muscle, sartorius muscle and gracilis muscle. 
(Wattjes et al. 2010, Mercuri et al. 2005c) There does appear to be more sparing of the 
vastus lateralis muscle in the thigh.  
In the lower leg, whilst there is again posterior preference in infiltration, there are more 
selective changes seen in the medial gastrocnemius muscle and soleus muscle than in 
LGMD2I, where the pattern of infiltration appears more diffuse. The tibialis anterior 
muscle is also less likely to be hypertrophied compared to LGMD2I. 
LGMD2B, dysferlinopathy, is caused by a mutation in the dysferlin gene. This mutation 
produces a predominantly distal Miyoshi myopathy and also a form of a distal anterior 
compartment myopathy (Liu et al. 1998, Illa et al. 2001). The MRI in this LGMD is 
different to LGMD2A and LGMD 2I, as both posterior and anterior compartments are 
affected in the thigh, with sparing of sartorius muscle and gracilis muscle. The pattern 
of muscle involvement can be more variable compared to other LGMDs. This is 
predominantly due to the variable clinical presentation of distal anterior weakness, distal 
posterior weakness and proximal lower limb weakness (Illa et al. 2001). It has been 
reported that changes in the posterior thigh exceeded the changes in the anterior thigh 
muscles (Cupler et al. 1998, Linssen et al. 1997, Mahjneh et al. 2001, Miyoshi et al. 
1986).   
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In the lower leg there is posterior involvement but with selective sparing of the medial 
head of the gastrocnemius muscle (Illa et al. 2007, Kesper et al. 2009). This is distinct 
from the other LGMDs described earlier (Fisher et al. 2005).  
Clinically LGMD2D can be differentiated from the other LGMDs, and in particular 
LGMD2I, as the calf muscles are often the earliest and most severely affected, leading 
to weakness of plantarflexion. This remains strong in LGMD2I patients even in 
advanced stages. There is also the absence of scapular winging and cardiac 
involvement, commonly seen in LGMD2I (Linsenn et al. 1997, Miyoshi et al. 1986, 
Weiler et al. 1999). 
(iii) Congenital Myopathies 
The congenital myopathies are generally characterised usually by non-progressive 
muscle weakness, hypotonia, and presentation at birth or shortly after with delayed 
milestones, plus or minus contractures. 
Collagen VI disorders primarily cause two forms of muscle disease. Bethlem myopathy 
is an autosomal dominant myopathy, characterised by early onset, with a slow 
progressive course and contractures, mainly the elbows, long finger flexors and ankles. 
The other condition is Ullrich congenital muscular dystrophy which is autosomal 
recessive and is characterised by generalised muscle weakness, hyper laxity of the distal 
joints with contractures of the more proximal joints. It is associated with early 
respiratory involvement and normal intelligence.   
The MRI images of these two conditions have characteristic findings. In the thigh of 
BM patients there is a consistent finding of an abnormal signal around the periphery of 
the vasti, with the central part spared (Mercuri et al. 2005a), another frequent finding is 
that of a „central shadow‟ seen in the rectus femoris. This had previously been observed 
in a family with BM using muscle ultrasound (Bonnemann et al. 2003).  
In Ullrich congenital muscular dystrophy, there was a more diffuse involvement at the 
thigh level with relative sparing of the gracilis, sartorius muscle and adductor longus 
muscles. The vastus lateralis muscle also exhibited the same concentric involvement as 
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seen in BM. The „central shadow‟ seen in BM was observed in the Ullrich congenital 
muscular dystrophy patients, however not as obvious (Mercuri et al. 2005a). 
In the lower leg level, there was a rim of peripheral involvement between the 
gastrocnemii muscles and the soleus. This change was more striking in the less affected 
BM patients. 
Mutations in the skeletal muscle ryanodine receptor RYR1 gene are associated with a 
wide variety of phenotypes including central core disease (CCD) (McCarthy et al. 
2000), CCD with nemaline rods ( Monnier et al. 2000), Multi-minicore disease (MmD) 
(Ferreiro et al. 2002, Jungbluth et al. 2002) and the malignant hyperthermia 
susceptibility trait without muscle biopsy abnormalities (McCarthy et al. 2000).  
The MRI shows a characteristic pattern with main involvement at the pelvic level in the 
gluteus maximus muscle, at the thigh level in the medial compartment (the adductor 
magnus muscle) and the anterior compartment (the vastus lateralis muscle and vastus 
intermedius muscle). Sparing of the adductor longus muscle, gracilis muscle and biceps 
femoris muscle is common. In the lower leg the soleus muscle and lateral head of 
gastrocnemius muscle are the most severely affected (Jungbluth et al. 2004). 
Congenital muscular dystrophy with early rigidity of the spine (RSMD1), due to 
recessive mutations in the selenoprotein N (SEPN1) gene (Mercuri et al. 2002a) often 
show a selective infiltrative pattern of the posterior thigh muscles and sartorius muscle 
with sparing of the quadriceps muscles and the gracilis muscle. 
2.3.6 - Discussion 
The importance of clinical muscular imaging is becoming increasingly evident when 
assessing patients with a suspected or known inherited muscle disease. Whilst muscle 
US is safe and easily transportable it is operator dependent and visualisation of deeper 
structures can be difficult. CT scanning on the other hand is quick, easy and operator 
independent but has limitations dues to its poor soft tissue contrast and high ionising 
radiation dose, therefore making it unsuitable for paediatric cases and longitudinal 
studies. MRI, whilst relatively expensive does not have these side effects.  
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Cross sectional data is available on numerous neuromuscular conditions and has defined 
the pattern of muscle involvement in many of the muscular dystrophies and congenital 
myopathies. This has provided guidance to clinicians for further investigations such as 
muscle biopsy, further imaging and genetic testing. 
Whilst in the past we have concentrated on the lower limbs and the pattern of muscle 
involvement seen in the thigh and lower leg, full body MRIs allow the imaging of 
organs and tissues other than striated muscle to be viewed. This would demonstrate 
further characteristics in these rare neuromuscular diseases which, as we become 
increasingly aware of the complexity of them, highlight the interplay they have with 
many vital structures such as the heart. 
More recently there has been a shift to using more quantitative methods to demonstrate 
pathological damage in striated muscle. Quantitative MRI techniques such as T2 
relaxation times, muscle fat quantification using the 3-point Dixon technique, magnetic 
resonance spectroscopy and perfusion images are all modes that can be employed to 
analyse the pathological changes seen in muscle. 
These techniques are extremely useful in longitudinal studies to accurately chart the 
change in muscle infiltration in individual muscle diseases. If therapeutics are to 
advance there needs to be a robust, sensitive and objective tool for monitoring 
improvement as well as disease progression. Further work is required to assess whether 
these methods provide a viable monitoring tool in the individual muscle diseases. In this 
study we used both the 3 point Dixon technique and magnetic resonance spectroscopy 
in assessing the LGMD2I patient cohort both on cross sectional basis and 
longitudinally. 
2.4 – Skeletal Magnetic Resonance Spectroscopy 
Magnetic Resonance Spectroscopy (MRS) is a non-invasive technique that measures the 
concentration of specific chemical compounds within a tissue using radiofrequency 
pulses and strong magnetic fields. MRS produces a spectrum which is a plot of signal 
intensity versus frequency that shows the chemical shift or frequency difference 
between different elements. The chemical shift is measured in parts per million (ppm). 
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The chemical compounds that can be detected depend upon the nuclei being studied 
(
1
H, 
13
C, 
31
P, 
23
Na). For these chemical compounds to be detected they also need to be 
of sufficient concentration and in the case of  
31
P (phosphorus-31), which we are using 
in our study, a concentration of approximately 1mM. It also needs to have a unique 
spectral line that has a chemical shift that distinguishes it from other chemical species 
containing 
31
P (Argov et al. 2000).  
2.4.1 - 
31
P MRS 
31
P (phosphorus-31) magnetic resonance spectroscopy has been used in the study of 
muscle disease since the early 1980‟s (Gadian et al. 1981, Ross et al. 1981). Phosphorus 
MRS records signals from phosphate-containing metabolites involved in energy 
metabolism in vivo. It is useful for studying muscle metabolism in the resting, 
exercising and recovery phase, both the oxidative and glycolytic pathways (Argov et al. 
2000). The phosphorus spectra consists of a number of  peaks, 3 from adenosine 
triphosphate (ATP), one from phosphocreatine (PCr), one from inorganic phosphates 
(Pi) and two other peaks detected are those from the phosphomonoesters (PME) and the 
phosphodiesters (PDE).  PDE has a role membrane in catabolism as the peak is seen to 
increase in membrane breakdown (Younkin et al. 1987). The area under each peak is 
proportional to the concentration of the metabolite (in the absence of T1 or T2 
weighting) and the horizontal distance between Pi and PCr that yields pH.  
Due to the non-invasive nature of MRS it can be repeated in a longitudinal study. It can 
also be used with the patient performing exercises as well as at rest; this will therefore 
provide information on muscle under stress as well as at rest and in the recovery phase.  
2.4.2 - The MRS at rest; 
Muscle homeostasis is maintained by the mitochondrial oxidative phosphorylation at a 
low metabolic rate. The ratio of muscle PCr to Pi is a measure of the energy state in 
muscle cells in vivo. Adenosine diphosphate (ADP) does not produce a peak that is 
visible on the spectra, as the unbound ADP concentration is too low at 10-25μM (Zohar 
et al. 2000). It does however regulate the rates of mitochondrial ATP production. The 
free ADP can be calculated using the creatine kinase (CK) equilibrium equation; [ADP] 
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= [ATP][Cr]/[PCr][H+]Keq, where Keq is the Creatine kinase equilibrium constant (1.7 x 
10
6
 L.mM, [TCr] is the total creatine concentration and is taken to be 42.5mM and 
[ATP] is adenosine triphosphate concentration and is taken to be 8.2mM (Arnold et al. 
1984, McGilvery et al. 1974).  
The Pi peak observed in the spectra is actually the combined peak of HPO4
2-
 and 
H2PO4. As the basic and acidic forms are in fast chemical exchange they are represented 
as one peak (Argov et al. 2000). The position of this peak is dependent on the 
concentration of protons in the chemical environment of the Pi i.e. the pH. The pH 
determined from this method is the cytoplasmic pH as the vast majority of the Pi peak 
originates from the cytoplasmic Pi, which is typically lower than the extracellular pH 
(pHi~7.0). This is due to the fact that the intracellular water space is approximately five 
times larger than extracellular water space and the intracellular phosphate concentration 
is approximately twice the extracellular concentration of phosphate in normal muscle 
(Bore et al. 1981).  
Inorganic phosphate  is removed from the cytoplasm by  transport into the mitochondria 
and by the ATPase reaction (Argov et al. 2000). Patients with mitochondrial disorders 
therefore have high Pi concentrations at rest, due to the dysfunctioning mitochondria. A 
raised Pi concentration can also been seen in conditions such as DMD and BMD as well 
as in patients with an inflammatory myopathy who do not have a primary mitochondrial 
disorder (Kemp et al. 1993, Younkin et al. 1987). 
2.4.3 - MRS during exercise; 
During exercise both glycolysis and oxidative metabolism generate ATP, which is used 
for muscle contraction, in mitochondria stimulated by raised concentrations of ADP. 
ATP is thus maintained at a steady state via the CK reaction which shuttles phosphoryl 
groups from PCr to ADP to generate ATP. This therefore maintains a constant 
concentration of ATP, however results in a decrease in PCr concentration and a 
corresponding increase in Pi concentration (Argov et al. 2000).   
During exercise the early changes in intracellular pH reflect the early proton 
consumption by PCr hydrolysis reaction and also the rising lactate levels from 
 52 
glycolysis. As exercise continues this may produce a more severe intracellular acidosis 
(pH<6.5) (Ryschon et al. 1997).  
2.4.4 - MRS during the Recovery phase; 
During the recovery phase, glycolysis ceases and oxidative phosphorlylation continues, 
therefore replenishing the phosphate stores used during exercise and restoring the pH to 
its resting value. The PCr concentration recovers post-exercise, because oxidative 
metabolism, stimulated by ADP continues to run at a high level, this produces ATP at a 
raised rate. A subsequent decrease in Pi and ADP is seen, as the pH returns to normal. 
The rate of recovery of these various metabolites provides information about the 
mitochondrial function (Argov et al. 1997). 
The PCr recovery rate is significantly affected by the pH generated during exercise 
(Arnold et al. 1984, Argov et al. 1996, Bendahan et al. 1990). The initial PCr 
resynthesis seems less affected by the pH in the first few seconds of recovery (Walter et 
al. 1997). As the type and intensity of exercise will affect the pH, this therefore is 
reflected in the PCr half time for recovery. ADP recovery is less affected by the pH 
after exercise compared to PCr (Iotti et al. 1993). ADP has been shown to be relatively 
unaffected by end-exercise conditions, such as pH and ADP concentrations. Initially the 
ADP rapidly falls and, depending on the degree of acidosis achieved with exercise, may 
fall below the resting ADP level. This „undershoot‟ reflects the degree of muscle 
acidosis (Argov et al. 1996, Wackerhage et al. 1998). The initial ADP decline and 
subsequent half life measurement appears to be an accurate reflection of mitochondrial 
function, both in healthy and disease states (Argov et al. 1997). 
The Pi recovery phase is 50% faster than that of PCr, this may be due to redistribution 
of the Pi into compartments that is not reflected in the MRS, such as the mitochondria 
(Iotti et al. 1991, Iotti et al. 1993, Miller et al. 1987). The observation is that activation 
of different muscle fibres might lead to the multiple Pi resonances and in our LGMD2I 
cohort may reflect the degree of fat fraction and the inhomogeneous nature that is seen 
(Yoshida et al. 1996). 
The recovery of the pH after acidifying exercise is dependent upon the proton efflux, 
the removal of protons from the cells, which requires active transport across the cell 
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membrane and removal from the extracellular space by perfusion.  PCr resynthesis also 
continues to produce protons, which adds to the acid load and means that pH may 
continue to fall for a time after cessation of exercise (Kemp et al. 1997). 
2.4.5 - Influencing factors 
There are a number of factors that need to be borne in mind when analysing results of 
MRS. These include gender and age, level of fitness, neuromuscular conditions 
including those with mitochondrial cytopathies, cardiopulmonary and respiratory status. 
In our study cohort of LGMD2I patients the age, level of fitness and the dystrophic 
process are the most likely contributors to the abnormal spectra. 
Generally women have a higher energy cost per muscle work and a larger consumption 
of PCr (Mattei et al. 1999) .Advancing age is associated with reduced oxidative capacity 
and hence response of pH and PCr will be different. The PDE peak increases with age 
(Taylor et al. 1997), and therefore it is important to have age matched controls in 
patients with muscle diseases, particularly those commencing in the older population, as 
in our cohort.  
The affects of physical fitness on MRS results have been extensively studied. 
Phosphorus MRS has been used to monitor skeletal muscle metabolic adaptations to 
aerobic training (McCully et al. 1988, Minotti et al. 1989, Takashashi et al. 1995). The 
type of exercise the individual does can influence the results and should be compared 
with a similar control individual. With deconditioning, such as in a chronic muscular 
disorder, there is a reduction in mitochondrial oxidative phosphorlylation, a lower pH 
during exercise and conversion to more anaerobic muscle fibre types evident. This is 
modest compared to patients with gross mitochondrial dysfunction( Argov et al. 2000).  
Cardiovascular and pulmonary reserve is obviously important in the oxidative 
metabolism and hence decreased oxygen delivery to the muscles will have a detrimental 
effect. This was evident both during exercise, with lower PCr and pH, and the 
prolonged recovery phase observed in normal healthy subjects who were exposed to 
reduced inspired oxygen (Haseler et al. 1999). Whilst primary lung disorders and 
peripheral vascular disease are not common in muscular dystrophies, cardiomyopathies 
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and respiratory failure (type II) are. These lead to a reduced oxygen tension and might 
cause impaired oxidative metabolism.  
In muscular dystrophy the main contributors to a change in the MRS metabolites could 
be aging, deconditioning and level of fitness. Cardiopulmonary impairment may have 
some influence on the spectra, however in our cohort neither the cardiac involvement or 
respiratory failure was severe. 
2.4.6 - MRS studies in Muscular Dystrophy 
There have been a number of studies examining patients with either DMD or BMD. 
These studies have demonstrated that in BMD and DMD there is a high intracellular Pi 
in association with a loss of PCr at rest (Kemp et al. 1993, Younkin et al. 1987, Griffiths 
et al. 1985, Newman et al. 1982). This therefore resulted in a high cytosolic ADP. It has 
been suggested that these changes could be the result of secondary mitochondrial 
dysfunction. There is also evidence of a progressive increase in the PDE peak possibly 
secondary to membrane breakdown (Younkin et al. 1987). These changes have also 
been demonstrated in the female carrier patients (Kemp et al. 1993, Barbiroli et al. 
1992a).  Membrane breakdown and sodium accumulation in the cells with associated 
“compensatory” proton extrusion has been postulated as leading to the intracellular 
alkalosis associated with the many neuromuscular patients.  Lodi et al. (1997) 
demonstrated that patients with a sacoglycanopathy, there was a direct relationship to 
muscle fatty infiltration detected on MRI and the cytosolic pH. The fatty fraction 
inversely correlated to the pH whilst directly correlating to the PCr/ATP ratio.  
During exercise there is an early reduction in PCr and a reduced acidosis is observed in 
BMD patients (Barbiroli et al. 1992b, Lodi et al. 1999). The reduced acidosis is not well 
explained to date. A reduced level of glycolytic or glycogenolytic activity has been 
assumed as there appears to be an abnormality in glucose metabolism that is common to 
dystrophinopathies. 
In DMD it has been shown with proton NMR studies that there are reduced levels of 
glucose, alanine and glutamine, a major gluconeogenic precursor. Further metabolic 
investigations have also demonstrated that there may be a reduction in the glycogenic 
pathway as reflected by a decrease in lactate and a relatively predominant oxidative 
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metabolism with an increase in α-ketoglutyrate. Loss of membrane integrity has been 
suggested due to a lowered choline and glycerophosphoryl choline (Sharma et al. 2003).  
Deconditioning cannot fully explain the changes either as you would expect an 
increased acidosis rather than a reduction (Argov et al. 2000). Normal mitochondrial 
function has been reported in BMD (Lodi et al. 1999), DMD (Kemp et al. 1993), 
sacoglycanopathy-deficient limb girdle muscular dystrophy patients (Lodi et al. 1997) 
and in oculopharyngeal muscular dystrophy (Zochodne et al. 1992) as demonstrated by 
the rate of ATP production during recovery.  
2.4.7 – Discussion 
31
P - MRS therefore represents a non invasive tool that can be quantified and 
longitudinally assessed in patients with neuromuscular disorders. These disorders 
studied to date do not include LGMD2I; rather concentrate on BMD and DMD. The 
only limb girdle muscular dystrophy studied with MRS has been LGMD2D, a 
sarcoglycan deficient LGMD. MRS can assess the level of muscle membrane stability 
and integrity reflected in the intracellular pH as well as in the PDE peak, and hence 
provide further insight into the muscles‟ handling of acidosis under stress such as 
exercise. This raises an interesting point that deconditioning can lead to a decreased pH 
and there is much debate at present as to the role of exercise in this group of patients 
and indeed whether programmed exercise can help. Further longitudinal studies would 
be needed to assess this in this cohort of patients.  
2.5 -Cardiac muscle imaging and spectroscopy 
2.5.1 - Conventional screening methods in detecting cardiomyopathy in muscular 
dystrophies 
The conventional tools for screening for cardiomyopathies are the electrocardiogram 
(ECGs) and transthoracic 2D echocardiogram (ECHO) used in combination. Muscular 
dystrophies are a heterogeneous group of conditions with variable phenotypes and 
prognosis. Cardiac complications occur in many muscular dystrophies, but the 
prevalence, precise nature and progression are specific to the genotype of the dystrophy. 
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Significant morbidity and mortality occurs due to the cardiomyopathy or conduction 
defects. Improvements in diagnostics, including molecular, histopathological and 
imaging have led to a greater understanding in the mutation-specific cardiac 
complications. This has subsequently led to improved surveillance and treatment. 
The dystrophinopathies, Duchenne muscular dystrophy and Becker muscular dystrophy, 
have cardiac involvement as do some of the limb girdle muscular dystrophies 
(LGMDs). Cardiomyopathies in particular occur in the sarcoglycanopathies (LGMD2D-
G) and in LGMD2I. Emery-Dreifuss muscular dystrophy (EDMD), an X linked 
recessive condition and the less common autosomal dominant EDMD, a  LGMD caused 
by a mutation in a gene encoding for lamin A and C, (LGMD1B), are also at risk of 
either cardiomyopathies or conduction defects (Beynon and Ray, 2008). 
In Duchenne muscular dystrophy, cardiac involvement is common and a considerable 
cause or morbidity and mortality with approximately 10-15% of all patients with DMD 
dying from the consequences of left ventricular dysfunction (Bushby et al 2003). There 
appears to be no correlation between the degree of skeletal involvement and heart 
involvement, but there appears to be a similar mechanism (Melacini et al. 1996). At 
autopsy the cardiac myocytes demonstrate hypertrophy, atrophy and fibrosis (Moriuchi 
et al. 1993). This is thought to be secondary to a loss of sarcolemmnal integrity leading 
to fibre necrosis and replacement with fat and connective tissue. The initial changes are 
usually seen after the age of 10 years; however there are reports of younger patients 
with cardiomyopathy (Vita et al. 2008). The initial change tends to be asymptomatic 
regional wall motion abnormalities with the posterobasal and lateral walls of the left 
ventricle affected. Conduction defects then become apparent as fibrosis becomes 
widespread. 50% of patients will show evidence of cardiomyopathy on ECHO at age 14 
years and this increases to almost 100% over 18 years of age with 75% showing cardiac 
symptoms (Beynon and Ray, 2008). 
Following an ENMC international workshop, guidelines for the screening of DMD 
patients and carriers were agreed (Bushby et al. 2003).  This involves cardiac screening, 
in the form of an ECG and ECHO at diagnosis or before the age of 6 years, with 
subsequent ECHO and ECG monitoring on a 2 yearly basis until 10 years then annually 
thereafter, unless an abnormality is detected earlier and requires intervention. For the 
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carriers, they are screened with an ECG and ECHO at diagnosis and then every 5 years, 
unless an abnormality is detected earlier and requires intervention. More recently the 
use of cardiac magnetic resonance imaging (CMR) has been used in these patients, 
particularly when borderline results are obtained. 
In Becker muscular dystrophy, as in DMD, the cardiomyopathy also does not correlate 
with the skeletal involvement: in particular, the cardiac involvement can predate the 
skeletal problems in BMD (Saito et al. 1996). In a study by Nigro et al. of 134 BMD 
patients, 50% had evidence of ECG changes by the age of 20 years and 40% had 
evidence of dilated cardiomyopathy on ECHO by 30 years. In the cohort of 134 
patients, 7 died over an average 8 year follow up period, 5 of those were from cardiac 
failure (Nigro et al. 1995). Guidelines for the monitoring of these patients were drawn 
up after the ENMC workshop (Bushby et al. 2003), similar to those of DMD. This 
involves cardiac screening, in the form of an ECG and ECHO at diagnosis, with 
subsequent ECHO and ECG monitoring on a 5 yearly, unless an abnormality is detected 
earlier and requires intervention. For the carriers, they are screened with an ECG and 
ECHO at diagnosis and then every 5 years, unless an abnormality is detected earlier and 
requires intervention. 
LGMD1B occurs both as an uncommon autosomal dominant and a rare autosomal 
recessive LGMD, both due to a mutation in the gene encoding for the nuclear proteins 
lamin A and C (Bonne et al. 1999). In LGMD1B left ventricular involvement is more 
common and increases with age independent of the skeletal involvement (Bonne et al. 
2000). Cardiac conduction defects are an ongoing problem, as in X-linked Emery 
Dreiffus Muscular Dystrophy (EDMD), and there is a high risk of sudden cardiac death. 
This risk of sudden death is not reduced by permanent pacemakers like in X-linked 
EDMD, suggesting a ventricular origin (Becane et al. 2000). Consideration therefore 
should be given to the placement of an implantable cardio defibrillator (ICD) if a 
pacemaker is required.  
In LGMD1B annual screening, as with X linked EDMD, with an ECG and holter 
monitoring should be undertaken, however in LGMD1B more frequent ECHOs are 
required as they do develop left ventricular involvement. 
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In LGMDs, cardiac disease is disease specific and hence accurate diagnosis is 
paramount. In the sarcoglycanopathies, LGMD2C-2F, the cardiomyopathy course can 
follow that of DMD and therefore screening as per DMD needs to be employed with 
annual assessments in the form of an ECG and ECHO. In LGMD2I, as referred to in 
chapter 1.1.2, previous studies have indicated variable degrees of cardiac involvement 
in LGMD2I patients with prevalence ranging from 10-50% in the literature using 
conventional screening tools such as the ECG and echocardiography. Reduced left 
ventricular ejection fraction (LVEF), increased end-diastolic volume (EDV) and dilated 
cardiomyopathy have all been reported in the literature (Wahbi et al. 2008,  Gaul et al. 
2006, Sveen et al. 2006, Poppe et al. 2003, Poppe et al. 2004, Boito et al 2005, Mercuri 
et al. 2003, Walter et al. 2004).  
The DGC is expressed in cardiac muscle as well as skeletal muscle and links the sub-
sarcolemmal cytoskeleton to the extracellular matrix. As already described in chapter 
1.1.1, dystroglycan is a key component of the DGC, consisting of the transmembrane 
protein, β-dystroglycan and the peripheral membrane protein, α-dystroglycan. It is 
suggested that abnormal FKRP function in LGMD2I leads to the dissociation of the 
tight bond between the DGC and the extracellular matrix and consequently to increase 
susceptibility to shear forces along the longitudinal axis of muscle fibres during cycles 
of contraction and relaxation. Loss of membrane integrity due to contraction-induced 
sarcolemmal damage will eventually lead to cardiomyopathy (Michele et al. 2009). 
In the normal mammalian heart there is a complex fibre architecture that varies 
fromsubepicardium through to subendocardium. In the human heart, the subepicardium 
fibres are oriented obliquely in a left-handed spiral at 75
o
 from the circumference of the 
heart and subendocardial fibres in the opposite direction at -70
o
 (MacGowan et al. 1997, 
Rademakers et al. 1994). Midwall fibres are oriented circumferentially. Important 
functional consequences occur as a result of these fibre oritentations (MacGowan et al. 
1997, Rademakers et al. 1994).  At the subepicardium, maximal fibre shortening occurs 
along the fibre length, whereas at the subendocardium maximal shortening occurs at 
almost right angles to the fibre direction. This subendocardial „cross-fibre‟ shortening is 
thought to be due to the greater radius and mechanical advantage of the subepicardium. 
Additionally due to its own contraction the subendocardium shortens in both the fibre 
and cross fibre directions. As there is shortening in 2 planes, there must be enhanced 
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thickening in a third plane to preserve volume. This results in marked radial thickening, 
which is an essential part of normal ejection. Torsion of the left ventricle occurs through 
shortening of the obliquely oriented subepicardial fibres partially counteracted by 
subendocardial fibre shortening (Arts et al.1979). 
 
Thus, normal left ventricular ejection is caused by a balance of subepicardial 
andsubendocardial strains (being the percentage shortening of the tissue). With respect 
toLGMD2I associated cardiomyopathy, impaired binding of the extracellular matrix 
components to α-dystroglycan could cause injury along  the fibre bundles leading to a 
selective loss of myocardial strains in the left ventricle, previously described in animal 
data (Michele et al. 2009).  
2.5.2 - Cardiac MRI (CMR) use in muscular dystrophy 
Information about wall mass, thickness and blood pool size in the diastolic and systolic 
phase can be obtained by analysing 25 cine images taken which cover the cardiac cycle 
in perpendicular orientations. This will be covered further in the methods chapter, 3.4.2. 
More recently CMR has been used in the detection of abnormalities in muscular 
dystrophy. In general these have mainly concentrated on DMD, including both mouse 
models of DMD and human studies with DMD.  CMR is more sensitive, in detecting 
cardiomyopathies compared to conventional screening methods, such as 
echocardiograms (Russel et al. 2008, Gaul et al. 2006, Grothues et al. 2002). Gaul et al. 
in 2006 evaluated nine patients, all with LGMD2I and homozygous for the common 
FKRP mutation, 826C>A. Cardiac involvement was detected in eight, however by 
conventional methods Gaul et al. (2006) only diagnosed cardiac involvement in 4 of the 
patients. The main pathological finding was left ventricular dysfunction (Russel et al. 
2008). As in the patients described by Poppe et al (2004) cardiac involvement is highly 
variable, even within the same family and may occur early in the disease (Muller et al 
2005). Wahbi et al. (2008) also detected a high prevalence of cardiac involvement in a 
group of 23 LGMD2I patients (22 of which were homozygous for the c.826A mutation). 
Of those that had CMR, 11 out of the 13 patients investigated had abnormalities, 2 of 
which had been normal on echocardiography. 
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CMR tagging works by nulling signal from the myocardium in a rectangular grid 
pattern in diastole and tracking the deformation of these tags through the rest of the 
cardiac cycle. It can be used to detect and calculate abnormalities in torsion. This will 
be covered further in the methods chapter, 3.4.2. Torsion is the wringing motion 
induced by the contraction of the left ventricular myofibres, in order to eject blood from 
the ventricle. During early diastole the rapid uncoiling is a major indicator of the 
restoring forces that contribute to the rapid filling. The myofibers orientation, structure 
and function reflect the health of the heart and abnormal torsion has been found to be a 
sensitive marker of systolic and diastolic dysfunction (Gotte et al. 2006). Subendo- and 
subepicardial myofibers are obliquely orientated in opposite directions, with a smooth 
transmural transition between fibres.  In the healthy heart, torsion occurs such that there 
is homogeneity of fibre shortening across the myocardial wall and is a marker of the 
dominance of epicardial fibres over endocardial fibres as a consequence of the greater 
radius in the epicardium. The relationship between torsion and strain can be 
approximated by a ratio of the peak epicardial torsion and the peak circumferential 
strain in the endocardial third of the myocardium and we refer to this as the torsion to 
endocardial strain ratio (TSR) (Lumens et al. 2006, van der  Toorn et al. 2002). This 
ratio has been shown to be near constant amongst healthy subjects of the same age, and 
to increase with both healthy ageing and disease. Thus, both torsion and the torsion to 
strain ratio are measures of epicardial – endocardial interactions 
The question as to whether regional torsion is useful clinically still remains unanswered.  
In comparing the circumferential segments and regional torsion, there appears to be a 
wide variation at only small variations in the axis of rotation (Russel et al. 2008). 
Torsion would appear to be a more global measurement, considering the orientation of 
fibres and its relation to torsion. Due to the connection of the myofibrils one would 
expect torsion of the whole heart to be affected even if only a regional circumferential 
location was detected as abnormal, for example with ischemia.  Transmural variations, 
resulting from abnormalities between the subendo- and epicardial oblique fibres, may be 
a suitable early tool for picking up subclinical heart failure (Russel et al. 2008).  
 61 
2.5.3 - Cardiac spectroscopy 
Cardiac phosphorus-31 magnetic resonance spectroscopy (
31
P-MRS) is still in the 
realms of research, rather than in clinical practice, however with future developments 
cardiac 
31
P-MRS may become a useful adjunct in the clinical setting. This would rely on 
improvements in spatial and temporal resolution, and would only be useful in the setting 
on an integrated cardiac MR examination. Cardiac 
31
P-MRS enables determination of 
the phosphocreatine to adenosine triphosphate ratio (PCr/ATP), which is an indicator of 
the energetic state of the cardiac muscle, ATP is needed to drive the myofibrils and that 
ATP is generated in the mitochdonria. The ATP is not directly transferred between 
these two sites, but the high phosphate bond is moved via PCr through two creatine 
kinase reactions. (Radda, 1986) This would allow for further evaluation of the 
morphology of the heart, global and regional function, perfusion, coronary anatomy and 
metabolism. As MR machines are now more widely available this may be the next 
development, but would need to be subject to thorough multicentre long-term clinical 
studies before routine use in the workup of patients with heart failure, valve disease and 
cardiac transplantation (Neubauer et al. 1998).  
The patients are positioned prone, as this produces fewer movement artefacts and a 
smaller distance to the 31-P coil. Cardiac muscle is also located behind a layer of chest 
wall skeletal muscle that gives rise to a strong 31-P signals that need to be suppressed. 
Due to the need to use additional localisation techniques, there is considerable signal 
loss and required voxel sizes need to be quite large (Neubauer et al. 1998).  
In a study of patients with dilated cardiomyopathy (Neubauer et al. 1992), the PCr/ATP 
ratio correlated inversely with the severity of the heart failure after grouping according 
to their clinical severity, the PDE/ATP however did not change. In an extended group of 
patients (Neubauer et al. 1995), correlations were also demonstrated between the 
PCr/ATP ratio and the left ventricular wall thickness and left ventricular ejection 
fraction. Patients with the thinnest left ventricular walls had the lowest PCr/ATP ratios. 
There was no other correlation with any other haemodynamic indices either on left or 
right heart catheterization. This reduction in PCr/ATP ratios with an increasing severity 
in heart failure, either ischaemic (Hardy et al. 1991) or non-ischaemic (Neubauer et al. 
1995, Hardy et al. 1991) has been documented in other studies. 
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Crilley et al. (2000) assessed DMD patients and carriers using cardiac 
31
P-MRS and 
demonstrated a significant reduction in the PCr/ATP ratio as compared to controls. The 
magnitude of the reduction was similar in both patients and carriers, whether 
manifesting or non-manifesting. This reduction was in the absence of any left 
ventricular (LV) systolic or diastolic dysfunction or an increase in LV wall thickness, 
implying that metabolic dysfunction in DMD precedes the deterioration of LV function, 
and not a result of it. 
2.5.4  Discussion 
In LGMD2I cardiac imaging is therefore a vitally important tool, due to the high 
prevalence of cardiomyopathy seen in this population. Whilst the conventional 
screening techniques are widely available, newer techniques such as cardiac MRI are 
emerging as useful and complementary imaging modality. It has better sensitivity and 
can detect ventricular hypokinesis, dilatation and hypertrophy, as demonstrated by Gaul 
et al. (2006) as well as fat infiltration and late enhancement in patients with normal 
echocardiography. 
Cardiac tagging can detect torsion and both torsion and the torsion to strain ratio are 
measures of epicardial – endocardial interactions. Abnormalities between the subendo- 
and epicardial oblique fibres may be a suitable early tool for picking up subclinical heart 
failure. 
And finally cardiac 
31
P-MRS may be useful in assessing early and preclinical change in 
the hearts of patients with muscular dystrophy and in particular LGMD2I as in the 
studies in DMD, Crilley et al. (2000) demonstrated the reduction the PCr/ATP ratio 
reflecting the myocardial energetic state pre-structural damage. As treatment of these 
cardiomyopathies associated with muscular dystrophy respond to early and possibly 
pre-clinical treatment with ACE inhibitors, the earlier that cardiac abnormalities are 
detected and treated the better. 
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Chapter 3 - Method 
3.1 – Participants – demographics and ethical approval 
Participants in the LGMD2I study were recruited from four main neuromuscular 
centres, Newcastle upon Tyne (NCL) and London (LON) in the UK, Copenhagen in 
Denmark and Paris in France. 
Participants were recruited from their local centre, using local patient databases for their 
area. The patients were then screened for suitability for entry into the study. Only after 
inclusion and exclusion criteria were met were the patients approached. The study and 
all it involved was explained by the local researchers and information leaflets and 
consent forms given to the patients (Appendix A and B). The patients were given 3-5 
days to consider the study before being contacted again and asked whether they would 
like to participate. 
All participants underwent informed consent locally. Ethical approval was obtained in 
Newcastle upon Tyne for the NCL and LON patients, and locally from the other two 
centres, using the protocols and manuals devised for the study. Data were acquired 
locally at all of the four centres at baseline between June 2009 and April 2010, and 
between June 2010 and April 2011 for the 12 month follow up assessment. Each centre 
used pre-agreed standardised MRI, clinical and functional assessments with a 
standardised reporting method. 
In NCL, 11 of the 13 patients underwent a total of four assessments, whilst the 
remaining two had the two assessments at baseline and 12 months later. The 
assessments at baseline and 12 months included the standardised physical assessments 
and MRI. On visits 2 and 3, the 11 patients underwent the physical assessment only, one 
for validation within four weeks of baseline and one 6 months later. The NCL cohort, in 
addition to the standardised physical assessments, underwent manual muscle testing and 
an adapted North Star Ambulatory Assessment (NSAA) for Limb Girdle Muscular 
Dystrophy. This was also completed at the Follow up visit after 12 months in all 13 
patients. Visits 2 and 3 were not completed by two of the patients as they were not local 
to Newcastle upon Tyne and travel would have been difficult.  
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The other three centres had the two assessments as outlined above, one at baseline and 
12 months with a standardised physical assessment and MRI. 
Accelerometry was also completed in two of the centres at baseline (NCL and 
Copenhagen) and results were retrievable from 14 patients.  
MRS analysis was completed in 2 centres (NCL and Paris) in 20 patients. 
Cardiac MR imaging was completed in one centre (NCL) in 11 patients.  
Inclusion and exclusion criteria 
Thirty eight patients fulfilled the inclusion criteria for entry into the study and 34 
completed the follow-up imaging. The inclusion criteria included identical genetic 
diagnosis with homozygous c.826C>A FKRP mutations, ambulant for more than 50 
metres, no ventilator requirements and able to lie flat with no contraindications for MRI 
scanning. All participants were asked to fill out a questionnaire by the MRI team to 
establish if magnetic resonance scanning would be safe and a further safety briefing was 
given to the patient prior to the scan.  
Two were unable to undergo the follow up MRI scan as they were in the early stages of 
pregnancy; one of these did complete the standardised physical testing as she was part 
of the NCL cohort and agreed to complete the fourth assessment. One participant was 
undergoing treatment for a recently diagnosed malignancy and one did not feel he could 
participate any further.  
Patient details 
The 38 participants at baseline (19 male and 19 female) were aged between 18 years 
and 64 years, mean ages of 41.7 years in the males and 39.5 years in the female group 
(table 3.1). Disease duration was 0-49 years with disease onset in childhood (less than 
16 years) recorded in 47.4%, 26.3% in childhood aged 10 years or younger.  
The first symptoms that predominate are difficulty in climbing stairs (28%), difficulty 
running (21.1%) and myalgia and cramps (21.1%). 10.5% of participants reported that 
falling and recurrent falls were a presenting complaint and 10.5% reported difficulty 
rising from a chair. 7.9% reported fatigue and one participant reported weight loss as an 
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initial complaint in his early 20‟s when he was attending a gym regularly to try and 
„bulk‟ up his muscles. One participant also reported that getting up from the floor was 
the initial symptom and one participant still remains asymptomatic. One patient was 
diagnosed following a routine blood test and had raised liver enzymes; his case is 
reviewed in chapter 4. 
The creatine kinase was recorded in 32 of the 38 participants and ranged from 222units/l 
to 23,858 units/l, with a mean of 5,142units/l. Cardiomyopathy was present in 16 of the 
38 patients (42%) as documented on echocardiography results. 77% of those with 
cardiomyopathy were male and 23% female, the age range was 21-64 years, with a 
mean age of 44.4 years and 25% of those with a cardiomyopathy were in their 20‟s and 
all male. 
Respiratory involvement as reported by the patients was present in 21% (n=8) of the 
cohort, however 33.3% had a forced vital capacity (FVC) </= 75% predicted value for 
their height. 16.6% had a >/= 20% decrease in their FVC in lying and 33.3% had a 10 – 
19% decrease in their FVC.  31% of the cohort that had a cardiomyopathy also had 
respiratory involvement (n=5).  
These figures are similar to previous studies of patients with LGMD2I, where cardiac 
involvement ranges between 10% and 55% (Walter et al. 2003, Poppe et al. 2004). 29% 
of LGMD2I patients were documented to have a cardiomyopathy by Sveen et al. (2008) 
with a higher prevalence in the male group (38%) compared to the female group (18%). 
Poppe et al. (2004) also reported similar findings with 83% males and 42% of females 
having either a confirmed or possible cardiac involvement. 
 
 
 
 
 
 
 63 
 
Patient Sex Age 
(years) 
First symptom Age First 
Symptom 
Serum 
CK 
Cardiomyopathy 
Y/N 
Respiratory 
involvement Y/N 
1 M 62 Flat feet, difficulty 
climbing stairs 
45 2335 Yes Yes 
2 M 64 Poor running and falls 15 2471 Yes Yes 
3 F 58 Difficulty getting out of a 
chair and climbing stairs 
43 n/a Yes No 
4 M 46 Weight loss 23 1212 Yes No 
5 F 55 Difficulty climbing stairs 
and falls 
41 n/a No No 
6 M 21 Toe walker and slow at 
running 
9 8050 Yes No 
7 F 25 Slow at running and odd 
gait when climbing stairs 
9 2600 No Yes 
8 M 33 Raised CK detected when 
giving blood. 
Early 20‟s 12000 No No 
9 M 28 Recurrent falls 24 3302 Yes No 
10 M 39 Poor at sport in school, 
unable to climb ropes. 
10 n/a Yes No 
11 M 54 Poor running and 
myoglobinuria 
Late 40‟s 1000 Yes No 
12 M 37 Recurrent falls Early teens n/a No No 
13 F 41 Slow at running and 
unable to climb school 
wall 
10 222 No No 
14 F 46 Difficulty climbing stairs 22 856 No Yes 
15 F 46 Difficulty climbing stairs 
after first pregnancy 
31 n/a No No 
16 F 29 Pain in thighs and 
difficulty climbing stairs  
12 13414 No No 
17 F 45 Difficulty climbing stairs 23 421 No No 
18 M 50 Difficulty climbing stairs 37 4950 Yes No 
19 M 30 Pain in buttocks and thighs 15 7545 No No 
20 F 27 Difficulty descending 
stairs 
17 23858 No No 
21 F 30 Pain and cramps in legs 10 n/a No No 
22 F 31 Cramps in calf muscles 10 2446 No No 
23 M 36 Difficulty getting out of a 
chair 
20 11421 No No 
24 F 47 Poor at running 10 1940 No Yes 
25 M 18 No symptoms Nil 3000 No No 
26 M 28 Cramps, myalgia 17 7000 Yes No 
27 M 51 Difficulty in running 14 1535 Yes Yes 
28 F 43 Cramps, myalgia 13 7260 No No 
29 F 42 Fatigability and difficulty 
climbing stairs 
33 1528 Yes No 
30 F 40 Cramps, myalgia 6 3170 No No 
31 F 26 Cramps, myalgia 7 5000 No No 
32 F 38 Fatigability and weakness 
in lower limbs 
16 5155 Yes No 
33 M 51 Fatigue with physical 
activities 
37 n/a Yes No 
34 F 58 Falling over 38 n/a Yes Yes 
35 F 40 Difficulty getting out of a 
chair 
32 n/a No No 
36 M 64 Difficulty getting up from 
the floor 
43 n/a   
37 M 45 Difficulty climbing stairs 34 n/a No No 
38 M 21 Difficulty running and 
rising from a chair 
10 n/a Yes Yes 
Table 3.1: Summary table of the clinical characteristics of the LGMD2I cohort (n=38). 
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Follow up assessments and analysis 
At follow up, 35 patients completed the physical assessment, 34 patients completed the 
MRI as part of the follow up and 32 participants were included in the final analysis at 
follow up (17 male and 15 female). They were aged between 19 years and 65 years, 
mean ages of 40.9 years in the males and 42.3 years in the female group.  
8 healthy adult controls (5M: 3F age range 23-61 years, mean 40 years) were recruited. 
These were recruited locally in NCL using advertisements in and around the university 
and the Newcastle Magnetic Resonance Centre (NMRC). The healthy controls matched 
the age group and gender that we had in our patient groups. 
3.2 – Tools and Protocols 
A detailed study protocol was distributed to all centres including the medical form to be 
completed by the assessor, a reference manual for performing the standardised physical 
examination including clinical photographs for positioning, a record sheet and the 
consent form (Appendix B, C, D, E).  
A detailed technical MRI protocol was sent to all the participating radiology 
departments outlining the technical data and pre-study quality assurance on water/fat 
phantoms and healthy subjects ensured that resulting images were quantitatively 
equivalent. This will be covered later in the chapter (section 3.4). 
Validation and reliability 
In NCL, the patients had two further visits in addition to baseline and twelve months. In 
order to validate the tests and assess test-retest reliability the patients were seen within 4 
weeks of the first assessment and a further assessment was performed at 6 months from 
baseline. These assessments in NCL included the repeat respiratory function, myometry 
and timed tests, but also included additional tests including manual muscle testing 
(MMT) and an adapted North Star Ambulatory Assessment (NSAA for LGMD). The 
MMT included both upper and lower body on the dominant side. 
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Medical History 
All the patients were reviewed and had a medical history taken including presenting 
symptoms and age at which they presented, best motor ability and age when this was 
achieved. Data was also collected on the current status of the patient including current 
motor ability, respiratory involvement, cardiac involvement, medications and any other 
concurrent medical conditions (Appendix E).  
Physical Examination 
All patients underwent a standardised physical examination. This was performed locally 
at each of the centres before the MRI examination. 
The assessment procedure was set out in a full manual with a standard recording sheet 
in the order that the tests should be performed. The manual and assessments were 
discussed with the other centres taking part via email and a teleconference call in order 
to standardise the study. All centres were familiar with the testing procedures and step 
by step instructions were laid out in the manual with photographic, as well as 
descriptive text, to describe the assessments and the position that the patient and 
examiner has to be in to perform them (Appendix C).  
All the patients performed respiratory function tests with hand held spirometry 
measuring the forced vital capacity (FVC) in sitting and lying. 
The strength assessments included myometry testing using a hand held device. This was 
used to test hip flexion, hip adduction and abduction, knee flexion and extension and 
ankle dorsiflexion. The best of three measurements were taken and recorded in pounds 
of force.  
The Newcastle upon Tyne (NCL) cohort was also tested with manual muscle testing 
(MMT) on visits 2,3 and 4, a familiar test with clinicians and neurologists, but in 
clinical trials it is considered a rather subjective measure compared to the myometry 
measurements (Merlini et al. 2002). The NCL cohort also completed the Adapted North 
Star Ambulatory Assessment (NSAA) for LGMD (Appendix C), not tested in the other 
centres, during assessments 1, 2, 3 and 4. The NSAA is regularly used in patients with 
DMD in the clinic setting and addresses many functional elements including some of 
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the timed tests that we had included in the original protocol. The NSAA was adapted for 
this adult cohort by taking out the item 11 „rise from the floor‟ and supplemented (S1) 
with a „squat‟. The „rise from floor‟ is functionally important in school age boys with 
DMD who need to be able to sit on the floor for school based activities. This becomes 
less important in an adult population and could also pose a health a safety risk with 
adult patients. A „squat‟ is more functionally appropriate for an adult population as this 
manoeuvre is used daily for retrieving low-lying items. This gives a score out of 34 that 
can be easily compared visit by visit. 
The timed tests included a 10 metre walk/run if able. This needed to be performed in a 
quiet corridor with a course set out with a 10 metre measuring tape and when the patient 
was ready the time taken to reach the 10 metre mark was recorded. As well as timing 
the assessment, the patient was also graded as to how well he performed the assessment. 
This included whether the patient needed any aids to walk with, picked up speed or not, 
was nearly running with double stance or could manage to run. These forms are 
included in the appendix (D).   
This grading method of recording function was applied to the other timed tests 
including the stair ascend and descend. The patient was timed on a standard set of four 
stairs both ascending and then descending. They were graded according to whether they 
climbed using the handrails either one handrail or both and whether they marked time or 
used alternate feet to climb the stairs.  
The chair rise and ‘Timed up and Go’ (TUG) test was performed using a standard chair 
with arm rests and the test was performed timing the patient in getting from the seated 
position to standing with arms by their sides and graded depending on whether they 
required additional help in getting out of the chair either by using their own legs to push 
up on, or other furniture or the arm rests (Appendix D). The TUG was a combined chair 
rise with a 3 metre walk from the chair and back again and the test was completed once 
the patient was seated again in the chair. This was a timed test only. 
The 6MWD was completed in a quiet corridor that was long enough to mark out a 25 
metre course and included a tape measure marking out the course, two traffic cones at 
both ends and a stop watch. The patient was required to walk from end to end 
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completing each lap which was timed and turning at either end at the cones to walk back 
down along the tape measure. The patient‟s blood pressure and pulse were taken both 
pre and post test. A chaser followed the patient in case they needed to stop or they fell. 
When the six minutes were completed, the patient stopped. The distance completed 
from either end of the cones was noted. This was then combined with the number of 
laps completed; each lap is equivalent to 25 metres, to give a total distance. The LON 
patients performed the 6MWD over a 10 metre course as there was no available space to 
set out a 6MWD course as above. This was recorded however the number of turns is 
therefore increased. This highlights the difficulty of performing this test particularly in a 
busy clinic setting. 
Data collection 
The data was recorded on excel spread sheets with centre codes and patient codes. The 
spread sheets were electronically transferred to NCL once completed from the other 
three centres. The four excel spread sheets were then combined for both the examination 
findings and medical history at baseline and 12 months. These were then recorded on 
the Statistical Package for the Social Sciences (SPSS) (version 17.0) data sheet for 
further analysis.  
The MRI scans were all sent either electronically or by compact disc (CD) to NCL. The 
CDs and scans were all coded for patient confidentiality and the same codes used 
throughout the study. The MRI analysis was performed at Newcastle upon Tyne and all 
the values recorded in log books at the time of analysis and then transcribed onto the 
excel spread sheet and SPSS data sheets for further analysis and statistical testing. The 
cardiac MR imaging was performed and analysed in NCL and the MRS data was sent 
from Paris and analysed with the NCL data. Further details on the technical aspects and 
analysis of the MRI scans, MRS data and cardiac data will be covered in the later 
section 3.4. 
Statistical Methods 
Non-parametric statistical tests were used for analysis using the SPSS version 17.0 
software (IBM, USA). Spearman‟s rank correlation (coefficient reported as rs) was used 
to compare the Dixon quantitative fat analysis and the following factors: age, disease 
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duration (time from symptom onset) and appropriate functional measurements. 
Comparisons of fat infiltration between muscles were analysed using the Wilcoxon 
signed-rank test and between genders using the Mann-Whitney U test. Median fat 
fraction and change over time was analysed using the paired Wilcoxon signed-rank test 
for both MRI fat infiltration and muscle strength and function. 
Rasch Analysis 
Item response theory (IRT) and the Rasch measurement are two new forms of 
psychometric methods which can be used to analyse the scores obtained from rating 
scales and how these relate to variable measurements. They are both based on a 
mathematical background and can therefore be rigorously tested to enable verification 
of the data. Both methods can be used for analysing data from rating scales as well as 
use for constructing appropriate rating scales. Mathematical models are extremely 
useful in formally expressing relationships between variables, and this can be used to 
determine how observations satisfy the „fit‟ of the predictions of the model, that is the 
extent to which the data satisfies the theory, and secondly can be used to predict future 
outcomes. The development of a mathematical model to predict how close a „fit‟ to a set 
of items in a group of individuals using the Rasch method was developed by Georg 
Rasch (Rasch. 1960, Wright. 1982). This model determines if a set of items forms a 
reliable and valid rating scale on which people can be located, preferably in interval-
level units. The IRT and the Rasch model focus on the relationship between a person‟s 
measurement and the probability of them responding to an item, rather than the 
relationship between a person‟s measurement and their observed total score on the 
scale. This is exemplified by Rasch‟s measurement theory. This postulates that the 
probability of a person‟s response to each of the categories of a rating scale is governed 
by the difference between where the person is on the scale and where the item is on the 
continuum measured by the item set. In essence, it measures the extent to which 
responses of the observed item accord with the responses of the mathematical model 
(Hobart et al. 2007). 
The benefits of a Rasch analysis are firstly, that it offers the ability to construct interval-
level measurements from ordinal-level data (Thurstone, 1925), which is essential from 
applying rating scales to clinical trials. Secondly it can be used for individual person 
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analyses rather than just group comparison studies (Hobart et al. 2007). Thirdly subsets 
can be used rather than all the items in the scale, and fourthly, it computes the missing 
data mathematically and uses an estimate based on the available data (Hobart and Cano, 
2009).  
The rating scale of the NSAA and the functional grades from the timed tests for the 
NCL patients has been subjected to the Rasch analysis. This method was applied to the 
scales used in order to define whether the items being used were appropriate for this 
group of patients and are reported in the results section (chapter 4.1). 
3.3 - Physiotherapy tools 
In the assessments of patients with neuromuscular disorders strength and functional 
ability are vitally important. It is important that the tests used for each patient group are 
appropriate for the particular disease and will detect both a „floor‟ and a „ceiling‟ in 
each participant‟s abilities. The tests also need to be standardised and validated, 
especially if using across centres and countries, and that agreement is sought before the 
study begins to enable consistency and comparisons to be made.   
The most fundamental approach in analysing muscle function is the measurement of 
force, whether this is by clinical scales or more quantitatively by dynamometry. 
Measurements involving functional scales reflect the activities of daily living and tend 
to have a more direct impact on a patients level of functioning and their perception of 
their strength. These scales both involve timed tests and a grading to demonstrate the 
ease of difficulty that they are performed. Task specific functions, such as hopping or 
balancing on one leg are recorded. In this following chapter the various methods of 
assessments used will be outlined. 
3.3.1 - Myometry 
Hand held myometry has gained popularity over the last few years with the need for 
more quantitative measures of strength in neuromuscular conditions (Cook and Glass, 
1987, Beck et al. 1999, Escolar et al. 2001). It has obvious advantages over manual 
muscle testing and other clinical scales, and due to its portability is useful in the clinic 
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setting. Reproducibility and interobserver agreement level is high (Wiles and Karni, 
1983, Bohannon and Williams 1987, Hosking et al. 1976, Beck et al. 1999, Escolar et 
al. 2001).  
Standard approaches need to be adhered to in order for the values to be comparable and 
measuring techniques using virtually isometric testing are used. Standard reference 
figures have been published for both adults and children. In some cases the normal male 
adult exceeds the dynamometer scale, however it was felt that expanding the scale 
would be of little use as these forces may be too difficult for the average examiner to 
measure.  
It has been demonstrated that the mean ratio of female to male adults is about two thirds 
in both the 5
th
 and 50
th
 centile values. There does not appear to be a significant 
influence over strength and measures obtained from height, weight or age and in 
particular little or no decline in strength before 60 years of age (Sepic et al. 1986, 
Vandervoort and McCormas, 1986). 
Variation between dominant sides does not appear significantly different. In a study by 
van der Ploeg et al. (1991) the 95% reference limits for the ratio left to right is on 
average 0.82 to 1.22, which means that the stronger side did not exceed the weaker by 
more than 22%. This is also reported in a paediatric cohort where a difference of less 
than 15% between the right and the left was seen in 80% (Hosking et al. 1976). 
Repeatability is tested by comparing either the „best of three‟ value or mean value 
within a set time, between a few days to a month, to test both repeatability and also intra 
and interobserver error. In van der Ploeg‟s study a good repeatability was demonstrated 
after one week, using the same myometer (van der Ploeg et al 1991). There were only 
small differences seen between muscles tested, which have also been confirmed in other 
studies (Wiles and Karni, 1983). It has been reported that measurements seldom differ 
by more than 20% from the first measurement. Wiles and Karni (1983) found that in 
measurements taken up to four days apart differed less than 20%, 80% of the time. 
In patients with neuromuscular conditions, dynamometry, whether fixed or hand held, 
appears to be more reliable than grading using the MRC scale (Beck et al. 1999, Escolar 
et al. 2001, Kilmer et al, 1997). It also is useful in non-ambulant patients in assessing 
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arm strength and small changes in these more severely affected patients. Quantitative 
muscle testing (QMT) has been used as an outcome measure in a number of 
neuromuscular studies including amyotrophic lateral sclerosis, DMD and spinal 
muscular atrophy (SMA) (Beck et al. 1999, Cook et al. 1990, Escolar et al. 2001, 
Stuberg and Metcalf, 1988, Merlini et al. 2002).   
Intra and interrater reliability has been previously published and is good, with intrarater 
results better than interrater and good results obtained (Intraclass Correlation 
Coefficient (ICCo) >0.85) in both upper and lower limbs except in ankle dorsiflexion 
(Merlini et al. 2002). This poor result for ankle dorsiflexion has been demonstrated in a 
number of other studies involving neuromuscular patients (Escolar et al. 2001, Kilmer 
et al, 1997, McMahon et al. 1992, Phillips et al. 2000). A number of reasons have been 
suggested, however, one of the main factors is the short lever arm used and the 
difficulty in getting the myometer in the correct position for measuring the line of force 
accurately. The position that ankle dorsiflexion is measured in also does not account for 
gravity as it is measured in the sitting position. In neuromuscular patients myometer 
positioning is often difficult and the results inconsistent if they have ankle contractures 
(Escolar et al. 2001).  
3.3.2 - Manual Muscle testing 
Manual muscle testing is the most common method used to evaluate muscle strength. It 
measures the strength of individual muscles using the Medical Research Council (MRC) 
scale (Medical Research Council, 1976, Haige et al. 2001). 
This scale is an ordinal scale from 0 to 5, where 0 is no contraction/flicker of movement 
in the muscle and 5 is normal power against gravity. Whilst this scale is easy to 
administer in a clinical setting, it is subjective, dependent of adequate training and 
difficult if the patient has contractures, as in many neuromuscular patients, and therefore 
limits its ability to demonstrate true weakness (Escolar et al. 2001). As this scale is only 
0-5 it is not particularly sensitive, especially when a patient is weak but cannot 
overcome gravity and also in patients who can overcome gravity but are still weak. The 
scale is also not sensitive enough to pick up small changes over time and hence the use 
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in longitudinal clinical trials is limited. Finally it has been demonstrated that there is a 
high rate of intra- and interrater variability which could compromise clinical studies 
3.3.3 – Functional testing and timed tests 
(i)Adapted North Star Ambulatory Assessment (NSAA for LGMD) 
The NSAA is a functional scale specifically designed for boys who are ambulant with 
DMD and recently this scale has been used as one of the outcome measures in the 
clinical trials for DMD.  With continued clinical trials, outcome measures and scales are 
constantly developed and hence the previous studies in patients with neuromuscular 
disorders primarily focused on strength, however more recently functional scales have 
been proposed. These scales have included the Gross Motor Function Measure (Russell 
et al. 1989), the Vignos scale (Vignos et al. 1963), the Hammersmith Functional motor 
scale in non ambulant patients with Spinal Muscular Atrophy (Main et al. 2003) or the 
Hammersmith Motor Ability Scale for DMD boys (Scott et al. 1982).  
The NSAA is a functional scale that has been designed specifically for ambulant DMD 
boys and was an adaption from the Hammersmith Motor ability scale, however included 
functional items such as hopping and running, not previously included and defined the 
scoring for each item. These items were included in order to detect improvement in the 
treated DMD cohort. The scale was developed and piloted in the United Kingdom by 
the North Star Clinical Network for Neuromuscular Disease Management. It 
demonstrated good intra and interobserver reliability and has been applied to a large 
multicentre study with positive outcomes. (Mazzone et al. 2009, Scott et al. 2006, 
Mercuri et al. 2008, Eagle et al. 2007) 
The NSAA consists of a scale of 17 items, ranging from standing, with or without 
compensation (item 1), to more difficult items such as standing on one leg, hopping and 
running. The scale includes items that are necessary to remain ambulant and 
functionally independent such as the ability to get from lying to sitting and from sitting 
to standing. These items, as in DMD, progressively deteriorate in patients with 
LGMD2I over time. Each item is scored on a 3 point scale using a simple criteria; 2-
normal and able to execute task without any assistance, 1 –modified but does not 
require any assistance from another person and 0 – unable to achieve independently. 
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The total score therefore achievable with 17 items is 34 and can range from 0 to the 
maximum score (Mazzone et al. 2010). 
The NSAA was adapted in this study for the adult patients with LGMD2I and is based 
on an appropriate construct for this group. „Rise from the floor‟ was replaced with a 
„squat‟. This was perceived as a more functional activity required of adults in their daily 
lives compared to the „rise from the floor‟ in children, who often spend considerable 
time on the floor either playing or at school and therefore is a very functional task for 
them. As adults we do not necessarily need to get up from the floor, whereas squatting 
to lift or pick up items from the floor, is more functional. Adults, with LGMD2I, have 
great difficulty in rising from the floor and many would object to performing this, 
however the „squat‟ item was designed that if a patient could squat with at least 90 
degrees of hip and knee flexion without using the arms for assistance and get back up 
from that position, they would score maximal points, 2,  if they could initiate a squat to 
more than 10 degrees flexion of hips and knees, they scored 1 and if they were unable to 
initiate a squat then they scored 0. 
In a recent study, the NSAA correlated well with the 6MWD in DMD boys, -.589 and 
the 10 metre walk/run correlated well with the 6MWD, -.601 (Mazzone et al. 2010). 
Both these were significant at p<0.01. It appeared that the boys that scored </=16 on the 
NSAA whilst able to complete the 6MWD, majority of them walked less than 300m 
(66%). 75% took more than 8 seconds to perform the 10 metre walk/run and 70% took 
more than 10 seconds to rise from the floor. In comparison, the boys who scored >/= 30 
on the NSAA, generally walked more than 400m (69%), took less than 8 seconds to 
perform the 10 metre walk/run (60%) and less than 5 seconds to rise from the floor 
(78%) ( Mazzone et al. 2010).  
(ii) 10 metre walk/run 
The gait speed spontaneously adopted by the patient was reported to be a reliable index 
of locomotor impairment in the patients with various pathologies of the lower limbs 
(Bernardi et al. 1999).  Extensive work has been done in the elderly population on gait 
speeds and the correlation with self-reported physical function as well as the need for 
referral to physical therapy, and the 10m walk to assess gait speed has been reported as 
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having a sensitivity of 80% and specificity of 89% in screening elderly patients as to the 
need for referral to physical therapy (Harada et al. 1995). The 10m test was considered 
as a reliable and valid measure in patients with amyotrophic lateral sclerosis (Goldfarb 
and Simon, 1984), immune mediated polyneuropathies (Merkies et al. 2003) and in 
patients with Charcot-Marie-Tooth neuropathy (Solari et al. 2008). Gait speeds in 
patients with DMD/BMD/LGMD was moderately correlated with activity limitations in 
those patients (Vandervelde et al. 2009)This item is included in the original NSAA for 
DMD but is equally applicable to ambulant LGMD patients. The grading is based on 
score 2 for „able to run‟ (no double stance phase), 1 for „can go faster than a walk‟ and 0 
as „unable to go faster than a walk‟. 
(iii)Timed up and Go test (TUG). 
The TUG test was introduced in 1991 by Podsiadlo and Richardson as a modification of 
the Get up and Go test of Mathias et al. (1986). Podsiadlo and Richardson (1991) 
described the TUG test as the time in seconds taken for an individual to - “rise from a 
standard armchair, walk to a line on the floor 3 metres away, turn, return, and sit down 
again”.  
It has been well documented that this test can be performed reliably with inter-rater 
agreement on the time scoring and is reproducible. Most of the work has been carried 
out in the elderly population who are prone to falls to assess their functional ability 
when rehabilitating them to get back home. Shumway-Cook et al. (2000) reported that 
TUG time scores greater than 13.5 seconds identify people who are likely to fall in the 
community; this test has a sensitivity and specificity of 87%. This test, however, also 
has implications for other disorders, such as vestibular disturbances with balance 
disorders as well as those with weakness that may affect their function. The TUG test 
includes basic mobility tasks encountered in daily life such as standing up, walking, 
turning and sitting down, which not only require strength but balance and coordination. 
The TUG has been shown to correlate with other rating scales such as the Berg Balance 
scale, gait speed/time, stair climbing and other functional indexes (Steffen et al. 2002). 
In our group of patients with LGMD2I, the stair climb, hill/slope climbing and getting 
out of a chair are the most difficult and many patients who are severely affected will opt 
to stand rather than sit as it is too exhausting to contemplate the chair rise. This is also 
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coupled with the fear of falling and then not being able to get up. This fear and lack of 
confidence has been documented in the elderly population for which this test is 
predominantly used for (Murphy and Issacs, 1982). The TUG test along with the stair 
climb is therefore a good test in the LGMD2I population. A chair height standardised at 
44-47cm with armrests should be used. The TUG test in the LGMD2I study was split 
into a timed and graded chair rise as well as the complete TUG test. The chair rise 
element seemed to pose the most difficulty as well as taking considerable time in some 
patients. The grading documented the use of the armrests, other furniture or their own 
thighs to assist on the chair rise.  
(iv) Six minute walk distance (6MWD) 
The six minute walk distance (6MWD) is an accurate, reproducible, simple to 
administer and well tolerated test. It has been validated for use in adults (ATS 
statement, 2002) and further studies have more recently been published in children as an 
outcome measure particularly in DMD (McDonald et al. 2010). The American Thoracic 
Society (ATS) guidelines use the 6MWD for evaluating the functional capacity in 
patients with heart- and lung-related problems (ATS statement, 2002). Functional 
capacity, including endurance is an important aspect of everyday living and has it has 
also been established that increases in the 6MWD by 10% -15% in patients with chronic 
lung disease are consistent with a considerable improvement in well-being (Redelmeier 
et al.1997). It has already been used in patients with neuromuscular conditions as a 
primary outcome measure in registration-directed studies of laronidase in 
mucopolysaccharidosis type I (MPS I) (Wraith et al. 2004), idursulfase in 
mucopolysaccharidosis type II (MPS II) (Muenzer et al. 2006) and alglucosidase-α in 
Pompe disease (Wokke et al. 2008). The 6MWD has also been used as a primary 
outcome measure in myotonic dystrophy (Takeuchi et al. 2008), spinal muscular 
atrophy (Kierkegaadr et al. 2007, Takeuchi et al. 2008, Montes et al. 2010), and more 
recently in DMD (Mazzone et al. 2010) and in a large international therapeutic trial with 
Ataluren (PTC 124) (McDonald et al. 2010). The test has required some modification 
for the paediatric population with neuromuscular conditions and for control values. In 
DMD it was noted by McDonald et al. (2010) that there was a strong correlation with 
age, height and weight, however the 6MWD subsequently decreased with increased age 
and height as the disease process of DMD progressed. The patients with DMD had a 
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progressive decrease in their stride, a widening of the base of their support, stride width 
and decreased cadence. It was also noted that there was consistency of walking velocity 
suggesting shorter distances or timings could be used as a measure of ambulation, 
minimising the effort and potential for falls. This particularly would be applicable to the 
adult LGMD2I group who are also prone to falls but unlike children avoid any activity 
that may precipitate a fall due to the difficulty of getting up again afterwards. 
3.4 - MRI specifics 
 3.4.1 – Skeletal MRI – technical data 
The study consisted of (i) standard T1w imaging, allowing for whole muscle qualitative 
evaluation and (ii) quantitative Dixon imaging optimised for localised analysis of fat 
fraction. These protocols were defined for use on 3.0T scanners (Philips Intera Achieva, 
Siemens TIM Trio) with surface arrays for signal detection. While the use of different 
scanners and vendors required the use of slightly different protocols, pre-trial quality 
assurance on water/fat phantoms and healthy subjects ensured that resulting images 
were quantitatively equivalent. 
(i) T1w imaging 
T1w imaging was performed with a turbo spin echo sequence (TR/TE = 671/10ms, 
(Newcastle/Paris) or 16ms (London), 12ms (Copenhagen), number of averages 2, 
acceleration factor 3, slice thickness 5mm, interslice gap 10mm, 256x192 matrix 
interpolated to 512x384). FOV 410mm using multiple stacks to cover both legs from 
the ankle to the pelvic crest.  
 
 (ii) Quantitative Dixon imaging 
 Spoiled gradient echo sequences which removes transverse coherences were used. 
Protocol details varied slightly between sites: Newcastle/London: 3 point Dixon images 
acquired in 2D with TR/TE=100/3.45, 4.6, 5.75ms, flip angle = 10 degrees, 10 slices of 
10mm slice thickness, 5mm gap; Paris: 3D acquisition of 2 point Dixon with correction 
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for B0
 
inhomogeneity (Coombs et al. 1997), 64 slices of 5mm slice thickness with 
TR/TE = 100/2.45, 3.675ms, flip angle = 10 degrees; Copenhagen: as per Paris but with 
36 slices per acquisition. In and out of phase echo times were determined locally due to 
variation in actual Bo magnitude between scanners (2.9-3.1T). Images were collected at 
mid-calf and mid-thigh: the central plane of acquisition was defined with respect to 
bone landmarks as follows: legs were positioned with the patella anterior; the calf 
images were centred by finding the broadest part of the calf muscle, and recording the 
distance from lower border of patella; thigh images were centred by locating superior 
border of patella, and the anterior superior iliac spine, with centreing 1/3 distance 
superior to the patella; the distance was recorded for follow up scans. Each leg was 
imaged individually using 160 x 160 matrix interpolated to 256x256, FOV 
200x200mm: in Paris, it was possible to scan both legs together at the same resolution 
using FOV 448x244mm. The data was analyzed to produce separate fat and water 
images (Coombs et al. 1997, Glover et al. 1991). The fat content of the image was 
expressed as a percentage of the total signal per voxel. 
(iii) Interpretation 
The T1w images were assessed on an individual muscle basis and graded according to 
the scale published by Mercuri et al. (2002a, 2002b) (table 3.2). Each individual muscle 
was assessed at all levels analysed from the proximal to the distal end of the muscle and 
a grade assigned to the muscle as a whole by averaging all the individual grades at all 
levels.  The quantitative fat images were analysed by defining regions of interest (ROIs) 
in individual muscles on the separated water image at the midpoint of both the lower leg 
and thigh. The cross sectional midpoint was then analysed using „image J‟ software and 
a fat fraction obtained for each individual muscle defined by its ROI. Each ROI was 
delineated and drawn by hand. This ROI and slice number were recorded and used in 
the re-analysis of the follow up scan to give the second fat fraction. The muscle groups 
analysed are shown later in Chapter 5.  The fat percentages in the 14 muscle groups 
analysed were averaged to give an „average fat percentage‟ for each patient, the 
hamstring muscles, the biceps femoris muscle, semitendinosus muscle and the 
semimembanosis muscle were averaged for each patient to give an „average hamstring 
fa t%‟ and the quadriceps muscles, vastus medialis muscle, vastus lateralis muscle and 
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the rectus femoris muscle were averaged for each patient to give an „average quadriceps 
fat %‟. The vastus intermedius muscle was not quantitatively analysed. 
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Table 3.2: Description of the qualitative muscle grading scale from Mercuri et 
al. (2002a) 
Grade  Description  
0 Normal appearance 
1 Early moth-eaten appearance with scattered small areas of increased 
signal 
2a Late moth-eaten appearance with numerous discrete areas of increased 
signal with beginning confluence, comprising less than 30% of the 
volume of the individual muscle 
2b Late moth-eaten appearance with numerous discrete areas of increased 
signal with beginning confluence, comprising 30–60% of the volume 
of the individual muscle 
3 Washed-out appearance, fuzzy appearance due to confluent areas of 
increased signal 
4 End stage appearance, muscle replaced by increased density of 
connective tissue and fat, with only a rim of fascia and neurovascular 
tissue distinguishable. 
 80 
3.4.2 – Cardiac MRI – technical data 
(i) Cardiac Magnetic Resonance Cine Imaging 
Cardiac examinations were performed on the NCL cohort (n=11), using a 3T Philips 
Intera Achieva scanner (Best, NL). A dedicated 6-channel cardiac coil (Philips, Best, 
NL) was used with the subjects in a supine position and electrocardiogram (ECG) 
gating (Philips vectorcardiogram). Cardiac magnetic resonance cine imaging was 
acquired to assess cardiac morphology, and systolic and diastolic function. A stack of 
balanced steady-state free precession images was obtained in the short axis view during 
breath holding covering the entire left ventricle (FOV = 350mm, TR/TE = 3.7/1.9ms, 
turbo factor 17, flip angle 40
o
, slice thickness 8mm, 0mm gap, 14 slices, 25 phases, 
resolution 1.37mm, temporal duration approx. 40ms per phase, dependent on heart rate). 
Image analysis was performed using the cardiac analysis package of the ViewForum 
workstation (Philips, Best, NL). Manual tracing of the epicardial and endocardial 
borders was performed on the short axis slices at end-systole and end-diastole. Details 
of the algorithm for contour selection and the methods for subsequently calculating left 
ventricular mass, systolic and diastolic parameters have been described elsewhere 
(Jones et al. 2010). The ratio of the left ventricular (LV) mass to the end-diastolic 
volume was calculated as this parameter is often quoted as a measure of concentric 
remodelling (Cheng et al. 2009). 
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(ii) Cardiac tagging 
Tagged images of the myocardium in the short axis were obtained at the same session as 
the morphological imaging using the same cardiac coil. Cardiac tagging works by 
nulling signal from the myocardium in diastole in a rectangular grid pattern and tracking 
the deformation of these tags through the rest of the cardiac cycle (figure 3.1).  By 
tagging two parallel planes it is possible to calculate myocardial torsion (figure 3.2) and 
in-plane analysis allows circumferential strains to be calculated across the myocardial 
wall. A multishot turbo-field echo sequence with TFE factor 9 was used 
(TR/TE/FA/NEX = 4.9/3.1/10
o
/1, SENSE factor 2, FOV 350x350mm, voxel size 1.37x 
1.37mm, orthogonal complementary spatial modulation and magnetization (CSPAMM) 
grid (Fischer et al. 1993) with tag spacing of 7mm). Two adjacent short-axis slices of 
10mm thickness were acquired at mid-ventricle with a 2mm gap. The Cardiac Image 
Modelling package (University of Auckland) was used to analyse the tagging data by 
aligning a mesh on the tags between the endo- and epi-cardial contours. Circumferential 
strain and the rotation of the two planes were calculated throughout the cardiac cycle. 
Circumferential strain is quoted for both the whole myocardial wall and the endocardial 
third of the wall thickness. The epicardial torsion between the two planes (taken as the 
circumferential-longitudinal shear angle defined on the epicardial surface) was 
calculated as previously described (Buchalter et al. 1990) to account for the radius of 
the ventricle (figure 3.2). 
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Figure 3.1: Cardiac cine-imaging (top) and cardiac tagging (bottom) at diastole (left) 
and systole (right), showing how a rectangular grid of nulled signal applied at 
diastole remains with the tissue through the cardiac cycle, allowing calculation of 
strain and torsion. 
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Longitudinal shortening was determined from cine-MRI in the 4-chamber view by 
determining the perpendicular distance from the plane of the mitral valve to the apex in 
systole and diastole, and expressing the difference in the measures as a percentage of 
the diastolic value. The myocardial wall thickness at systole and diastole were 
determined from the standard imaging at the same mid-ventricular level as the cardiac 
tagging by averaging the distance between the epicardial and endocardial countours 
around the left ventricle, and the percentage increase in wall thickness (radial 
thickening) from diastole to systole was calculated.  
(iii) Cardiac spectroscopy 
Cardiac high-energy phosphate metabolism was assessed using 
31
P MRS on the same 
occasion as the other assessments. Data were collected using a 3T Intera Achieva 
scanner (Philips, Best, NL) with a 10cm diameter 
31
P surface coil (Pulseteq, UK) for 
transmission/reception of signal. Subjects were placed in a prone position and moved 
into the magnet so their heart was at magnet isocentre (figure 3.3 and figure 3.4). 
Localising images were collected using the in-built body coil to confirm location of the 
heart. Shimming was performed using a cardiac triggered, breath-held field map (Schar 
et al. 2002). A slice-selective, cardiac gated 1-dimensional chemical shift imaging (1D-
Figure 3.2: Tagging in two parallel sections allows the calculation of the torsion 
(the longitudinal-circumferential shear angle ) between the two planes. 
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CSI) sequence was used with a 7cm slice selective pulse applied foot-head to eliminate 
contamination from the liver, with spatial pre-saturation of lateral skeletal muscle to 
avoid spectral contamination. 16 coronal phase-encoding steps were used, yielding 
spectra from 10mm slices (TR = heart rate, 192 averages at the centre of k-space with 
cosine-squared acquisition weighting, approx. 20 mins acquisition time). Spectral 
locations were overlaid onto an anatomical image and the first spectrum arising entirely 
beyond the chest wall was selected. Quantification of phosphocreatine (PCr), the  
resonance of adenosine triphosphate (ATP) and 2,3-diphosphoglycerate (DPG) was 
performed using the AMARES time domain fit routine in the jMRUI processing 
software (Vanhamme et al. 1999). After fitting, the ATP peak area was corrected for 
blood contamination by 1/6 of the amplitude of the combined 2,3-DPG peak (Conway 
et al. 1998), and the PCr/ATP ratios were calculated and corrected for saturation, with 
T1 values of cardiac phosphocreatine and ATP taken from the literature (Tyler et al. 
2006). Flip angle correction was made using a gadolinium-doped 20mM phenyl 
phosphonic acid phantom at the centre of the coil and a calibration dataset (Buchli et al. 
1993, Haase et al. 1984). 
 
 
 
 
 
 
 
(iv)Ultrasound examination 
Routine clinical cardiac ultrasonography reports, performed for screening purposes, 
were sought for the LGMD2I subjects, for qualitative comparison with MRI findings. 
Figure 3.3: prone position for 
the cardiac MRS 
Figure 3.4: surface coil 
for cardiac MRS 
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(v) Statistical Analysis 
Statistical analysis was performed using SPSS version 17. Data are presented as mean 
and standard deviation and comparisons were drawn between LGMD2I patients and 
control subjects using Student‟s t-test with Bonferroni correction for multiple 
comparisons. Where the LGMD2I group was divided, comparisons were made between 
group means using ANOVA with post-hoc comparison with Bonferroni correction. 
Correlations were performed between measures of cardiac energetics wall motion from 
cardiac tagging, morphological and functional measures. Correlations were executed as 
a two-tailed test using the Pearson correlation method. Statistical significance level was 
set at p<0.05. 
3.4.3 – Skeletal MRS acquisition - technical data 
Phosphorus MRS records signals from phosphate-containing metabolites involved in 
energy metabolism in vivo. It is useful for studying muscle metabolism in the resting, 
exercising and recovery phase, both the oxidative and glycolytic pathways (Argov et al. 
2000). The objective was to assess whether there was any abnormalities in the 
metabolism of the muscles studied that predated any MRI (both qualitative and 
quantitative) or clinical changes. In this chapter I will describe the two methods used to 
obtain the results in the two centres that were able to perform the MRS, NCL and Paris. 
(i) NCL data 
MRS data were acquired using a 3T Intera Achieva scanner (Philips, Best, NL) with a 
14cm diameter 
31
P surface coil for transmission/reception of signal and the in-built body 
coil for anatomical imaging. A purpose-built exercise apparatus was developed for 
operation within the MRI scanner (figure 3.5).  
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This apparatus permitted a controlled plantar flexion to exercise the soleus and 
gastrocnemius muscles with the patient lying supine: restraining straps prevented the 
recruitment of other muscle groups (e.g. quadriceps). Subjects performed two periods of 
exercise, consisting of three minutes rest, three minutes of plantar flexion at 0.5 Hz and 
3 minutes of rest to measure recovery to equilibrium. The first period used a fixed load 
of 25% of the Maximum Voluntary Contraction (MVC, determined prior to 
spectroscopy) to accurately measure oxidative metabolism in recovery whilst changing 
pH levels as little as possible (Kemp et al. 1994). The second 3 minute period was 
carried out after a total of ten minutes rest, it used a higher fixed load (35% of MVC) to 
produce greater anaerobic metabolism and allow measurement of pH handling. 
Phosphorus spectra were collected at 10s intervals throughout the exercises using a fully 
adiabatic 1D-ISIS sequence to localise signal to gastrocnemius and soleus muscles. 
Quantification of phosphocreatine (PCr), inorganic phosphate and pH was performed 
using the AMARES time domain fit routine in the jMRUI processing software 
(Vanhamme et al. 1999), assuming single Lorentzian resonances for Pi, PDE and PCr, 
with the α, and  moieties of ATP modelled as doublets of equal area with 17Hz 
separation, and the β-ATP moieties modelled as a triplet with 17Hz separation and area 
ratio 1:2:1. We assume a concentration of 8.2 mM ATP at rest and correct for relative 
saturation by comparison with a fully relaxed spectrum (TR = 25s, 4 averages) (Kemp 
et al. 1997). pH was calculated by measuring the difference in chemical shift between 
the fitted Pi and PCr resonances and applying the formula (Kemp et al. 1994): 
Figure 3.5: Exercise apparatus 
in the MRI. 
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A mono-exponential fit to the PCr data in recovery was made to estimate the half-time 
for recovery of PCr to equilibrium, with correction for end-exercise pH value (Iotti et al. 
1993). The ratio of Pi/PCr is quoted as this is often quoted in other muscular dystrophy 
studies and may be taken to represent an alteration of the set-point of the creatine kinase 
equilibrium, perhaps due to damaged cell membranes. 
(ii) Paris data 
MRS data were acquired using a 4T Bruker scanner using an elliptical 6 x 8 cm surface 
coil. Muscle acidication during aerobic plantar flexion exercise and efficiency of 
oxidative phosphorylation at recovery were measured by 
31
P MRS (TR = 1.5s, 4 
averages). Exercise (1 plantar flexion/1.5s) was performed in the magnet using a 
computer driven pneumatic ergometer. The initial load was determined from the cross-
sectional area of the widest part of the calf and adjusted for level of muscle degradation: 
the load was adjusted incrementally and the 
31
P spectra were monitored until the subject 
depleted the PCr resonance by approximately 40%. Data of PCr recovery were 
measured for 15 minutes following cessation of exercise – in the Paris protocol this 
extended period allows for the simultaneous measurement of leg perfusion. 
Metabolite concentrations were evaluated by baseline correcting the spectra, and 
integrating the resonances of the phosphorus metabolites using fixed chemical shift 
boundaries (Pi: 5.6-3.8ppm, PDE: 3.5-1.9ppm, PCr: 1.5-(-1.5)ppm, -ATP: (-1.5)-(-
3.5)ppm, α-ATP: (-6.2)-(-9.2)ppm, β-ATP (-14.2)-(-17.1)ppm). Again the concentration 
of ATP is assumed to be 8.2mM as per the Newcastle method. pH values were 
calculated by picking the peak of the Pi resonance and PCr resonance and using the 
formula detailed above. Phosphocreatine recovery was modelled as per the method 
outlined for NCL above. 
Of the 7 patients and controls studied, 1 patient had good resting spectra, but exercise 
spectra which were unsuitable for analysis. The data from a further LGMD2I patient 
was poor shimmed, and this data point was discarded.
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Chapter 4 – Strength and Functional measure Results 
One objective of this study was to examine whether standardised physical tests, 
including strength and functional measurements would be firstly, the appropriate 
measures to use in a cohort of adult patients with LGMD2I, secondly, how well would 
these measures correlate with the fat infiltration seen on the quantitative MRI, and 
thirdly would these measures detect change in the follow up time period of 12 months. 
4.1 – Assessments scales  
The assessment scales drawn up to address this cohort of LGMD2I patients were, as 
stated in chapter 2, largely decided from a combination of previous experience in the 
trials with DMD, prior research into scales that have proved useful in patients with 
proximal muscle weakness and the knowledge of the difficulties encountered by 
patients with LGMD2I, notably climbing stairs and slopes and getting out of low chairs. 
The initial assessments that were performed at all the centres on the 38 patients included 
respiratory function, with forced vital capacity (FVC) in both sitting and lying, strength 
testing, using hand held myometry, of the dominant side of the lower limbs, goniometry 
of the ankles, and timed tests. These timed tests included a stair climb and descend of 4 
standard stairs, time to rise from a chair, the TUG test, 10 metre walk/run and the 
6MWD. 
4.2 - Cross sectional results of assessments 
(i)Respiratory function 
FVC recordings, in both sitting and lying, were obtained in a total of 30 patients. The 
results show that the median values of the FVC in sitting and lying were 78% and 71% 
respectively. The maximum values were 107% sitting and 105% lying, and the 
minimum values were 51% sitting and 36% lying. 
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At baseline; 33.3% had an FVC </= 75% predicted value for their height in sitting. 
16.6% had a >/= 20% decrease in their FVC in lying and 33.3% had a 10 – 19% 
decrease in their FVC.   
 (ii)Myometry 
All 38 patients attempted myometry; at baseline all patients registered a recording with 
hip abduction, hip adduction, ankle dorsiflexion, knee extension and knee extension. 
One patient was not able to generate enough force to produce a reading at baseline. The 
hip abductors were significantly stronger than the hip adductors (p<0.01), and stronger 
than hip flexion (ns). The knee extensors were significantly stronger than knee flexors 
(p<0.01). The ankle dorsiflexors were the strongest on myometry with a range of 5.6 to 
86.3 pounds, median 38.5 pounds of force (table 4.1). 
 
 
 
 
 
 
 
 
There was strong correlation between the „hamstrings average fat percentage‟ and knee 
flexion (r = -.73, p<0.01). The „Hamstrings‟ average fat percentage, was calculated by 
averaging the fat fraction of the hamstring muscles including the semimemebranosus 
muscle, the semitendinosis muscle and the biceps femoris muscle for each individual.  
There was strong correlation between the „quadriceps average fat percentage‟ and knee 
extension (r = -.655, p<0.01) and a strong correlation with hip flexion (r = -.494, 
Muscle Baseline min Baseline max Baseline median 
Hip flexion (pounds) 2.2 81.1 15.7 
Hip Abd (pounds) 1.4 86.1 18.2 
Hip Add (pounds) 1.6 58.9 14.0 
Knee Flex (pounds) 1.9 66.1 18.6 
Knee Ext (pounds) 4.3 156.6 24.9 
Ankle DF (pounds) 5.6 86.3 38.5 
Abd = abduction, Add =adduction, Flex=flexion, Ext=extension, DF=dorsiflexion. 
Table 4.1: Minimum, maximum and median values of the myometry 
measurements at baseline. 
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p<0.01). In the same way the „quadriceps‟ average fat percentage was calculated, by 
averaging for each individual the fat fraction of the quadriceps muscles including the 
vastus lateralis muscle, the vastus medialis muscle and rectus femoris muscle.  
(iii) 10 metre walk/run 
The 10 metre walk/run was completed by all but one patient. This patient did not feel 
confident to perform the 10 metre walk/run without her stick. The times for the 10 
metres were very variable from 2.25 seconds to 21.5 seconds. Whilst some able bodied 
and more confident were able to run the course (n=9; minimum time; 2.25 seconds, 
maximum time; 4.8 seconds, median time; 3.46 seconds), others were less confident and 
fearful of falling, hence took the 10 metre walk at a slower pace.  
The 6MWD is currently a primary outcome measure in several clinical trials, however 
in a busy clinic setting and in the spaces allocated for clinics, a clear corridor of 25 
metres is often unavailable. As can be seen from figure 4.1 there is strong correlation (r 
= -.88, p<0.01) between the 10 metre walk and the 6MWD, suggesting that this can be 
as valid a test in LGMD2I, where speed and stride length are constant.  
 
 
Figure 4.1: Correlation between the 10m timed walk and the 
6MWD. 
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(iv) 6MWD 
Only one patient who was ill with a flu like illness was unable to perform the 6 MWT. 
The results varied from a minimal value of 67 metres to values within normal limits at 
625 metres. Three of the patients were reported as using the walls at times for balance 
and support, although none of them needed these for full support often their confidence 
and fear of falling would be appeased by touching or having the wall to hand. One 
patient found turning at the cones slightly difficult, and he appreciably slowed at the 
cones, as he felt unbalanced. In general the speed and step numbers were consistent, 
with neither quickening nor slowing of pace. In LON there was no available 25 metre 
walkway, so 6 of the patients did their 6MWD using a 10 metre course with more 
frequent turns. 
The 6MWD strongly correlated with the 10 metre walk time, r = .88 (p<0.01) (figure 
4.1), suggesting that the 10 metre walk /run could be used as an alternative to the 
6MWD in this group of patients. This is particularly so in this group of adult patients as 
their speed and stride length varied very little in the 6MWD and appeared constant, 
compared to children who at times, speed up and slow down.  
(v) TUG and timed chair rise 
At baseline six of the patients were unable to perform the TUG test and this was 
mirrored in the chair rise test as 5 were unable to perform this, 4 of who had been in the 
group unable to do the TUG test. The times taken for patients to do this varied greatly 
with mildly affected patients achieving times less than 5 seconds (minimum 4.3 
seconds) for the TUG and less than one second (minimum 043 seconds) for the chair 
rise. More severely affected patients found this test extremely challenging, with some 
patients taking up to 50.5 seconds to achieve the TUG and 48.5 seconds to achieve the 
chair rise (not in the same person). In order to achieve this more severely affected 
patients would adopt a wide based gait and would even need other furniture, such as 
another chair in front of them, to pull themselves up. Other patients would propel 
themselves forward and lock out their legs with their head dropped to the ground and 
gradually crawl up their legs or use the wall to climb up in order to become erect 
(figure 4.2). This obviously uses up a lot of energy as well as being time consuming. 
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(vi) Timed stair climb and descend 
33 completed the stair climb and descend, 5 were unable to attempt it. The median time 
to climb the stairs was 5.4 seconds (minimum; 1.43 seconds, maximum 46.2 seconds) 
and the median time to descend was 3.8 seconds (minimum; 1.07 seconds, maximum 39 
seconds). Majority of patients (n=28) descended the stairs on average 31.5% quicker. 
Four maintained the same speed and one increased in time required. Four patients 
improved on their grading coming down the stairs as they were able to mark time and 
use alternate feet when descending, one came down backwards, and one sideways.  
 
 
 
(a)     (b)  
Figure 4.2: One of the patients 
more severely affected with 
LGMD2I, attempting the TUG. 
Figure 4.3: (a) This figure shows one of our more able patients with LGMD2I, 
who was able to ascend the stairs marking time. (b) This figure illustrates a more 
severely affected patient using the rails for support and needing to nudge his foot 
gradually further onto the step as unable to fully lift his leg in hip flexion. 
 93 
(vii) Manual Muscle Testing 
Manual muscle testing (MMT) was performed on the 13 NCL patients on visits 2, 3 and 
4 (table 4.2). The MMT was conducted on the dominant side, right sided in 12 patients 
and left in one. The MMT in hip abduction, hip adduction and knee extension correlated 
with the results obtained with myometry (r = 593, p<0.05; r = .757, p<0.01; r = .607, 
p<0.05 respectively). The other measurements did not correlate and this may be due to 
the subjective nature of the test, although in NCL this was usually performed by the one 
physiotherapist experienced in MMT. It may also be due to the patient‟s ability to 
compensate with other muscle groups particularly in hip flexion and knee flexion, 
which may go unchecked with the MMT manoeuvre compared to using the myometer. 
 
 (viii) Accelerometry 
Accelerometers were worn by the patients for seven days following their assessments to 
monitor their activity. Activity was graded according to how strenuous it was and how 
long it lasted. Length of time in supine and sleep time was also recorded. Average steps 
taken per day were correlated with average fat percentage and the 6MWD. 
Accelerometry readings were obtainable in 14 of the subjects and out of this small 
group a strong correlation was seen with average fat percentage (r = -.68, p<0.01) and 
the 6MDW (r =.62, p< 0.05). 
Muscle Baseline minimum Baseline maximum Baseline median 
Hip Flex 
2 5- 2+ 
Hip Ext 1 5- 2 
Hip Abd  1 5- 3- 
Hip Add  1 2 4 
Knee Flex  0 5 3+ 
Knee Ext  2 5 4- 
Ankle DF 5 5 5 
Ankle PF 5 5 5 
Abd = abduction, Add =adduction, Flex=flexion, Ext=extension, DF=dorsiflexion, PF=plantar flexion 
Table 4.2: Minimum, maximum and median values of the 
manual muscle test scores at baseline. 
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(ix) The adapted North Star Ambulatory Assessment for LGMD 
In the NCL cohort (n=13), the patients were seen within 4 weeks to establish reliability 
of the testing, between the two assessments. The adapted North Star Ambulatory 
Assessment (NSAA) was also completed at visit 1, 2, 3 and 4 in 11 of the patients and 
twice in two of them. The NSAA is used widely in the DMD population. As mentioned 
in chapter 3 this scale is useful for assessing a patient‟s ability, using the activities 
needed for independent daily living. Whilst all these patients were ambulant, the spread 
of ability was wide, to include those that could still run and were very active with no 
apparent limitations to those that only just fulfilled the inclusion criteria of being 
ambulant for more than 50m, however, not able to get up from a standard height and or 
climb the stairs. Timed walking tests, such as the 10m and 6MWD were therefore 
manageable, albeit slow but the TUG, chair rise and stairs were not possible. The 
NSAA is more detailed and grades in a standardised way several functional activities 
important for daily living such as standing, standing on one leg, and sitting up from a 
lying position (See Appendix C) 
Whilst the NSAA is widely used in the DMD community, such a scale has  not been 
employed in an adult population with a limb girdle muscular dystrophy before or in the 
clinical setting - routine assessments often comprise of manual muscle testing and 
comparing these scores with the previous ones. It is imperative, that as clinical trials 
continue to expand to include the rarer neuromuscular disorders, there needs to be 
robust, validated, sensitive and reliable outcome measures. In order to assess whether 
the adapted NSAA and TUG would be suitable for this patient cohort, Rasch  analysis 
was applied to analyse the spread of the items used and whether the tests showed a good 
„fit‟ for this cohort.  
4.3 - Rasch analysis of the North Star Ambulatory Assessment (NSAA) 
The adapted NSAA was tested on the 13 adult patients from NCL. The NSAA was 
adapted from the original design to measure ambulatory function in DMD, by replacing 
item 11 on the form, rise from the floor, with S1, „squats‟. The analysis also included a 
functionally graded run, rise from chair and stair climb and stair descend.  
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The full testing schedule was carried out twice on two individuals and four times on 
eleven individuals giving a total of 48 assessments spanning one year. 
These data were examined using Rasch analysis techniques (Hobart et al. 2007) for item 
fit, targeting, clinical cohesiveness, independence, reliability and stability of items to 
better understand the clinical utility of these items to measure change in this specific 
group. Mayhew et al. (2011) has demonstrated that the NSAA is an effective 
measurement tool, using Rasch analysis. The numbers however were small and 
therefore this has to be borne in mind when reviewing this. The patients used were just 
the NCL cohort, and comprised of 11 patients assessed on 4 occasions and 2 patients 
assessed on 2 occasions. 
(i)Cohort description 
48 assessments were included in the dataset for the 12 month period. Data were entered 
onto the software program Rasch Unidimensional Measurement Model (RUMM2030). 
No invalid records were noted. No extreme individual scores were noted. Table 4.3, 
illustrates the fit statistics, the item fit addresses whether the „items‟ or tests used for 
this group are appropriate and the Fit Residual Mean (FRM) should ideally be close to 
zero and the standard deviation (SD) close to one, which suggests a good item fit. The 
person fit, refers to the fact that the entire group had a similar pattern of involvement 
and predictably fitting the pattern, again the FRM is close to zero and the SD is close to 
one, suggesting a good person fit. 
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Table 4.4 illustrates that the items had a progression of difficulty to them. The item 
person fit residual for each item summarises the fit of the observed data to the statistical 
model from the perspective of the items. A residual is the difference between the 
observed response (score) of a person to an item and the expected value of that person 
to that item as predicted by the model. For each item, residuals are generated for every 
person in the sample who responds to that item. These residuals are then combined 
across persons to give a summary value which is then standardised and transformed so 
that perfect fit has a mean of 0 and standard deviation of 1. Larger fit residuals mean 
worse fit of observed data to the measurement model. Values in the range −2.5 to +2.5 
are considered within statistically acceptable limits (Andrich et al. 2004). Thus, the size 
of the fit residual indicates the degree to which observed responses to items are 
inconsistent with predictions based on the mathematical model. The accompanying 
positive or negative sign gives information as to the nature of this misfit. All but two 
 Fit Residual 
Mean (FRM) 
SD  
Item Fit 0.081 1.226 Suggesting good item fit 
Person Fit 0.108 0.680 Suggesting good person fit 
Chi Squared 
Probability 
0.000   
Degrees of freedom 42   
Pearson Separation 
Index (PSI) 
0.97  The power of your construct to discriminate 
between the respondents. Showing the test is able 
to discriminate between four groups or more. 
High reliability. 
SD=standard deviation, PSI=person separation index 
Table 4.3: Summary Test of Fit Statistics; this illustrates that the item fit is 
good as the FRM is close to zero and the SD is close to one. The person fit is 
also good suggesting that the involvement fits the pattern expected. 
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items fit the construct, with an FRM between -2.5 and + 2.5.  The highlighted items are 
are a slight source of misfit within the scale but significantly. There are no hugely 
misfitting items. The negative items, such as walk and stand, may suggest a redundancy 
of the item within a scale. All patients were able to do this and did not help differentiate 
degrees of severity within the ambulant group. The scale reflects a sensible clinical 
order of difficulty with rise from chair and standing up from a seated position as the 
most difficult to achieve items. Hop was also graded as being particularly difficult for 
this group, however many of the adults were surprised at the request as not many adults 
tend to „hop‟ on a regular basis. The group also found balancing on either leg, an 
activity not usually attempted, and many surprised themselves that they could do this.  
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Item Item 
description Location SE FRM ChiSq Prob 
I0002 Walk -8.506 0.64 -0.065 1.937 0.379721 
I0001 Stand -7.875 0.56 -0.071 1.386 0.500117 
I0004 SLS R -2.243 0.381 0.089 8.618 0.013449 
I0011 Lifts head -2.1 0.336 0.169 64.661 0 
I0005 SLS L -1.701 0.372 0.458 4.782 0.091517 
I0008 Down step R -0.88 0.349 -0.469 2.624 0.2693 
I0009 Down step L -0.78 0.349 -0.439 2.832 0.242673 
I0018 Graded Run  -0.688 0.284 -1.114 1.282 0.526826 
I0006 Up step R -0.484 0.347 -0.381 2.801 0.246423 
I0007 Up step L -0.282 0.343 -0.517 2.966 0.226913 
I0020 Stairs down 0.658 0.205 1.713 5.22 0.073534 
I0012 Heels 0.868 0.34 0.01 4.376 0.11215 
I0019 Stairs up 1.614 0.194 3.333 9.258 0.009764 
I0013 Jump  1.856 0.282 -0.031 0.614 0.735698 
I0010 Lie to sit 2.179 0.38 2.835 12.039 0.002433 
I0017 Squat 2.441 0.377 -2.183 4.347 0.113806 
I0016 Run 2.455 0.366 -0.325 1.386 0.500003 
I0003 Stand up 2.812 0.459 -0.335 2.259 0.323247 
I0014 Hop R 3.244 0.407 -0.62 3.255 0.196381 
I0015 Hop L 3.471 0.403 -0.594 0.724 0.696169 
I0021 
Graded rise 
from chair 3.94 0.28 0.249 7.371 0.025083 
SLR= single leg stance, R=right, L=left, FRM= Fit Residual Mean 
 
  
Table 4.4: Individual Item Fit for the 17 Items in item location (i.e. order of 
difficulty, easiest to most difficult). The FRM should be between +2.5 and -
2.5 if the items fit the construct. Two items highlighted below do fall outside 
of the FRM, but only just and are assessed to be clinically relevant. 
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(ii)Threshold ordering  
The ordering of item threshold statistics indicates the extent to which the item response 
categories are working as intended, to define a progression from „less‟ to „more‟ 
functioning. Thresholds are transition points for adjacent categories. They mark the 
points on the continuum at which a person is equally likely to respond to one or other of 
two adjacent categories. 
 
 
 
 
  
Figure 4.4: Threshold Map for the Adapted NSAA showing 3/17 disordered 
thresholds for the original NSAA scale (lifts head, jump and hop (right) and 
4/4 disordered thresholds for the graded items (graded run, stair climb, stair 
descend and rise from chair). SLS=single leg stance, R=right, L=left. 
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(iii)Category Probability Curves 
The Item characteristic curves (ICC) for each item is a graphic indicator of fit which 
provides complementary qualitative information about the fit of the observed data to the 
model, from the perspective of the trait measured by the items. The ICC is the plot of 
the expected value for an item (y-axis) against the latent variable measured by the set of 
items (in this case, physical or psychological functioning). That plot includes the 
observed mean scores for the people in each class interval defined by their level of 
functioning. The better the fit of the data to the model, the closer the proximity of the 
observed scores to expected values. As a person‟s ability increases (from left to right on 
the graphs, negative to positive logits) there should be distinct points where they are 
more likely to score from 0 to 2 or from 0 to 5 (graded items). The Category Probability 
Curves (CPC) below maps the grading issues with the four graded items. 
 
 
 
 
(a)  
Figure 4.5: (a) Category Probability Curves for Graded Run (a) compared to 
original Run Item (b). In 4.5a, there is clear progression from grade 1 to 2, 2 
to 3 and 3 to 5, with limited progression in 4 indicating that this could be 
combined with grade 3. In 4.5b, whilst there are less grades, 0-2, there is a 
clear progression seen. 
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(b)  
In figure 4.5 it can be seen that there is not a clear progression illustrating grade 4 
(defined as nearly running) could be combined with grade 3, for a better progression. It 
can be seen from some of the other categories that increasing the number of categories 
has added sensitivity although not all the new categories are working correctly. 
(iv)Differential Item Functioning(DIF). 
This DIF outlined in Table 4.5 is difficult to explain with such a small data set, 
however the item, descend step right and left, is graded higher in all levels of severity in 
the women compared to the men in the group. This is seen more visually in the graph, 
figure 4.6, where the female patients score higher compared to the male patients. This is 
an important finding given the gender differences demonstated on the quantitative MRI 
and the pattern on involvement of the vastus medialis in the med compared to the 
sparing of this muscle seen in the female group (Chapter 5.2.1). 
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Item MS F Prob  MS F Prob 
I0001 0.14176 0.43161 0.514704  -0.11644 -0.35453 0.999999 
I0002 0.10295 0.49802 0.484176  -0.09264 -0.44818 0.999999 
I0003 0.22931 0.32384 0.572267  -0.16892 -0.23856 0.999999 
I0004 2.63787 2.90301 0.095632  12.65412 13.92603 0.000553 
I0005 0.96164 0.31141 0.57971  18.80671 6.09024 0.017649 
I0006 1.19312 3.90855 0.054475  -0.80087 -2.62359 0.999999 
I0007 0.03956 0.1153 0.735845  0.42341 1.23393 0.272818 
I0008 2.18754 19.90332 0.000058  -1.00825 -9.17352 0.999999 
I0009 1.99042 18.47603 0.000097  -0.97535 -9.05364 0.999999 
I0010 0.68887 0.22532 0.637419  1.27743 0.41783 0.521457 
I0011 349.2626 13.89507 0.00056  -90.8856 -3.61579 0.999999 
I0012 0.03549 0.04109 0.840319  5.14167 5.95215 0.018897 
I0013 1.14361 6.18128 0.016874  1.65653 8.95362 0.004573 
I0014 0.05765 2.00366 0.164123  0.03218 1.11843 0.296163 
I0015 0.26433 1.65901 0.204627  0.13186 0.82757 0.368048 
I0016 0.06909 0.09472 0.759751  0.40413 0.55407 0.460709 
I0017 0.10937 0.52682 0.471879  2.36546 11.39402 0.001572 
I0018 0.7132 1.34415 0.252701  0.24682 0.46518 0.498869 
I0019 13.12267 3.62902 0.063482  42.9942 11.88988 0.001275 
I0020 1.34541 0.5135 0.477502  17.66956 6.74393 0.012825 
I0021 5.50319 7.21033 0.010256  -1.38819 -1.81882 0.999999 
Table 4.5: DIF by Gender; This shows that the female patients perform 
better than the male patients independent of the severity in the items I0008 
and I0009 (I0008, steps down box right, I0009, steps down box left,). 
 
 
 103 
 
 
 
 
 
 
 
 
Figure 4.7: Person Item Threshold Distribution; The columns in the top half 
are the person locations; the columns in the lower half are the item locations. 
The locations of both items and persons are on the same, equal-interval 
metric. The metric is unbounded and, therefore, runs (theoretically) from –∞ 
to + ∞ and is centred around 0 because the analysis always centres the mean 
of the item locations at zero. Clearly, people located at different places on the 
continuum are assumed to have different levels of mobility. Likewise, the 
adapted NSAA items (functional tests) located at different places on the 
continuum need different amounts of mobility. 
Figure 4.6: DIF for descends box step right. The females consistently 
score higher (red) compared to male patients. 
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In figure 4.7 the spread of the items is wide and the spread equal for the population 
(blue blocks underneath) being measured but there is a number of items at either end 
which are not necessary to measure ability in this population, those items such as stand, 
which is too easy for the cohort. There are also some areas where some of the 
population are not being tested, and hence a true representation of their ability may not 
be reflected. The cohort studied however was small, and therefore may not be a true 
reflection of this group of patients and will need to be extended to include the other 
LGMD2I patients form the other centres. 
 Conclusion of the assessment scales 
All the tests employed were acceptable to the patients and although some patients felt 
less confident due to the risk of falls, most were able to complete the assessment. There 
were no falls or adverse events. All the patients were aware of their limitations and in 
some cases were surprised at the ability that they still had for certain tests, such as; 
standing on one leg. This for many was a task that had not been attempted for a long 
time. Others in the cohort whilst weak proximally on myometry, still had excellent 
functional ability, being able to run, squat and perform normal values in the 6MWD. 
Using the limited Rasch analysis to assess the goodness of „fit‟ and suitability of the 
adapted NSAA to use for individuals with LGMD 2I has proved reasonably successful 
in this cohort. Many of the items have ordered thresholds, which are clinically relevant, 
and the targeting of the scale is appropriate. The limitations in this study were the size 
of the cohort, using the adapted NSAA, and therefore further research needs to be 
completed using this scale in a larger cohort of LGMD2I. This could also be applied to 
assessing other LGMDs to assess motor performance and functional ability. 
4.4 – Correlations with MRI changes 
Whilst the patients in this study were well motivated and keen to achieve the best results 
with the strength and functional testing, this is a subjective measurement and hence may 
not always reflect the true status, extent and indeed progression of the muscle disease.  
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MRI is an objective measurement and as will be seen in the results chapters 5 and 6 can 
accurately delineate the muscles affected as well as detect change longitudinally. Cross 
sectional analysis was made on the 38 patients at baseline, correlating the degree of fat 
infiltration with the standardised physical testing.  
Strong correlations were demonstrated between myometry measures and fat infiltration 
in appropriate muscle groups. The „hamstring average fat %‟ correlated strongly with 
knee flexion r = -.73 (p<0.01) (figure 4.8) and the TUG test (r = .580, P<0.02). There 
was also strong correlation between „hamstring average fat %‟ and the stair climb (r = 
.52, p<0.01), the stair descent (r = .46, p<0.01) and the 6MWD (r = -.79, p<0.01). 
The vastus lateralis muscle (r = -0.75), vastus medialis muscle (r = -0.68) and the rectus 
femoris muscle (r = -0.79) correlated strongly with knee extension. All were significant; 
p=0.01. The „quadriceps average fat %‟ strongly correlated with the stair climb             
(r = .718, p<0.01), the 6MWD (r = -.832, p<0.01), the timed chair rise (r = .743, p<0.01) 
and the TUG test (r = .753, p<0.01). 
 
 
  
Figure 4.8: Hamstring average fat% correlated with knee 
flexion myometry (pounds). This shows a strong correlation r 
=-.73 (p<0.01).  
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The 6MWD, used as an outcome measure in many clinical trials, was also correlated 
against average fat infiltration and the hamstrings. The „average fat percentage‟ is the 
mean across the 14 muscles quantitatively analysed and calculated per person. This 
therefore gives 38 average fat infiltration measurements. This measurement was 
strongly correlated with the 6MWD, r = -.73 (p<0.01) (figure 4.9). The „hamstring 
average fat %‟ also strongly correlated with the 6MWD at r = -.79 (p<0.01) (figure 
4.10). 
 
 
 
  
Figure 4.9: Average fat% correlated with the 6MWD. This 
shows a strong correlation r = -.73 (p<0.01). 
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4.5 – Longitudinal analysis of the assessments 
In this subchapter I will discuss the findings of the longitudinal analysis of the physical 
and functional assessments performed. 
Table 4.6 illustrates that over the 12 month period there was no significant changes in 
the patients standardised physical test measurements. The analysis was performed on 35 
paired individuals (3 did not complete the assessment at follow up, one due to early 
pregnancy, one had recently received a diagnosis of prostate cancer and undergoing 
treatment and one, did not want to participate any further). 
  
Figure 4.10: Hamstring average fat % correlated with the 
6MWD. This shows a strong correlation r = -.79 (p<0.01). 
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Muscle Baseline 
min 
Baseline 
max 
Baseline 
median 
12 
months 
min 
12 
months  
max 
12 
months 
median 
Difference 
(sig) 
Hip Flex 
(pounds) 
2.2 81.1 15.7 3 64 13.2 0.313 
Hip Abd 
(pounds) 
1.4 86.1 18.2 5.2 78.5 12.4 0.442 
Hip Add 
(pounds) 
1.6 58.9 14.0 4.0 74.8 9.10 0.120 
Knee Flex 
(pounds) 
1.9 66.1 18.6 0 70.5 17.9 0.2 
Knee Ext 
(pounds) 
4.3 156.6 24.9 4.4 142.3 21 0.74 
Ankle DF 
(pounds) 
5.6 86.3 38.5 4.0 93.6 45.0 0.249 
Stair climb 
time (secs) 
1.43 46.16 5.32 1.69 ∞ 5.47 0.149 
Stair 
descend 
time (secs) 
1.80 39.9 3.23 1.25 ∞ 3.9 0.501 
Chair rise 
time (secs) 
0.43 27.61 2.60 0.62 ∞ 2.94 0.882 
TUG (secs) 4.3 50.5 11.1 4.1 ∞ 9.8 0.64 
10 metre 
time (secs) 
2.25 21.46 8.30 2.45 25.0 8.8 0.221 
6MWD 
(metres) 
67 625 318.5 50 717.5 354 0.992 
∞ - the maximum time used for the analysis was infinity, as some of the patients were no longer able to 
do this test. Abd = abduction, Add =adduction, Flex=flexion, Ext=extension, DF=dorsiflexion, 
TUG=timed up and Go, 6MWD=six minute walk distance. 
Table 4.6: Minimum, maximum and median values of myometry and the timed tests at 
baseline and follow-up in 35 paired individuals (Non-parametric paired Wilcoxon 
signed rank test). There is no significant difference found between the results at 
baseline and at follow up. 
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All 35 patients attempted the myometry; at baseline all patients registered a recording 
with hip abduction, hip adduction, ankle dorsiflexion, and knee extension. 1 patient was 
not able to generate enough force to produce a reading at both baseline and follow up 
for hip flexion and knee flexion. At follow up there was one further patient that was not 
able to produce enough force to register a recording in both hip flexion and knee 
flexion.  
 
 
 
 
Whilst the time required to perform the 10 metre walk/run and stair climb increased in 
60% of the cohort (n=21), this was not statistically significant. There was no change in 
the time required to descend the stairs in the cohort. 
At baseline six of the patients were unable to perform the TUG test and this was 
mirrored in the chair rise test as five were unable to perform this, four of who had been 
in the group unable to do the TUG test. At follow up the number achieving the TUG test 
had remained the same as baseline; however one of the patients that could not do it at 
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Figure 4.11: Myometry measurements from baseline to 12 months. This figure 
demonstrates that there is a general trend of decreasing strength apart from ankle 
DF which remains strong. (Abd = abduction, Add =adduction, Flex=flexion, 
Ext=extension, DF=dorsiflexion) 
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baseline managed to at follow up and one of the other patients had deteriorated over the 
year and could no longer achieve this task. 
All patients were able to perform the 6MWD at follow up, however one patient at 
baseline did not feel able to as he had flu like symptoms and did not feel he had enough 
energy to sustain his walking for that length of time. This illustrates the subjective 
nature of these assessments; if the patient has not had adequate sleep, or is unwell with a 
viral type illness or does not feel motivated at the time of their assessment, this can lead 
to some misleading values. 
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Figure 4.12: Functional Assessments from baseline to 12 months. This figure shows 
no major changes in the timed tests. (TUG=Timed up and Go, 10m=10 metre 
walk/run) 
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The functional tests were also graded in relation to their difficulty; 1; unable to do, 
whilst a grade 6; is able to do task normally, i.e.: run in the 10metre walk and climb the 
stairs alternate feet with no need for rails. These grades enable scoring of a patient who 
has deteriorated. Whilst they may still able to do the activity, the timing of the activity 
may not reflect the functional loss or compensation that the patient has developed. 
Therefore a patient may take longer to rise from the chair at baseline, but not use their 
hands to push up on the arms of the chair, therefore achieving a better grade (grade 4), 
whereas at follow up they may have deteriorated but have a faster time on the test, as 
they are now compensating and using their arms to push up from the chair, thereby 
scoring a lower grade (grade 2). The timings if taken in isolation may therefore present 
a false result. 
Analysis of the grades for stair climb, 10 metre walk/run and rise from chair at baseline 
and follow up was undertaken (table 4.7). This showed no significant change over the 
12 month period. The majority of the cohort scored the same grade at both baseline and 
follow up, there were a small number who decreased in grades with the stair climb and 
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Figure 4.13: Six Minute Walk Distance (6MWD) changes from baseline to 12 
months. This figure demonstrates no change in the median value of the 6MWD at 
baseline (318.5 metres) and at follow up (354 metres). 
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rise from the chair, however in the 10 metre walk/ run, there were more patients who 
had improved (8/35) compared to those that had deteriorated (4/35). 
 
 
 
FVC changes longitudinally 
As previously stated in this chapter, respiratory involvement as reported by the patients 
was present in 21% (n=8) of the cohort, however when formally tested 33.3% had an 
FVC </= 75% predicted value for their height in sitting. 16.6% had a >/= 20% decrease 
in their FVC in lying and 33.3% had a 10 – 19% decrease in their FVC.  
 At follow up FVC recordings, in both sitting and lying, were obtained in a total of 27 
patients (table 4.8). The results show that the median values of the FVC in sitting and 
lying were 75% and 67% respectively. The maximum values were 100% sitting and 
100% lying, but the minimum values were 48% sitting and 28% lying. 
 
 
 
 
Timed test Number decreased 
grade 
Number increased 
grade 
Number same 
grade 
P value 
Stair climb 
7 2 26 0.150 
10 metre 
walk/run 
4 8 23 0.153 
Rise from chair 6 4 25 0.834 
Table 4.7: The grading of the timed tests, stair climb, 10 metre walk/run and rise from 
the chair, at baseline and follow-up in 35 Paired individuals (Non-parametric paired 
Wilcoxon signed rank test). 
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52% had an FVC </= 75% predicted value for their height in sitting. 19% had a >/= 
20% decrease in their FVC in lying and 19% had a 10 – 19% decrease in their FVC.   
One patient in the cohort now receives nocturnal continuous positive airway pressure 
(CPAP). This did not prevent her from completing the MRI. 
As can be seen in figure 4.14, the FVC changes are apparent in this cohort of patients. 
The FVC measurements were obtained from 27 paired patients paired at baseline and 
follow up. This showed that the majority of patients had a decrease in both their sitting 
and lying FVC, with the decrease in the FVC sitting significant at p=0.001 and lying at 
p<0.05. 
 
 
 
 
 
 
 
 FVC sitting 
(baseline) (n=28) 
FVC lying  
(baseline) (n=28) 
FVC sitting 
(follow up) (n=27) 
FVC lying       
(follow up) (n=27) 
Minimum 
51% 36% 48% 28% 
Maximum 107% 105% 100% 100% 
Median 78% 71% 75% 67% 
Table 4.8: The minimum, maximum and median FVC measurements in % predicted 
for height in both sitting and lying, at baseline and follow-up in 28 patients and 27 
patients respectively. 
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Figure 4.14: Forced Vital capacity (FVC) changes from baseline to 12 months, with 
a significant decrease in both sitting (p=0.001) and lying FVC (p<0.05). 
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4.6 – Discussion 
The assessments performed in this cohort of ambulatory patients with LGMD2I were all 
acceptable to the patients taking part, and no patient fell or injured themselves during 
the assessments. The assessments themselves were labour intensive and required at least 
2 physiotherapists/clinicians to perform them safely and accurately. The 38 patients that 
took part in the initial baseline assessment showed great variability in their disease 
severity, illustrating the heterogeneous nature of this condition and were equally 
matched in both age group and gender. As in previous reports, our cohort had 
respiratory involvement in about a third of patients with 50% of them demonstrating a 
postural drop in their FVC on lying.  
The 6MWD was attempted by all except one at baseline, due to a flu like illness, and 
again this demonstrated great variability in the distances covered. Some patients were 
able to walk at a normal pace, whilst others had to use the wall for reassurance and 
support if they felt as if they were falling. Of interest is the fact that these patients 
generally did not alter their speed and hence the pace and number of laps completed 
were stable. This was also reflected in the 10 metre walk/run, where the majority did not 
pick up speed or alter their pace. The time for the 10 metre walk/run strongly correlated 
with the distance attained on the 6 MWD (r = -.88, p<0.01), therefore the 10 metre 
walk/run maybe an alternative to the 6MWD in this group of patients. This may not 
however be ideal for other conditions, and in particular in children where there is often 
great variability in pace. This would therefore mean that this would be a more 
acceptable and user friendly measurement that could be regularly used in a clinical 
setting due to the space and time required to perform it. 
The Rasch analysis, performed on 13 of the patients, 48 assessments in total, proved 
that the adapted NSAA test items were a good fit for this cohort of LGMD2I, although 
this was in a very small cohort and repeated measurements in the same individuals. It 
did highlight items that did not particularly test the patients abilities, such as walking 
and standing, whereas at the other extreme, some items, in particular the rise from a 
chair and hopping, proved difficult. The Rasch analysis does however show a good 
spread of items and clear progression in order of the tests, with the majority testing the 
group. There was an interesting gender difference, illustrating that the women 
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irrespective of their disease severity, performed the descend step in both right and left 
leg differently to the men. The results are limited due to the analysis being performed 
on a small cohort of the larger group. In order to fully assess the „goodness of fit‟ of 
these items for assessing LGMD2I, one would need to expand the numbers tested. As 
LGMD2I is a relatively rare disorder, this would need to be coordinated on an 
international basis and hence the use of the FKRP registry to do this may be the key. 
The correlations between the quantitative MRI were strong including the functional 
assessments, particularly the 6MWD and 10 metre walk. There was strong correlation 
between the hamstrings and stair climb, stair descend as well as the myometry 
measurements of knee flexion and extension. Knee extension and hip flexion correlate 
strongly with the quadriceps muscles, which in turn correlate with the 10 metre 
walk/run and 6MWD. 
The detection of change over time with standardised physical tests did not show any 
statistical significant change apart from the FVC in both the sitting and lying positions. 
Whilst these functional and strength tests were not significantly different over the 
twelve months, many of the patients did feel that there had been a change in their 
abilities especially in those that were moderate to severely affected. This was not 
reflected in the testing results at 12 months in the group. There are many reasons why 
this may occur. From the literature we know that LGMD2I, whilst a heterogeneous 
condition, does tend to progress slowly with time compared to the more rapid 
progression of DMD and therefore one reason that change may not be appreciated, is 
that a longer interval between examinations may be required. Adult patients also adapt 
very well to a slowly progressive condition and devise ways and means of 
compensating for their weakness, such as employing other muscles to do a manoeuvre 
when the principle muscle is affected by the disease. There is also a threshold as to 
when a muscle becomes so infiltrated with fat and connective tissue that it affects 
function. The patient may then experience a sudden loss of function, such as ambulant 
to non-ambulant, although the process has been slowly ongoing for many years.  
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Chapter 5 – The cross sectional MRI results. 
The aims and objectives in this study were to examine whether quantitative MRI could 
be applied to a cohort of LGMD2I patients and to compare this data with the qualitative 
MRI grading technique.  In this chapter I have reported the MRI scoring using the 
qualitative grading technique in 38 LGMD2I patients and the quantitative fat fraction 
percentage as analysed using the 3 point Dixon technique. These have then been 
compared against each other as well as with some of the functional parameters reported 
in Chapter 4. 
5.1 Semi-quantitative analysis – T1w images 
Pelvis, thigh and lower leg T1w images were analysed for the patient group (n=38), with 
only 22 muscles (1.9%) assessed to be normal (grade 0) and 103 (9.1%) having early 
changes (grade 1), compared to 474 (41.7%) scoring grade 3 and 4. (table 5.1). 
Although the gluteus maximus muscle was not acquired quantitatively, the analysis of 
the T1w images revealed that 80% of the patients scored grade 3 or 4.  In the lower leg, 
involvement of the gastrocnemii and soleus muscles was most noticeable with relative 
sparing of the tibialis anterior until a late stage (figure 5.1a-e). This was most striking 
in patients who had relatively severe involvement of the gastrocnemii with little change 
in the tibialis anterior muscles. The fat fraction in the calf muscles was specific with a 
variegated, striped appearance of the soleus (figure 5.1a-c) and a lacy, reticular pattern 
in both lateral and medial gastrocnemius, commencing initially from the internal 
borders (figure 5.1b & d). The peroneus longus muscle demonstrated „salt and pepper‟ 
speckling (figure 5.1b & e). 
  Figure 5.1: T1weighted images of the lower leg in LGMD2I patients with increasing fat 
fraction (a-e). In image (a) there is involvement of MG and sol compared to image (e) 
where all but TA is severely infiltrated. 
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In the literature it has been reported that there is initial posterior involvement in the 
thigh with gradual progression anteriorly as the disease progresses (Wattjes et al. 2010, 
Fischer et al. 2005). In this cohort there appeared to be the general trend of fewer 
changes seen on MRI in those with milder symptoms compared to those with more 
severe symptoms. The biceps femoris (long head) muscle was most severely affected 
with the semimembranosus and the semitendinosus muscles next (figure 5.2b- e). These 
muscles had a reticular pattern of involvement from the more internal borders out to the 
periphery (figure 5.2c). The vastus lateralis muscle was generally spared until late in the 
disease process. The vastus lateralis muscle demonstrated peripheral sparing, (figure 
5.2d), a reverse of the pattern in Bethlem and Ullrich congenital myopathy when central 
sparing is seen (Mercuri et al. 2005a). The sartorius and gracilis muscles were relatively 
spared and had a stippled appearance with hypertrophy when initially affected (figure 
5.2a, b, c & e), however become atrophied as the fat fraction increases. The rectus 
femoris was also relatively spared with gross hypertrophy in less severe participants 
(21.1% of study cohort) (figure 5.2d). Atrophied recti were seen in patients with more 
extensive changes, as with the sartorius muscle and the gracilis muscle.  
  
(a) (b
) 
(c) (d
) 
(e) 
Figure 5.2: T1weighted images of the thigh in LGMD2I patients with 
increasing degrees of fat fraction (a-e). In (a) this is almost normal, however in 
(e) only sparing of gracilis and sartorius is seen. 
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Table 5.1: Percentage of LGMD2I patients in each category of each qualitative grade for individual 
muscle groups using the Mercuri et al. (2002a) scale, with the median grade for each muscle. 
Semi quantitative grade 0 1 2a 2b 3 4 Median 
grade 
Muscle        
Gluteus Maximus (GM) 0 0 10.5 10.5 26.3 52.6 4 
Biceps Femoris long head (BFLH)  0 2.6 10.5 10.5 13.2 63.2 4 
Semitendinosus (ST)  0 5.3 13.2 10.5 31.6 39.5 3 
Semimembranosus (SM) 0 0 18.4 26.3 18.4 36.8 3 
Biceps Femoris short head (BFSH) 0 8.6 31.4 25.7 25.7 8.6 2b 
Sartorius  (SAR) 2.6 7.9 34.2 28.9 21.1 5.3 2b 
Vastus Medialis (VM) 0 15.8 26.3 13.2 26.3 18.4 2b 
Gracilis (GRAC) 2.6 10.5 42.1 13.2 21.1 10.5 2a 
Vastus Lateralis (VL) 5.3 5.3 21.1 28.9 28.9 10.5 2b 
Rectus Femoris (RF) 10.5 15.8 26.3 21.1 15.8 10.5 2a 
Medial Gastrocnemius (MG) 5.3 7.9 18.4 23.7 21.1 23.7 2b 
Lateral Gastrocnemius (LG) 2.6 18.4 18.4 23.7 28.9 7.9 2b 
Peroneus Longus (PL) 0 18.4 26.3 34.2 18.4 2.6 2b 
Soleus (SOL) 2.6 5.3 42.1 26.3 18.4 5.3 2a 
Tibialis Anterior (TA) 7.9 34.2 47.4 10.5 0 0 2a 
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Comparison of the qualitative grading and the quantitative Dixon imaging across all the 
analysed muscles in the LGMD2I patients (rs = 0.87, p < 0.01) correlated strongly 
(figure 5.3). The grey bars represent the middle 50% of the distribution between the 
upper and lower quartile and their corresponding fat fraction. The dots and stars 
represent points which lie more than 1.5 times but less than 3 times the interquartile 
range (dots) or beyond (stars) 3 times the interquartile range from the upper quartile. 
Whilst this demonstrates that the techniques of grading correlate with the quantitative 
fat fraction percentage values, there is still considerable spread within each grade and a 
high degree of overlap between the grades, suggesting poor specificity. 
 
 
 
Figure 5.3: This figure illustrates the variability seen in patients with LGMD2I; a 
comparison between the semi-quantitative scores and the 3 point Dixon analysis. rs = 
0.87, p < 0.01.  
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5.2 - Quantitative analysis –3 point Dixon technique 
Nine muscles mid thigh and five muscles mid lower leg, a total of 14 muscles per 
patient, were analysed in all 38 subjects. Figure 5.4 summarises the quantitative results. 
The degree of muscle pathology varied significantly from severe, as in the biceps 
femoris long head muscle (median fat percentage 69.7%), to very mild involvement in 
the tibialis anterior muscle (median fat percentage 5.9%). Table 5.2 highlights that all 
muscles in the LGMD2I cohort were affected compared to the control group according 
to the measured quantitative Dixon fat fractions.  
 
 
 
 
  
Figure 5.4: The grey bars illustrate the quantitative fat percentages for LGMD2I 
patients with median qualitative score at the left of the bars. Box indicates lower and 
upper quartiles with median bar; stems show range with outliers more than 1.5 
Interquartile ranges marked separately). 
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Table 5.2: The median values of fat fraction (%) in the patient group and the control group. 
The p values represent Mann-Whitney U test between patients and controls 
Muscle Median 
LGMD2I 
Median 
Control 
P value 
Biceps Femoris long head (BFLH)  69.7 3.9 0.0001 
Semitendinosus (ST)  49.0 2.3 0.00001 
Semimembranosus (SM) 48.6 2.9 0.0001 
Biceps Femoris short head (BFSH) 25.5 3.2 0.001 
Sartorius (SAR) 24.2 3.9 0.001 
Vastus Medialis (VM) 23.3 3.0 0.01 
Gracilis (GRAC) 16.4 3.0 0.0001 
Vastus Lateralis (VL) 14.3 5.5 0.04 
Rectus Femoris (RF) 9.4 3.3 0.03 
Medial Gastrocnemius (MG) 25.1 2.2 0.001 
Lateral Gastrocnemius (LG) 19.4 2.1 0.001 
Peroneus Longus (PL) 16.0 4.9 0.01 
Soleus (SOL) 10.5 3.0 0.001 
Tibialis Anterior (TA) 5.9 2.8 0.02 
The pattern of involvement is illustrated in figure 5.5, with increasing severity in the 
thigh from normal (in a control) (a) to severe (d). These figures illustrate the gradual 
loss of muscle and replacement with fat as seen in the T1w images. The biceps femoris 
long head muscle is particularly affected in figure 5.5b and as can be seen in figure 
5.5c there is increased loss of muscle particularly in the posterior thigh muscles 
affecting the biceps femoris (long head) muscle, semimemebranosus muscle and 
semitendinosus muscle, adductor magnus muscle (not quantitatively measured) and the 
gracilis muscle and sartorius muscle. The anterior thigh muscles are spared. Figure 5.5d 
represents the late stage of this disease with minimal muscle seen with mostly fat and 
fascia visible. This patient, although severe was still ambulant. 
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5.2.1 - Gender differences 
There were some striking gender differences in muscle pathology in our LGMD2I 
cohort. In table 5.3 it can be seen that in the female group there was diffuse 
involvement of both the gastrocnemii muscles; however in the male group the lateral 
gastrocnemius muscle had a lower fat fraction. This contrasts with previous LGMD2I 
studies (Wattjes et al. 2010, Fischer et al. 2005), which had reported diffuse and equal 
involvement of medial gastrocnemius and lateral gastrocnemius compared to 
LGMD2A, where medial gastrocnemius is more involved than lateral gastrocnemius.  
The hamstrings have previously been reported as more severely affected compared to 
the anterior thigh muscles (Wattjes et al. 2010, Fischer et al. 2005). In the female 
subjects there was a trend towards semimembranosus being spared relative to 
semitendinosus (median 28.2% compared with 47.3%). In males these muscles were 
similarly affected, 56.2% and 51.8% respectively.  
The gracilis and sartorius muscles have previously been reported as being relatively and 
equally spared (Wattjes et al. 2010, Fischer et al. 2005). In our male cohort the gracilis 
muscle is more preserved compared to sartorius (p = 0.01). In the female group the 
gracilis and sartorius muscle were equally affected.   
Figure 5.5: Quantitative Dixon fat fraction from a control thigh (a) and of LGMD2I 
patients with increasing fat fraction (b)-(d). 
 
 124 
 
The anterior thigh muscles also demonstrated gender differences; in the female subjects 
the vastus lateralis and vastus medialis were affected similarly (18.2% and 18.9%,) 
whilst in the male subjects there was a greater fat fraction, 45.7% in vastus medialis 
compared to 11.2% in vastus lateralis (p<0.005) (figure 5.6). This result is particularly 
interesting given the results of the Rasch analysis on the adapted NSAA reported in 
chapter 4 (table 4.5), where the women regardless of their disease severity, completed 
the task of descend box step, right and left, consistently better than the male patients and 
when visualising their walking appeared to walk straighter without a compensatory turn 
out of the feet and side to side swing of the legs as seen in many of the male patients. 
This however was carried out on a small cohort (n=13) of the larger group and would 
therefore need to be extended to the other centres to examine whether this finding is 
replicated in the larger group. 
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Table 5.3:  Median values of the fat fraction for the study cohort (19 males and 19 
females). It illustrates significant differences between the anterior thigh muscles in the 
male group and preferential sparing of the gracilis compared to sartorius. These features 
are not found in the female group.  
Muscle Male Female 
Semitendinosus (ST)  51.8 45.3 
Semimembranosus (SM) 56.2
* 
28.2 
Sartorius  (SAR) 24.0 25.1 
Gracilis (GRAC) 13.7
** 
25.0 
Vastus Lateralis (VL) 11.2 18.2 
Vastus Medialis (VM) 45.7§ 18.9 
Medial Gastrocnemius (MG) 22.2 28.0 
Lateral Gastrocnemius (LG) 15.1† 33.7 
* p = 0.05 compared to male ST 
** p = 0.01 compared to male SAR 
 § p < 0.005 compared to male VL 
† p = 0.05 compared to male MG 
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(i)         (ii)        
Interfamilial differences 
There were changes also seen with two sisters who were of similar ages (58 years, 55 
years), who were both similar with regards to their strength and functional ability 
however on MRI their lower leg images were very different with one sister obtaining 
results within normal limits (figure 5.7), whilst the other had a significant increase in 
fat fraction of both her gastrocnemius muscles (figure 5.8). 
     
 
Figure 5.7: Sister 1 (58 
years); within normal limits. 
 
 
Figure 5.8: Sister 2 (aged 55 years); 
increased fat fraction in the  medial and 
lateral gastrocnemius muscles. 
 
 
Figure 5.6:  These MRI scans illustrate the medial vastus changes seen 
in the male (i) and the preservation seen in the female (ii). 
 
 
 127 
 
5.2.2 – Correlation with the patients age and duration of symptoms. 
Cross sectional analysis was made on the 38 patients at baseline, correlating the degree 
of fat fraction with age, duration of symptoms and the standardised physical testing (as 
previously reported in chapter 3).  
There was a positive correlation seen between average fat percentage and age (r =.48, 
p<0.01) (figure 5.9), but there was no correlation between average fat percentage and 
the duration of symptoms (figure 5.10).  
 
 
 
 
 
Figure 5.9: Age correlated with average fat%. This shows a correlation r =-.48 
(p<0.01). 
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5.3 - Discussion 
This is the largest reported cross sectional MRI study (n=38) of patients with LGMD2I 
due to the common mutation in the FKRP gene. Both traditional qualitative grading and 
quantitative fat imaging have been employed to measure the differing degrees and 
pattern of muscle involvement, quantitative fat percentage and the relationship with 
functional tests. Disease progression and severity of individual muscle involvement in 
patients with LGMD2I can often be difficult to assess clinically and therefore there is 
need for reliable objective measures.  
Within the literature T1w MRI analysis of patients with LGMD2I demonstrated 
pathology in the posterior thigh muscles (Bushby and Beckmann, 1995, Wicklund and 
Hilton-Jones, 2003, Wattjes et al. 2010, Fischer et al. 2005, Mercuri et al. 2005b). More 
Figure 5.10: Duration of disease symptoms correlated with average fat%. This 
shows no correlation. 
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specifically the changes seem to occur in the biceps femoris and internal adductor 
muscles first and with further disease progression the rest of the hamstring muscles 
become involved and to a lesser degree the vastus intermedius and lateralis muscles. 
Fischer et al. (2005) reported that involvement of the vastus medialis and rectus femoris 
muscles was only observed in those patients with advanced disease. The results from 
this study confirmed the qualitative findings of these previous studies; however we have 
also demonstrated that in the male group there was a more severe and earlier 
involvement of the vastus medialis muscle compared to the vastus lateralis muscle 
unlike in the female group. This has been detected as a difference in the functional 
assessments, as reported in chapter 4, that the female patients descend the box step 
better than the male patients, regardless of their severity. Descending steps depend upon 
functioning quadriceps and if there is a difference in the level and pattern of fraction 
within the quadriceps muscles, this will alter the way in which this task is performed.  
In the gastrocnemius muscles, diffuse and equal involvement (Wattjes et al. 2010, 
Fischer et al. 2005) has previously been reported. However in our study, the male group 
demonstrated a predominantly medial involvement.  
This cross sectional part of the study has demonstrated that there are a few potential 
target muscles that could be used for the assessment of pathological changes for clinical 
trial purposes. This will be explored further in chapter 6 when reporting on the 
longitudinal data. Figure 5.4 highlights the suitability of certain muscles for these 
assessments based upon the fat fraction. The muscles that appear to be the most suitable 
demonstrate a wide range of fat fraction within the cohort. The biceps femoris long 
head, semimemebranosus and semitendinosus muscles may be considered less suitable 
to monitor as they have more than a 50% fat fraction in at least 50% of the LGMD2I 
population. Conversely the tibialis anterior muscle would also be considered less 
suitable due to limited pathology even in the severely affected patients. 
There have been a number of studies addressing the more severe type of muscular 
dystrophy, DMD, highlighting both the natural history and its effect on muscles 
assessed by MRI (Mercuri et al. 2005c, Fischer et al. 2005). DMD is now subject to 
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clinical trials and at present therapeutic success is assessed by muscle biopsy and by 
functional outcomes, such as the 6MWD. These tests however are either invasive or are 
highly dependent on patient cooperation. MRI is both non-invasive and objective and is 
therefore a powerful quantitative tool for trials when considered along with the strength 
and functional measures. Wren et al. (2008) demonstrated that the quantitative Dixon 
technique correlated well with functional outcome measures in DMD as well as age. 
The severity of muscle involvement in our cohort was not related to the onset of 
symptoms (disease duration) but was associated with age of the patient. There were 
strong correlations seen between fat percentage and functional timed tests which may 
reflect disease severity, such as the 6MWD (Chapter 4; figure 4.12) and the TUG test (r 
= .633, p<0.01). Whilst some of these tests are now being employed in therapeutic drug 
trials in patients with DMD (McDonald et al. 2010), with the 6MWD as a primary 
outcome, the correlations need to be taken in conjunction with both the clinical 
examination and findings.  
Myometry was found to significantly correlate with some muscle MRI fat percentages 
as previously described in chapter 4. Our cohort of patients was well motivated and the 
functional tests were performed to their best. This demonstrated that these tests were 
well matched and correlated if the patients were performing to their full potential. In the 
usual clinic setting this may not be possible in all patients.  
There remains variability between the two methods of assessment which is not 
accounted for on an individual patient basis: a result of 250m on the 6MWD can be 
associated with a fat fraction between 10 and 70%. This is a wide range and whilst MRI 
is an objective measure of muscle health, it cannot be interpreted in isolation.  
MRI therefore may be useful as a monitoring tool on an individual patient basis to 
assess change/deterioration or in the advent of a therapy to monitor improvement. 
Longitudinal analysis of this cohort will therefore assess whether change has occurred 
over time in this cohort, and this is reported in Chapter 6. 
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Limitations; This MRI study, although carried out in the largest LGMD2I cohort to 
date, was still small and would ideally need to be extended to include more 
asymptomatic and paediatric patients. The assessment was also limited to analysis of the 
quantitative Dixon scans at one level mid point in the lower leg and thigh. Ideally one 
would assess the ROIs at all levels and analyse the variability that is seen within each 
muscle. This may give further information as to how the process of muscle damage 
occurs in this condition and potential muscles that can be used in clinical trials as 
biomarkers.  
The cross sectional part of this study has shown that quantitative fat imaging provides 
an objective measurement of the fat fraction that is more sensitive than the previous 
qualitative technique. We have found a similar pattern of muscle involvement as 
previously described in the literature but have also demonstrated gender differences not 
previously reported. These quantitative techniques could be used on an individual 
patient basis to monitor both disease progression and in the future, improvement in the 
advent of a therapeutic agent. 
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Chapter 6 – The longitudinal MRI results. 
The aims and objectives of this study were to assess the progression of muscle 
pathology in patients with LGMD2I by muscle MRI, both qualitatively and 
quantitatively. I also compared quantitative MRI to qualitative MRI and analysed 
whether MRI would be a sensitive enough biomarker to detect change over a 12 month 
period of time, and hence a possible outcome measure to monitor disease progression. 
The results of this work are outlined in this chapter and include the longitudinal 
qualitative results, the longitudinal quantitative results and discussion of these findings. 
6.1 - Analysis of T1w images 
The follow up analysis was limited to 32 participants of the original 38 due to the 
following reasons. Two patients could not take part due to early pregnancy since the 
first visit and this was one of the contraindications to undergoing an MRI in a research 
setting and was outlined in the ethical approval for the study. MRI during pregnancy has 
not be proven to cause deleterious effects on human embryos or foetuses and represent 
an excellent imaging mode if the clinical need dictates and ultrasound scanning is not 
sufficient (Levine et al. 1999, Amin et al. 1999). Due to limited data on MRI safety 
within the first trimester, it was agreed that for study purposes, patients in the early 
stages of pregnancy be excluded (Levine et al. 1999). One further participant was 
unable to complete the follow up MRI as he was undergoing treatment for a recently 
diagnosed malignancy and one participant did not want to remain in the study.  
34 participants therefore underwent the follow up MRI scans; however two of the 
follow-up scans were not adequately repositioned for analysis and therefore were 
excluded from the final statistical testing. 
The statistical analysis has therefore been performed on the 32 paired participants (17 
male and 15 female; aged between 19 years and 65 years, mean ages of 40.9 years in the 
male group and 42.3 years in the female group) and their qualitative and quantitative 
results. 
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Pelvis, thigh and lower leg T1w images were scored for the patient group (n=32), as in 
the cross sectional study. The whole muscle was analysed and scored according to the 
Mercuri et al. (2002a) grading scheme (table 6.1). 48 muscles (5%) were assessed to be 
normal (grade 0) and 94 (9.8%) had early changes (grade 1), compared to 414 (43.1%) 
scoring grade 3 and 4. Although quantitative 3 point Dixon data for the gluteus  
maximus muscle was not acquired, the scoring of the T1w images revealed that 81.3% 
of the patients scored grade 3 or 4.  
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Table 6.1: Percentage of LGMD2I patients in each category of each semi-quantitative 
grade for individual muscle groups using the Mercuri et al. (2002a) scale, with the 
median grade for each muscle. Follow up data 12 months from baseline 
Semi quantitative grade 0 1 2a 2b 3 4 Median 
grade 
Muscle        
Gluteus Maximus (GM) 0 3.1 12.5 3.1 25.0 56.3 4 
Biceps Femoris long head 
(BFLH)  
3.1 3.1 9.4 9.4 9.4 65.6 4 
Semitendinosus (ST)  3.1 6.3 9.42 9.4 18.8 53.1 4 
Semimembranosus (SM) 3.1 6.3 12.5 15.6 18.8 43.8 3 
Biceps Femoris short head 
(BFSH) 
3.1 9.4 21.9 25.0 21.9 18.8 2b 
Sartorius  (SAR) 3.1 6.3 37.5 18.8 21.9 12.5 2b 
Vastus Medialis (VM) 9.4 12.5 18.8 6.3 28.1 25.0 3 
Gracilis (GRAC) 3.1 12.5 34.4 12.5 25.0 12.5 2b 
Vastus Lateralis (VL) 6.3 12.5 9.4 25.0 28.1 18.8 2b 
Rectus Femoris (RF) 9.4 15.6 21.9 21.9 15.6 15.6 2b 
Medial Gastrocnemius (MG) 6.3 6.3 12.5 28.1 18.8 28.1 2b 
Lateral Gastrocnemius (LG) 6.3 12.5 15.6 18.8 37.5 9.4 2b 
Peroneus Longus (PL) 6.3 6.3 40.6 25.0 15.6 6.3 2a 
Soleus (SOL) 3.1 12.5 28.1 28.1 21.9 6.3 2b 
Tibialis Anterior (TA) 9.4 25.0 56.3 9.4 0 0 2a 
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In the semitendinosus muscle, the median score changed from grade 3 to grade 4. In 
reviewing table 6.1, it can be appreciated that there was a shift in percentages of scans 
scored a grade 4 at follow up (53.1%) compared to at baseline (39.5%). The majority of 
this increase has come from previously graded scans being scored a grade 3, 31.6% at 
baseline and 18.8% at follow up. The percentages of muscles scored in grade 0-2b are 
fairly constant for this muscle from baseline to follow up. 
In the vastus medialis muscle, the median score changed from a grade 2b to a grade 3. 
This is due to an increase in scans scored a grade 4 at follow up (25%) compared to at 
baseline (18.4%). The majority of this increase appears to come from previously graded 
scans scoring a grade 2b, 13.2% at baseline and 6.3% at follow up. This represents a 7% 
increase of scans scoring a grade 3 at follow up from a grade 2b at baseline, and 
likewise a subsequent 7% increase in scans scoring grade 4 from grade 3 at baseline, 
therefore maintaining a constant percentage scoring grade 3 at baseline and follow up. 
Peroneus longus, unlike the other muscle groups, the median score changed from 2b to 
a follow up score of grade 2a. Whilst the percentage scoring a grade 0 and 1 appears to 
be greater than the baseline scan, the numbers of patients actually scoring a grade 0 and 
1 is a total of 4, compared to the baseline where a total of 7 patients scored grade 1. 
There also appears to be an increase in scoring a grade 2a in the follow up scan, 40.6%,  
compared to the baseline of 26.3%, however this refers to 10 and 13 patients 
respectively and in total the number of patients scoring grade 0, 1 and 2a equates to 17 
patients in both the baseline and follow up scans. 
Further analysis of the changes from baseline to the follow up scan in the qualitative 
T1w scans show no significant differences with little change either increasing or 
decreasing in the scoring and grades (table 6.2).  
Whilst overall the grades remain the same with no significant changes, there are some 
grades that increase and others that decrease. This is seen particularly in the peroneus 
longus muscle, as discussed earlier. There is an apparent increase in the numbers of 
patients scored a grade 0, 1 and 2a where in fact patient numbers scoring these grades in  
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Table 6.2; Number of patients with a decreased, increased or „same grade‟ 
qualitative grade at from baseline to follow up. (Non-parametric paired Wilcoxon 
signed rank test) 
Muscle Number 
decreased grade 
Number 
increased grade 
Number same 
grade 
Gluteus Maximus (GM) 3 4 25 
Biceps Femoris long head 
(BFLH)  
2 1 29 
Semitendinosus (ST)  5 4 23 
Semimembranosus (SM) 7 5 20 
Biceps Femoris short head 
(BFSH)* 
5 4 20 
Sartorius  (SAR) 5 8 19 
Vastus Medialis (VM) 8 8 16 
Gracilis (GRAC) 5 4 23 
Vastus Lateralis (VL) 5 10 17 
Rectus Femoris (RF) 4 6 22 
Medial Gastrocnemius 
(MG) 
4 7 21 
Lateral Gastrocnemius 
(LG) 
4 10 18 
Peroneus Longus (PL) 10 7 15 
Soleus (SOL) 4 5 23 
Tibialis Anterior (TA) 3 3 26 
* BFSH was graded in 29 participants. 3 were scans were impossible to grade due to poor image 
resolution severe infiltration or positioning. 
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both baseline and follow up scans are the same. It is the distribution of these grades that 
is altered. This reflects the difficultly and the poor specificity of the grading system 
when performing longitudinal studies. A scan that appears to have a fat fraction of 
approximately 30% may be given a grade of a 2a or a 2b as the cut off limit is 30%, as 
with grade 1 and 2a, a mild degree of pathology and less than a 30% fat fraction 
respectively. It can be difficult to appreciate when a scan changes from mild to less than 
30% and hence a score of 1 or 2a.  
6.2 - Quantitative analysis  
As in the cross sectional study (Chapter 5.2) nine muscles mid thigh and five muscles 
mid lower leg, a total of 14 muscles per patient, were analysed in all 32 subjects. In each 
scan the midpoint of the thigh and lower leg was identified and the ROI highlighted 
from the baseline (S0) scan was matched to the follow up (S1) scan. The „goodness of 
fit‟ depended on the positioning of the patient at follow up and landmarks used as set 
out in the protocol. For some patients the original ROI shapes required adjustment for 
the altered shape of the patient leg.  
The degree of muscle pathology, as at baseline, varied significantly from severe, in the 
biceps femoris long head muscle (median fat fraction 75.2%), to very mild involvement 
in the tibialis anterior muscle (median fat fraction 5.2%).  
As can be seen in table 6.3, the median fat fraction increased from baseline (S0) to 
follow up (S1) and was significant in 9 out of the 14 muscles and in 2 there was a non-
significant increase. The 3 muscles that did not increase were the peroneus longus 
muscle, the tibialis anterior muscle and biceps femoris short head muscle. Whilst the 
median fat fraction appeared to decrease in these muscles, none of them reached 
significance levels.  
The biceps femoris short head muscle decreased by 0.6% however the minimum and 
maximum level of pathology increased from baseline (2.7% - 78.1%) to follow up 
(4.1% - 82.3%), likewise in the peroneus longus muscle.  
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In the tibialis anterior muscle, there was only at 0.3% decrease in the median fat 
fraction, which is within the limits of error of the technique (0.5%) (Lim et al. 
2011).The minimum and maximum values at baseline and follow up were closely 
matched. 
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Table 6.3: Median values of the fat fraction at baseline (S0) and follow up (S1). (Non-
parametric paired Wilcoxon signed rank test) 
Muscle S0 min S0 max S0 
median 
S1 min S1 max S1 
median 
S1-S0 
differenc
e (sig) 
TA 1.4 24.6 5.5 1.3 23.5 5.2 0.627 
MG§ 1.1 90.3 21.7 1.3 90.3 22.6 0.009 
LG§* 0.8 88.4 19.3 0.8 87.8 23.9 0.009 
PL 2.8 55 15.1 3.2 61.8 14 0.896 
SOL 1.5 84.9 9.1 2.1 86 10.9 0.246 
SAR§* 0.85 88.9 24.2 3.4 87.5 25.3 0.010 
GRAC
§* 
2.3 81.7 25.3 3.9 84.2 26.6 0.018 
SM§ 2.6 94.1 49 2.9 95.6 54.2 0.015 
ST§ 2.3 100 55.7 2.1 96.1 59.7 0.021 
VL§* 0.6 82.1 15.6 1.2 82.1 20.9 0.025 
VM 1.1 89.1 25.6 0.8 83.5 30.9 0.065 
RF§* 0.4 81.3 10.9 0.8 82.1 12.3 0.028 
BFSH 2.7 78.1 25.5 4.1 82.3 24.9 0.065 
BFLH§ 1.5 97.3 71.6 2.2 94.4 75.2 0.004 
Av Fat 
PC§ 
1.9 69.1 28.5 2.4 67.1 31.3 0.003 
§ - significant differences between S1 and S0 
BFLH=Biceps Femoris long head, ST= Semitendinosus, SM= Semimembranosus, BFSH=Biceps 
Femoris short head, SAR= Sartorius, VM=Vastus Medialis, GRAC=Gracilis, VL=Vastus Lateralis, 
RF=Rectus Femoris, MG=Medial Gastrocnemius, LG=Lateral Gastrocnemius, PL=Peroneus Longus, 
SOL=Soleus, TA=Tibialis Anterior. 
* - possible muscles for future longitudinal analysis; In lower leg; LG, In thigh; SAR, GRAC, VL and 
RF. 
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The nine muscles identified above were those that reached significant differences 
between S0 and S1.  
The semitendinosus, gracilis and rectus femoris muscles which had increased 
significantly quantitatively did show a shift in qualitative grades from a 3 to a 4, 2a to 
2b and 2a to 2b respectively, although these were not significant. Although the soleus 
and vastus medialis muscle also showed a shift in qualitative grading from a 2a to a 2b 
and 2b to 3 respectively, they did not show a significance change when analysed 
quantitatively. Six of the muscles that had increased significantly on quantitative 
analysis did not show any change in qualitative grades. These included the lateral and 
medial gastrocnemius muscles, vastus lateralis muscle, sartorius muscle, 
semimembranosus muscle and biceps femoris long head muscle.  
In considering future longitudinal studies and even larger therapeutic trials, the data 
presented in table 6.3 has identified potential muscle groups that might be suitable as 
outcome measures in further longitudinal studies in LGMD2I. The muscles that have 
been identified from table 6.3 have been further defined based on the amount of fat 
fraction on the quantitative MRI scan and the range of spread of that fat fraction.  In the 
lower leg the soleus, the Peroneus longus and tibialis anterior muscles did not change 
significantly, whilst both medial gastrocnemius and lateral gastrocnemius muscle did. 
Both were similarly affected however the medial gastrocnemius muscle would be 
preferential as the ROI mid calf was easier to delineate. 
In the thigh there was more significant change seen in the sartorius, gracilis, 
semimembranosus, semitendinosus, vastus lateralis, rectus femoris and the biceps 
femoris long head muscles. The semimembranosus, semitendinosus and the biceps 
femoris long head muscles generally had a high fat fraction with median levels of 
54.2%, 59.7% and 75.2% respectively and hence would be more difficult to monitor on 
a longitudinal basis.  
The gracilis and sartorius muscles showed overall very similar levels of change over the 
12 month period, however the gracilis muscle is the easier of the two muscles to 
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identify midthigh as the sartorius muscle often had ill defined fascial borders and 
baseline ROIs appeared to have a better fit on follow up scans with the gracilis muscle.  
The rectus femoris and vastus lateralis muscles are also easy muscles to delineate in the 
thigh and could be useful in monitoring.  
As in chapter 6.1, the quantitative scores were analysed to assess the number of 
participants with either increased or decreased fat fraction percentage values. Unlike the 
qualitative scoring there were no participants with figures identical to the baseline, 
however those within the limits of error of the technique, (0.5%) were regarded as 
unchanged. As demonstrated in table 6.4, most of the participants have had an increase 
in their fat fraction; however some have had a decrease. The average decrease in fat 
fraction was 4.88%, with some muscles such as semitendinosus, biceps femoris short 
head and peroneus longus having the highest fat fraction decrease and this may 
represent poor repositioning on the follow up scan as these muscles were some of the 
more difficult ones to realign, and hence could result in the fat fraction being analysed 
and recorded at a different level. This therefore highlights that the precision in 
realignment is vital for accurate analysis.  
Amongst the participants that had a decrease in fat fraction there were 8 who appeared 
to be more commonly associated with a decrease in fat fraction and this may reflect the 
repositioning of those participants. Out of the 8 participants that had the majority of the 
recorded decreases in fat fraction, 2 were mildly affected and in these participants, 1/3 
of the muscles remained unchanged and 1/3 decreased, 2 were moderately affected 
participants and again approximately 1/3 remained unchanged and 1/3 had a decrease in 
fat fraction, the other 4 patients were more severely affected. The most changes were 
seen in semimembranosus, with a fat fraction decrease of 8.6% in these patients and this 
muscle was the more difficult to delineate especially in those patients who were more 
severely affected. Therefore the majority of decreases in fat fraction or unchanged fat 
fractions were seen in a 8 of the participants, this therefore could reflect overall poor 
repositioning and particularly in those more severely affected, difficultly in ROI 
delineation and hence accurate measurements.  
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Table 6.4: Number of patients with a decreased or increased fat fraction at 12 months. 
Muscle Number % 
decreased 
Number % 
increased  
Unchanged 
Biceps Femoris long head 
(BFLH)  
4 23 4 
Semitendinosus (ST)  6 19 7 
Semimembranosus (SM) 6 20 5 
Biceps Femoris short head 
(BFSH) * 
8 15 6 
Sartorius  (SAR) 5 19 8 
Vastus Medialis (VM) 6 16 10 
Gracilis (GRAC) 5 21 6 
Vastus Lateralis (VL) 6 17 9 
Rectus Femoris (RF) 5 21 6 
Medial Gastrocnemius (MG) 5 19 8 
Lateral Gastrocnemius (LG) 7 18 7 
Peroneus Longus (PL) 9 14 9 
Soleus (SOL) 8 11 13 
Tibialis Anterior (TA) 9 9 14 
* BFSH was graded in 29 participants. 3 were scans were impossible to grade due to poor quality, severe 
infiltration or positioning. 
 
6.3 - Gender differences 
As reported in chapter 5 (section 5.2.1) striking gender differences were described. 
These differences of muscle pathology were seen in the sartorius and gracilis muscles, 
the medial lateral gastrocnemius muscles, the hamstring muscles and most significantly 
between the vastus lateralis and vastus medialis muscles (p<0.005). The gender 
differences (table 6.5) seen in the follow up scans were not as significant as seen at 
baseline. At baseline there were 38 patients analysed, however as the follow up data was 
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only on 32 patients, there is a less significant difference seen. This maybe due to the 
loss of key patients or possibly the need for greater numbers to illustrate this.  
The female subjects continued to demonstrate diffuse involvement of both the 
gastrocnemii muscles (22% and 23.5%) with no significant difference. The medial 
gastrocnemius muscle in the male group continues to have a fat fraction of 38.7% which 
is higher compared to the lateral gastrocnemius muscle (24.2%) which has a similar fat 
fraction to the female subjects, however the result is not significant (p=0.08).  
In the female subjects there was a trend towards semimembranosus being spared 
relative to semitendinosus at baseline (median 28.2% compared with 47.3%), however 
this value was not seen when only the 32 at follow up were analysed at baseline, 
indicating that possibly the loss of 4 female patients has influenced these values. The 
differences has now equalised and there is similar fat fraction in the hamstrings both in 
the male (60.3% and 59.2%) and the females (51.7% and 51%), with no significant 
differences.  
In the male subjects the gracilis muscle continued to be better preserved (15.8%) 
compared to the sartorius muscle (24.2%) but does not reach significance (p = 0.06). In 
the female group the gracilis and sartorius muscle are equally affected and similar to the 
male fat fraction in the sartorius muscle (28.8% and 26.3% respectively). 
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Table 6.5:  Median values of fat fraction for the study cohort (17 males and 15 females) 
at baseline (S0) and at follow up (S1). It illustrates significant differences between the 
anterior thigh muscles in the male group and preferential sparing of the gracilis muscle 
compared to the sartorius muscle. These features are not found in the female group.  
Muscle Male S0 Female S0 Male S1 Female S1  
Semitendinosus (ST)  60.4 50.9 60.30 51.70 
Semimembranosus 
(SM) 
51.8
* 
43.8 59.2
*
 51.0 
Sartorius  (SAR) 24.0 24.2 24.2 26.3 
Gracilis (GRAC) 15.5
** 
26.1 15.8
**
 28.8 
Vastus Lateralis (VL) 14.3 18.2 20.5 24.6 
Vastus Medialis (VM) 45.6§ 23.3 50.0§ 26.2 
Medial Gastrocnemius 
(MG) 
28.7 17.8 38.7 22.0 
Lateral Gastrocnemius 
(LG) 
19.6† 19.3 24.2† 23.5 
* p = 0.03 compared to male ST 
** p = 0.02 compared to male SAR 
 § p = 0.001 compared to male VL 
† p = 0.08 compared to male MG 
* p = NS compared to male ST 
** p = 0.06 compared to male SAR 
 § p = 0.02 compared to male VL 
† p = 0.08 compared to male MG 
 
BFLH=Biceps Femoris long head, ST= Semitendinosus, SM= Semimembranosus, BFSH=Biceps Femoris 
short head, SAR= Sartorius, VM=Vastus Medialis, GRAC=Gracilis, VL=Vastus Lateralis, RF=Rectus 
Femoris, MG=Medial Gastrocnemius, LG=Lateral Gastrocnemius, PL=Peroneus Longus, SOL=Soleus, 
TA=Tibialis Anterior. 
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The anterior thigh muscles continued to demonstrate gender differences; in the female 
subjects the vastus lateralis and vastus medialis muscles are affected similarly (24.6% 
and 26.2%) whilst in the male subjects there continues to be a greater degree of fat 
fraction, 50.0%, in vastus medialis muscle compared to 20.5% in vastus lateralis muscle 
(p=0.02). 
6.4 - Case study 
Case A was a 33 year old male that was initially diagnosed as having a „liver problem‟ 
following a biochemical profile which suggested liver inflammation. He had raised liver 
enzymes identified after routine bloods before donating blood. Following this he 
underwent lengthy gastroenterology investigations and cut out any alcohol he was 
drinking. His CK continued to be raised at 12,000units/l and eventually a muscle 
problem was suspected. He had no family history and no symptoms of note. In his early 
20‟s he noticed some slowing of his running ability, however he continued to be very 
active running 9 miles out of a 13 mile run in 2009. On formal testing, he did have 
weakness in his hip flexors, hip adductors and abductors, but was otherwise strong. He 
ran the 10m walk and achieved normal values for the 6MWD and other timed tests. He 
has obvious proximal weakness when getting up from lying, however is not limited in 
his chair rise or TUG test. 
He was assessed on four occasions for the standardised physical examination, the 
second examination, not recorded here, was within four weeks of the first examination 
for inter-rater reliability and test-retest validity. As it can be seen from figure 6.1, he 
showed no changes over the 12 months in his myometry strength recordings. He also 
showed no change in his 6 MWD and NSAA as shown in figures 6.2 and 6.3 
respectively. 
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Whilst Case A‟s strength and functional testing remained stable, his quantitative MRI 
results showed significant changes (figure 6.4) particularly in his medial gastrocnemius 
muscle (28.7% fat fraction at baseline and 49.7% at follow up) and biceps femoris long 
head muscle (77.1% fat fraction at baseline and 86.5% at follow up). These changes can 
Figure 6.1: Baseline, 6 months and 12 months myometry results in patient A. 
This shows no deterioration in results. (flex=flexion, add=adduction). 
 
Fig 6.2: Six minute walk test (6MWD) 
at baseline, 6 and 12 months, showing 
stability over 12 months    
Fig 6.3: adapted NSAA at baseline, 6 
and 12 months, which is stable 
scoring 33/34 for all assessments. 
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be appreciated in the 3 point Dixon figures 6.5 and 6.6. There is also a significant 
increase in the fat fraction in the medial and lateral vastus muscles as well as peroneus 
longus muscle. The changes in the medial gastrocnemius muscle were evident on the 
T1w image, but the other changes were not visible. Neither were they reflected in the 
qualitative scores, where the biceps femoris long head, vastus lateralis and Peroneus 
longus muscles remained the same (grade 4, 2b and 2b respectively). The medical 
gastrocnemius muscle scoring changed from a grade 2b to a 3, however this was 
because the change occurred across a boundary point of 30%, which was reflected in the 
score. 
 
 
  
 
  
Figure 6.4: Baseline and 12 months quantitative MRI results, showing an 
increase in the fat fraction of MG (Medial Gastrocnemius), BFLH (Biceps 
Femoris long head), PL (Peroneus Longus), VM (Vastus Medialis) and VL 
(Vastus Lateralis) muscles. There was no change in the TA (Tibialis Anterior) 
muscle. 
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(i)  (ii)  
 
(i)  (ii)  
This case illustrates that quantitative MRI imaging longitudinally by 3 point Dixon does 
pick up changes prior to clinical change. These changes were significant and seen in a 
patient who was one of the less affected participants and hence the ideal candidate if a 
therapeutic trial was imminent. Current clinical trials have functional measures, such as 
the 6MWD, and strength measurements as primary and secondary outcome measures 
(Chapter 4), but these would not have detected any change in case A over a 1 year 
period. MRI could become a useful adjunct in defining the outcome of a study. 
Figure 6.5 - Baseline MRI using 3 point Dixon mid lower leg (i) and mid thigh 
(ii). 
 
Figure 6.6: Follow up MRI 3 point Dixon mid lower leg (i) and mid thigh (ii) 
illustrating in 6.6(i) the obvious fat increase in the medial gastrocnemius muscle 
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6.5 - Discussion 
The longitudinal quantitative study demonstrated changes to a significant level in the 
majority of muscles. This was in contrast to the longitudinal qualitative study which did 
not demonstrate any significant change in any muscle group. The lack of significant 
change in the qualitative study is mainly due to the broadness of the grading system 
which does not enable small changes to be detected unless they occur across one of the 
boundary points of the scale, such as 30% or 60% muscle fat. Some of the grades are 
less well defined such as grade 1 and 2a, this therefore reduces the power of the 
qualitative scoring scheme for longitudinal studies or accurate monitoring of early 
disease progression, which is potentially the crucial time for effective treatment and 
prevention of progression. 
Even though LGMD2I is a slowly progressive condition, the results revealed that 
significant changes in fat infiltration did occur over the twelve month period. The 
changes occurred in the majority of the muscle groups but whilst some muscles were 
severely affected at baseline, others demonstrated a more modest level of infiltration 
and showed a variable spread. 
Limitations; As highlighted earlier two participants from the Copenhagen cohort were 
excluded after being scanned, as the positioning of the patient at follow up was different 
to baseline and this made it difficult to accurately compare the two scans. Other 
repositioning issues were of a different order of magnitude making placement of the 
ROI drawn at baseline difficult to apply to the follow up scan. Using the baseline ROI 
ensured that the slice level that was being assessed on the follow up scan was at the 
same level as the baseline. ROI placements, in well positioned patients and with a good 
quality scan, fitted well with little need for adjustments in some cases (figure 6.7), some 
however were less well aligned and needed some adjustments to get a good fit (figure 
6.8). 
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(i) (ii)  
(iii) (iv)  
  
Figure 6.7: Baseline (i and iii) and follow up (ii and iv) MRI scans using the 3 
point Dixon technique – example of a good ROI fitting due to precise leg 
repositioning. 
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(i)        (ii)   
Registration is vitally important and recording measurements from baseline scans is 
paramount. Whilst the legs can be kept still and in position with straps, foam pads or 
vacuum bags, care needs to be taken not to induce any outward pressure on the legs as 
seen in some scans (figure 6.8(i)). 
As seen in table 6.3 significant changes were seen after only 12 months in the LGMD2I 
cohort and these were seen in a majority of muscles. In a large multicentre longitudinal 
study or therapeutic trial, measurements of all these muscles would not necessarily be 
feasible and on this basis we would aim to highlight three or four possible candidate 
muscles that would illustrate the changes. Reviewing the table this would therefore 
mean that the medial gastrocnemius muscle in the lower leg and the gracilis muscle, 
vastus lateralis muscle and rectus femoris muscle in the thigh would be potential 
candidate muscles for future analysis. These muscles have been identified due to their 
significant change over time, level of fat fraction, ease of identification and consistent 
ROI placements on a longitudinal basis 
Figure 6.8: Baseline (i) and follow up (ii) MRI scans using the 3 point Dixon 
technique – example of a poor ROI fitting due to imprecise leg repositioning. 
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Chapter 7 - Skeletal MRS Results 
Skeletal muscle MRS was performed in two of the centres taking part as it was not 
possible to perform MRS in the other centres. As a result 20 of the patients from NCL 
and Paris underwent MRS as part of the MRI examination. As discussed in chapter 3, 
this was conducted in different but comparable ways in NCL and Paris. MRS was 
primarily performed to assess whether any metabolic abnormalities could be detected in 
this cohort of patients and in particular whether any of the changes observed predated 
the changes seen on the qualitative and quantitative MRI scans or clinical changes. If 
this were the case this may indicate that MRS could be used as a preclinical/early 
biomarker. 
In this chapter I will therefore report on the results that were found in the two cohorts, 
both as a whole and separately. 
7.1 - The patient cohort 
The NCL cohort was older at a mean age of 43.3 years and percentage fat in the MR 
signal was increased compared to the Paris cohort (mean age 38.3 years). The MRS 
method, as discussed in chapter 3, obtained spectra from the gastrocnemius and soleus 
muscles under rest, exercise and recovery conditions. The mean fat fraction for the 
soleus muscle was 20.8% in the NCL cohort versus 7.8% in the Paris cohort, the 
gastrocnemius muscle was 39% in the NCL cohort versus 16% in the Paris cohort and 
for their „average fat percentage‟ was 32.8% in the NCL cohort versus 12.5% in the 
Paris cohort.  
7.2 - Resting metabolite concentrations 
PDE resting concentrations for the LGMD2I patients were on average 44% higher than 
those of the control group (table 7.1, p = 0.002). The concentration of inorganic 
phosphate (Pi) was also raised (by 36%, p = 0.0002) at rest, whilst the concentration of 
phosphocreatine (PCr) showed no significant change at rest. The ratio of the initial 
Pi/PCr reflected these contributions, rising by 35% (p = 0.0002).  
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7.3 - Oxidative function during exercise 
There was no significant difference in the half-time for PCr recovery (table 7.1), either 
uncorrected or corrected for end-exercise pH, indicating that there is no impairment in 
maximal oxidative function in the LGMD2I patients. 
7.4 - pH handling 
The baseline pH prior to exercise was found to be raised for the LGMD2I patients as a 
whole group (7.056 for patients with LGMD2I vs 7.039 for controls, p = 0.05) and 
continued to remain high at the cessation of exercise (7.077 for patients with LGMD2I 
vs 6.9763 for controls, p = 0.025) and at the minimum pH obtained during the recovery 
(6.990 for patients with LGMD2I vs 6.835 for controls, p = 0.03).  
7.5 - Correlation with degree of fat fraction 
Neither the percentage fat in the MR signal of the gastrocnemius, soleus or their average 
was found to correlate with the concentration of PDE, Pi or the ratio of Pi/PCr when 
applied to the group as a whole. When analysed separately, the NCL group did have 
some correlations with the fat fraction in their lower legs. The decrease in PCr 
positively correlated with the fat fraction in the gastrocnemius muscle (r = .599, 
p<0.05), and also with the average fat fraction of the soleus and gastrocnemius muscles 
together (r = .615, p<0.05) (figure 7.1). These correlations were not seen in the Paris 
cohort. 
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There were also negative associations between the inorganic phosphate and the pH 
(r =-.835, p<0.01) and the PDE was also negatively associated with the Pi/PCr 
(r = -.659, p<0.05). Neither of these associations were seen with the Paris cohort of 
patients. Table 7.2 therefore shows the two groups split into the Paris cohort and the 
NCL cohort 
7.6 - Discussion 
The skeletal muscle MRS part of this study has examined both the phosphorus 
metabolite metabolism at rest and under exercise in just over half (n=20) of the total 
LGMD2I cohort.  
  
Figure 7.1: This illustrates the correlation seen between the average fat 
percentage in the soleus and gastrocnemius muscles and the drop in PCr 
concentration. (r = .615, p<0.05) 
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Resting metabolite concentrations 
The alterations in resting metabolite concentrations are consistent with measurements 
made in other muscular dystrophies. The 36% increase of inorganic phosphate 
concentration is smaller than that reported for DMD (68%, Younkin et al. 1987, 109% 
in Kemp et al. 1993, and 60%, Banerjee et al. 2010), and to some extent in BMD (16% 
Lodi et al. 1999, 47% Kemp et al. 1993). This is in contrast to a previous study on 
LGMD due to sarcoglycan deficiency, where a fall in inorganic phosphate concentration 
was reported (Lodi et al. 1997). 
There was a 44% increased concentration of PDE seen in the patients with LGMD2I 
and again this is less marked compared to the changes found in DMD (2300% increase 
in Younkin (1987), and 162% increase in Banerjee (2010). The PDE measurements are 
not reported by Lodi and colleagues (1999) in BMD patients, however Kemp et al. 
(1993) does not show a significant difference compared to controls. The study on 
LGMD due to sarcoglycan deficiency did not measure the PDE (Lodi et al. 1997).  
Although the Pi/PCr ratio was increased, the resting phosphocreatine (PCr) 
concentration was not significantly different to the control group. The raised Pi/PCr 
ratio was solely due to the raised Pi concentration. In the previous studies in patients 
with DMD and BMD (Kemp et al. 1993, Younkin et al. 1987, Griffiths et al. 1985, 
Newman et al. 1982) it has demonstrated that there is both an increase in the Pi 
concentration as well as a decrease in PCr concentration, suggesting a decrease in total 
creatine concentration. The changes seen in LGMD2I suggest that the total creatine 
concentration is less affected than in DMD and BMD. 
The raised Pi concentration and PDE suggest a loss of membrane integrity and hence 
membrane breakdown (Younkin et al. 1987). This appears less marked in the LGMD2I 
cohort compared to the more severely affected patients with BMD and DMD where the 
increases are more significant.  
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Oxidative function during exercise 
Comparable depletions of phosphocreatine were achieved in the LGMD2I patients and 
controls, suggesting mitochondrial oxidative function post-exercise is not impaired in 
LGMD2I.  This has been described in previous studies, with normal mitochondrial 
function reported in BMD (Lodi et al. 1999), DMD (Kemp et al. 1993) and 
sacoglycanopathy-deficient limb girdle muscular dystrophy patients (Lodi et al. 1997).  
pH handling 
Resting pH is higher in LGMD2I patients compared to the controls (p=0.05). pH at the 
cessation of exercise was also higher for LGMD2I than controls and remained higher at 
minimum exercise. 
Analysis method 
The acquisition hardware and analysis were not identical at the two sites, which reflects 
the established practice at the two centres. In this analysis, „peak picking‟ of the Pi 
resonance has been used to calculate pH. The Pi peak is usually symmetrical 
conventionally as shown in figure 7.2. In some LGMD2I patients with advanced 
disease, however, the Pi resonance is not symmetrical at baseline and there is a small 
component which has a chemical shift, appearing as a shoulder, suggestive of a more 
alkaline component. 
This component has been disregarded in the present analysis: in principle it would be 
possible to account for this component by integrating the Pi resonance and finding the 
centre of mass of the resonance. This process has been attempted on the NCL and Paris 
data, but owing to its sensitivity to the baseline of the phosphorus spectra, no robust and 
unified approach could be agreed. Resolving this issue will form the basis of future 
studies in this cohort. 
In conclusion therefore, this cohort of LGMD2I patients does have similar, albeit less 
marked, changes to those seen in DMD and BMD. There is an increased concentration 
of resting inorganic phosphate and raised PDE levels at rest, which suggest a loss of 
membrane integrity and hence membrane breakdown. There was no evidence of 
mitochondrial dysfunction. Whilst there was evidence of some correlations with the fat 
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fractions seen on the quantitative MRI, this was only present in the NCL cohort, who 
were more severely affected than the Paris cohort. Further longitudinal work will need 
to be conducted to assess whether skeletal muscle MRS is a valuable early biomarker of 
the disease process. 
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 LGMD2I 
patients (n = 
20) 
Controls  
(n = 14) 
p-value (not 
corrected for 
multiple 
comparisons) 
Age  41 ± 12 38 ± 12 ns 
PDE concentration prior to 
exercise (mM) 
 
2.91 ± 0.90  
 
1.96 ± 0.69  0.002 
Pi concentration prior to exercise 
(mM) 
4.24 ± 1.04  
 
3.09 ± 0.45 0.0002 
PCr concentration prior to 
exercise (mM) 
 32.7 ± 3.6  33.2 ± 1.9 ns 
Ratio of Pi/PCr (-)  0.1298 ± 
0.0294  
0.0944 ± 
0.013 
0.0002 
Baseline pH prior to exercise (-) 7.056 ± 0.033  
 
 
7.039 ± 
0.015 
0.05 
pH at cessation of exercise (-) 
 
7.077 ± 0.060  
 
6.976 ± 
0.144  
0.025 
Minimum pH during exercise (-)  6.990 ± 0.045  6.835 ± 
0.231 
0.03 
Depletion of PCr during exercise 
(%) 
34 ± 11 42 ± 15 ns 
Half-time for PCr recovery, 
uncorrected (s) 
36.6 ± 11.4  38.7 ± 9.3 ns 
Half-time for PCr recovery, 
corrected for end-exercise pH (s) 
36.6 ± 11.4 35.2 ± 7.1 ns 
Percentage fat in gastrocnemius 
(%) 
31.8 ± 22.7 2.5 ± 0.9* - 
Percentage fat in soleus (%) 16.4 ± 14.5 2.9 ± 1.0* - 
Average fat in gastrocnemius and 
soleus (%) 
26.1 ± 19.0 2.6 ± 0.9* - 
Table 7.1:  
31
P MRS results for the two centres (NCL and Paris) as one group with 
controls (* control fat fraction data only available for NCL controls n=7). 
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 LGMD2I 
Paris  
(n = 7) 
LGMD2I 
Newcastle 
(n = 13) 
Controls Paris 
(n = 7) 
Controls 
Newcastle 
(n = 7) 
Age  38 ± 9 43 ± 14 35 ± 10 40 ± 15 
PDE concentration 
prior to exercise 
(mM) 
 
2.64 ± 0.86 
 
3.04 ± 0.92  1.72 ± 0.83  2.20 ± 0.46  
Pi concentration 
prior to exercise 
(mM) 
4.87 ± 0.95  
 
3.95 ± 0.98 3.26 ± 0.43 2.92 ± 0.42 
PCr concentration 
prior to exercise 
(mM) 
34.0 ± 0.7 
 
32.1 ± 4.2 33.4 ± 2.2 33.0 ± 1.6 
Ratio of Pi/PCr (-) 0.143 ± 0.029 0.123 ± 0.028 0.100 ± 0.013 0.089 ± 0.012  
Baseline pH prior to 
exercise (-) 
7.080 ± 0.035 
 
 
7.046 ± 0.027 7.035 ± 0.016 7.044 ± 0.035 
pH at cessation of 
exercise (-) 
7.086 ± 0.111 
 
7.073 ± 0.030 6.907 ± 0.179 7.045 ± 0.038 
Minimum pH (-) 6.975± 0.043 6.996 ± 0.046 6.681 ± 0.242 6.989 ± 0.042 
Depletion of PCr 
during exercise (%) 
43 ± 7 
 
30 ± 11 50 ± 16 34 ± 8 
Half-time for PCr 
recovery, 
uncorrected (s) 
 
38.1 ± 10.7 36.1 ± 12.0 41.8 ± 11.3 
 
35.6 ± 6.0 
Half-time for PCr 
recovery, corrected 
for end-exercise pH 
(s) 
41.2 ± 11.9 34.9 ± 10.3 36.3 ± 9.0 
 
34.0 ± 4.9 
Percentage fat in 
gastrocnemius (%) 
17.3 ± 16.1 38.7 ± 23.4 n/a 2.5 ± 0.9 
Percentage fat in 
soleus (%) 
7.8 ± 7.9 20.8 ± 15.7 n/a 2.9 ± 1.0 
Average fat in 
gastrocnemius and 
soleus (%) 
12.5 ± 10.3 32.8 ± 19.6 n/a 2.6 ± 0.9 
Table 7.2: 
31
P MRS results for the two centres (NCL and Paris) considered 
separately, together with their controls. 
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Figure 7.2: Phosphorus spectrum from the gastrocnemius and soleus of a healthy 
control at 3.0T showing relative concentrations of inorganic phosphate (Pi), 
phosphodiesters (PDE),  phosphocreatine (PCr) and adenosine triphosphate (ATP) 
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Figure 7.3 : A selection of phosphorus spectra acquired from the gastrocnemius and 
soleus of an LGMD2I patient at 3.0T during recovery from a plantar flexion exercise. A 
decreasing concentration of inorganic phosphate (A) and the replenishment of 
phosphocreatine (B) can be measured. The rate of recovery of the phosphocreatine acts 
as a surrogate measure for maximal mitochondrial function. 
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Chapter 8 - Cardiac muscle imaging and spectroscopy results 
Cardiac MRI was performed on the NCL cohort following the 12 month follow up 
skeletal MRI. The main objective of this part of the study was to assess whether cardiac 
MRI is more sensitive in detecting cardiac change in these patients as reported by Gaul 
et al. (2006). If this is the case then early intervention with cardioprotective drugs could 
be commenced, preventing further damage. 
8.1 - Cardiac Morphology and function by standard cine-MRI 
Cine-MRI was successfully interpreted in all ten LGMD2I subjects. One male patient 
with LGMD2I was excluded from the study due to previous use of recreational drugs 
which is known to have an effect on cardiac function and can cause a cardiomyopathy 
(Ghuran and Nolan, 2000). The patient cohort therefore comprised of 7 male patients 
and 3 female patients, with a mean age of 47 years, ranging from 22 - 65 years (table 
8.2).  Five of the patients were known to have a cardiomyopathy and were on 
appropriate medication as listed in table 8.1. Five did not have a known 
cardiomyopathy and reportedly had normal echocardiograms. 
 
Subject 
 
Medications 
1 perindopril 4mg, fluvostatin, torteridine, fenesterate 
2 perindopril 8mg, nebivolol 2.5mg 
3 perindopril 6mg, bisoprolol 5mg, calcium with Vitamin D 
4 lisinopril 10mg, bisoprolol 5mg, losec 20mg, frusemide 40mg 
5 lisinopril 10mg (for BP), arimidex (breast Ca) 
6 perindopril 8mg, bisoprolol 5mg 
7 nil 
8 painkillers (solpadol) 
9 nil 
10 nil 
 
  
Table 8.1: List of patient medication 
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10 gender, age-, weight- and BMI- matched subjects were recruited by advertisement as 
controls (table 8.2). All the control subjects were screened with a 12-lead ECG to 
exclude cardiac abnormalities and blood pressures were recorded to exclude those with 
hypertension (systolic blood pressure greater than 150 mmHg and/or diastolic blood 
pressure greater than 90 mmHg).   
The most significant functional impairments found by cine-MRI in the LGMD2I 
patients were reduced ejection fractions (mean 47% vs 58% in controls, p = 0.017) and 
reduced stroke volume (61ml vs 81ml, p = 0.038, table 8.2). 
The decrease in stroke volume arose mostly from the trends of increased end-systolic 
volume and reduced end-diastolic volumes in LGMD2I patients, though neither of these 
reached statistical significance in themselves. The resting heart-rates were no different 
between the patients and controls. Neither left ventricular mass nor left ventricular 
index were raised significantly for the group as a whole and there was no significant 
difference in cardiac wall thickness at either diastole or systole between the LGMD2I 
patients and the control group 
In diastole, the peak early filling rate was reduced by 26% in LGMD2I (283 ml/s vs 380 
ml/s). This was not significant under multiple correction and there was no significant 
difference in any other measure of diastolic function (late filling rate, E/A ratio or early 
filling percentage).  
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Parameter LGMD2I Controls p 
n 10 10  
Age (years) 47 ± 14 48 ± 12 ns 
Weight (kg) 80 ± 2 81 ± 1 ns 
Body mass index (kg/m
2
) 26.8 ± 4.0 27.5 ± 3.6 ns 
Body surface area (m
2
) 1.92 ± 0.24 1.88 ± 0.21 ns 
Systolic blood pressure (mmHg) 137 ± 10 132 ± 15 ns 
Diatolic blood pressure (mmHg) 86 ± 11 76 ± 9 ns 
    
Ejection fraction (%) 47.3 ± 7.4 58.1 ± 4.4 0.017 
Stroke volume (ml) 61.1 ± 1.1 80.9 ± 1.3 0.038 
Resting heart rate (bpm) 62 ± 9 58 ± 9 ns 
Cardiac output (l/min) 3.8 ± 0.7 4.6 ± 0.5 ns 
End diastolic volume (ml) 134 ± 38 140 ± 27 ns 
End systolic volume (ml) 72 ± 28 59 ± 16 ns 
Left ventricular mass (g) 116 ± 31 109 ± 21 ns 
Left ventricular index (g/m
2
) 60 ± 15 58 ± 7 ns 
Left ventricular mass/end diastolic 
volume (g/ml) 
0.88 ± 0.08 0.78 ± 0.10 ns 
    
Torsion to endocardial strain ratio (rad) 0.31 ± 0.05 0.51 ± 0.14  0.028 
Peak torsion (deg) 3.9 ± 1.3 6.4 ± 1.5 0.038 
Longitudinal shortening (%) 17.0 ± 3.0  18.4 ± 3.5 ns 
Peak whole wall circumferential strain 
(%) 
16.4 ± 3.2 18.3 ± 3.5 ns 
Peak endocardial circumferential strain 
(%) 
21.4 ± 4.2 22.2 ± 2.7 ns 
Peak circumferential strain rate in 
systole (%/s) 
0.082 ± 0.016 0.082 ± 0.010 ns 
Diastolic wall thickness (mm) 7.08 ± 0.85 6.84 ± 1.01 ns 
Systolic wall thickness (mm) 10.86 ± 1.17 10.69 ± 1.92 ns 
Radial thickening (%) 54 ± 14 56 ± 13 ns 
PCr/ATP ratio 1.50 ± 0.24 1.94 ± 0.12 0.0001 
    
Peak ejection rate (ml/s) 271 ± 69 366 ± 109 ns 
Early filling rate (ml/s) 283 ± 87 380 ± 114 ns 
Late filling rate (ml/s) 192 ± 63 226 ± 69 ns 
E/A ratio 1.67 ± 0.79 1.89 ± 0.92 ns 
Early filling percentage 67 ± 10 71 ± 10 ns 
Table 8.2: Cardiac parameters for LGMD2I and controls subjects (mean ± s.d.) 
p values result from Student t-tests with Bonferroni correction for multiple 
comparisons 
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8.2 - Cardiac tagging measurements: Selective reduction in torsion related to 
changes in global left ventricular volumes and function. 
Cardiac tagging was successfully analysed in eight subjects, two of the datasets had 
respiratory artefact. The peak cardiac torsion was significantly reduced in the LGMD2I 
patients compared to the controls (mean 3.9
o
 vs 6.4
o
, p = 0.038, table 8.2), while there 
was no significant change in peak circumferential strain (whole wall) achieved (16.4% 
vs 18.3%, ns). 
The torsion to endocardial strain ratio (TSR) was also found to be significantly reduced 
in LGMD2I patients (mean 0.31 ± 0.05 vs 0.51 ± 0.14, p = 0.028). This was due to 
reductions in torsion alone, as there were no changes in the endocardial circumferential 
strain (normal controls 22.2 ± 2.7%, and LGMD2I 21.4 ± 4.2%). Longitudinal 
shortening, which is generally reduced in association with age-related cardiac changes, 
was not significantly altered in LGMD2I patients compared to controls (17.0 ± 3.0 vs 
18.4 ± 3.5 %). Therefore the LGMD2I patients appear to have a selective loss of torsion 
with other strains preserved. In the two LGMD2I patients with normal values of torsion, 
endocardial circumferential strain rates were actually higher than those of normal 
controls (p = 0.008, figure 8.1). This suggests a loss of subepicardial function in these 
patients, though the interactions between layers is preserved, or even increased.  
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(i) 
 
(ii) 
 
         
Figure 8.1: (i) Peak endocardial circumferential strain compared between the 
controls, LGMD2I patients with markedly reduced peak torsion (< 4 degrees) and 
those with normal peak torsion ( > 5 degrees). (ii) Plot showing the basis of division 
of the LGMD2I group, where 2 subjects have normal peak torsion compared to the 
rest. 
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Impairments in peak cardiac torsion and the torsion to endocardial strain ratio correlated 
strongly with impairment in ejection fraction (r = 0.93, p < 0.001 and r = 0.88, p < 0.004 
respectively, figure 8.2), though the change in peak torsion and TSR was much larger 
than that of LVEF (39% for torsion, 39% for TSR and 19% for LVEF). Peak torsion 
and circumferential strain were strongly correlated (r = 0.94, p = 0.001).   
 
 
(i) 
 
 
 
 
 
 
(ii) 
 
 
 
 
 
 
 
Figure 8.2: For the LGMD2I patients, correlation between LV ejection fraction and 
(i) peak torsion, (ii) torsion to endocardial strain ratio. 
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8.3 - Cardiac spectroscopy 
The cardiac spectrum for one LGMD2I patient had insufficient (signal to noise ratio) 
SNR for analysis. The ratio of PCr/ATP was significantly reduced in the LGMD2I 
patients compared with the control group as a whole (mean 1.50 vs 1.94, p < 0.0005, 
and figure 8.3). Cardiac energetics were not correlated with peak cardiac torsion, 
though there was a borderline correlation between reduced PCr/ATP ratio and reduced 
cardiac output (r = 0.66, p = 0.05) 
 
  
Figure 8.3: PCr/ATP ratio for the LGMD2I patients and controls 
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8.4 - Correlation of cardiac parameters with age 
Within the LGMD2I group, reduced stroke volume correlated strongly with increasing 
age (r = -0.78, p = 0.007) and a reduction in LV mass and LV index correlated with 
increasing age (r= -0.77, p = 0.009, figure 8.4i), which was not found in the control 
group (figure 8.4ii). However, there was no direct correlation between ejection fraction 
or peak cardiac torsion with age. By dividing the LGMD2I patients into two groups 
about their median age, 45 years, and considering the LV index and PCr/ATP ratio 
(table 8.3), there was a trend of worsening cardiac energetics with increasing age, 
which may suggest an initial rise in LV index in younger patients before a decrease with 
ageing (table 8.2). 
 
 
(i) 
 
 
 
 
 
(ii) 
 
 
 
Figure 8.4: Correlation between LV index and age for (i) LGMD2I patients and (ii) 
control subjects. 
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8.5 - Ultrasound findings 
Routine clinical cardiac ultrasonography, performed for screening purposes, was 
available for 7 of the 11 subjects recruited, including the one patient subsequently 
excluded from the study. The main abnormalities noted were dilation of the left and 
right atria (4/7) and low ejection fraction (5/7): these features were also identified on 
cine MRI. The right ventricle was reported to have normal size and function for all 
patients. The four valves were reported to have normal structure and function in 6 
reports with trace/mild mitral regurgitation in 5 subjects. The diastolic function as 
measured by E/A and E/Ea ratios correlated strongly with MRI measures but was only 
available for 5 of the LGMD2I patients. 
 
 
 
 Control Younger LGMD2I Older LGMD2I 
PCr/ATP ratio (-) 1.94 ± 0.12 1.65 ± 0.19 1.37 ± 0.21 * 
Left ventricular index 
(g/m
2
) 
58 ± 7 69 ± 15 51 ± 6 ‡ 
Stroke volume (ml) 81 ± 13 67 ± 6 55 ± 12 
Cardiac output 
(l/min) 
4.6 ± 0.5 4.1 ± 0.4 3.4 ± 0.8 
Peak torsion (
o
)  6.4 ± 1.5 4.0 ± 1.7  3.8 ± 1.0  
Ejection fraction (%) 58 ± 4 46 ± 9 48 ± 6 
‡ p = 0.07 vs young LGMD2I by ANOVA, * p = 0.02 vs young LGMD2I by ANOVA. 
PCr = phosphocreatine, ATP  = adenosine triphosphate. 
Table 8.3: The two LGMD2I groups; younger (<45 years) and older (> 45 years).  
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8.6 - Discussion 
This is the first time cardiac energetics and myocardial motion by MR tagging in 
patients with LGMD2I has been examined. It has demonstrated impaired cardiac 
energetics, and significantly reduced torsion and torsion to endocardial strain ratio in the 
absence of a significant reduction in peak circumferential strain or longitudinal 
shortening.  Cine imaging revealed that left ventricular ejection fractions and stroke 
volumes were significantly reduced, however there was no significant increase in 
myocardial mass, whether or not it was normalized for body surface area. 
The combination of reduced torsion and preserved circumferential strains found in 
LGMD2I is unique compared to changes found in other cardiomyopathies: in idiopathic 
cardiomyopathy there is a significant reduction in peak circumferential strain without 
significant change in peak torsion (MacGowan et al. 1997). A similar finding was 
reported for one study of DMD patient (Ashford et al. 2005), though other DMD studies 
have not reported torsion results, but only reduced circumferential strains (Hor et al. 
2009, Hagenbuch et al. 2010). 
The study of the development of cardiac disease in the mdx mouse model of DMD (Li 
et al. 2009) showed a biphasic change in cardiac torsion and strain, where mdx mice at 2 
months showed increased peak torsion and circumferential strain, at 7 months 
demonstrated comparable torsion and strain to control mice and at 10 months torsion 
and strain were decreased compared to controls. This was accompanied by reduction in 
ejection fraction and stroke volume, and with continued increase in cardiac mass with 
age. There was no evidence in this study for any of the cohort having increased torsion 
compared to the controls, though the endocardial circumferential strain was 
significantly raised in two of the LGMD2I patients with normal peak torsion. In a -
sarcoglycan null mouse model, circumferential strains were mostly impaired at 8 
months with reduction in ejection fraction, but torsion was not assessed (Wansapura et 
al. 2011). 
The timely release of torsion and strain during diastole is crucial for good early diastolic 
filling, and the low peak torsions achieved by the LGMD2I patients may underlie the 
reduced early filling rate observed (26% lower than control subjects, in comparison with 
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a 18% reduction for the mdx mice vs wild-type) though the peak ejection rate was also 
26% lower than controls.  
In previous work (Hollingsworth et al. 2010) on healthy young (mean age 31 ± 6y), 
middle-aged (mean age 50 ± 9) and older groups (mean age 62 ± 2y), it was found that 
the TSR remained constant between the young and middle-aged groups (mean 0.45 and 
0.46 respectively), while it was raised by 41% in the oldest group (mean 0.62). The 
increase in torsion and TSR in older control adults indicated that there had been an 
alteration in the transmural distribution of strain, and, in particular, that subendocardial 
fibres were not making a proportionate contribution to systolic ejection compared to the 
subepicardial fibres, with a consequent increase in torsion. It has been observed that the 
endocardium is particularly sensitive to insult, as has been shown in histopathology of 
ischemic tissue (Ishijima et al. 1990), by studies of transmural wall motion in stunned 
myocardium that has recovered from an ischemic insult (Bolli et al. 1989, Mazhari et al. 
2001) and in patients with aortic valve stenosis (Van der Toorn et al. 2002). The 
significantly reduced torsion and torsion to endocardial strain ratio in LGMD2I patients 
are in contrast to the above studies and indicate that the pathogenesis and localization of 
disease is rather different to the ageing phenotype. This indicates that, rather than a 
preferential dysfunction in the endocardium as per ageing, myocardial impairment in 
LGMD2I is concentrated at the epicardium and that there is abnormal transmission of 
mechanical forces from endo to epicardium. 
Impairments in cardiac energetics have been measured previously in DMD and BMD 
patients (Crilley et al. 2000). In that study the PCr/ATP ratio was 36% lower for both 
patients and carriers compared to matched controls, in contrast to 23% lower obtained in 
this study. Crilley et al (2000) demonstrated that there was no correlation between 
energetics, ejection fraction, or left ventricular mass. The origins of changes in cardiac 
energetics were investigated by a study in 8 months old mdx mice (Zhang et al. 2008). 
The PCr/ATP ratio was reduced by 29%: this was concurrent with a 22% fall in total 
creatine and a 38% fall in PCr. This was not accompanied by any change in left 
ventricular dimensions or systolic function. In this study cardiac total creatine was not 
analysed, due to the techniques used. The wall stresses arising from unequal fibre 
shortening between endo and epicardial walls in the LGMD2I patients may alter oxygen 
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consumption within the tissue, leading to changes in cardiac energetics as found 
elsewhere (Strauer et al. 1977, Arts et al. 1982). 
8.7 - Conclusion 
The limitations of this study include the small number of patients studied (n=10), and, 
the fact that this data was acquired at the same time as a comprehensive skeletal muscle 
MRI and a full physical examination. It was therefore not possible to collect delayed 
late gadolinium enhancement (LGE) images which look for the presence of myocardial 
fibrosis. There are few studies demonstrating this in LGMD2I (Yilmaz et al. 2009), but 
it is also clear from cardiac tagging studies of DMD that abnormalities in cardiac 
tagging parameters can be detected before myocardial fibrosis is visible on LGE MRI 
(Ashford et al. 2005). Due to the limited quantitative information reported from routine 
ultrasound imaging, it was not possible to objectively compare the two techniques. 
This data gives an insight into the pathogenesis of cardiac dysfunction, with early 
reduction in myocardial energetics which worsens with age, and early reductions in 
cardiac torsion and ejection fraction. Despite the small numbers, there is the suggestion 
that cardiac mass increases early in the disease course before decreasing. These results 
therefore demonstrate, for the first time, the strength of cardiac spectroscopy and 
cardiac tagging to distinguish changes in cardiac function in LGMD2I patients. Further 
longitudinal studies in large multi-centre cohorts will be required to assess the cardiac 
progression in LGMD2I. 
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Chapter 9 – The International FKRP patient registry 
In this chapter I will discuss the importance of patient registries for rare diseases, such 
as LGMD2I and the setting up of the International FKRP patient registry as part of my 
project. I will discuss how the International FKRP patient registry works and how such 
a registry may contribute to “trial readiness” for this group of patients. 
9.1 Preparing the patients for future trials/registries 
Those diseases that are termed „rare‟, whilst clinically heterogonous and individually 
rare make up a substantial proportion of the population as a whole, 6-8% at some stage 
in life (Schieppati et al. 2008). Within the neuromuscular world, inherited 
neuromuscular diseases are thought to affect between 152,000 and 228,000 people, with 
prevalence between 75-2,800 people with LGMD2I, based on an EU population of 
501million. There is no curative treatment, however with clinical trials now ongoing in 
Duchenne muscular dystrophy, Spinal Muscular Atrophy and Pompe disease, 
collaboration is essential. 
Cooperation with partners both in Europe and International is key to projects working in 
such rare diseases. Such collaborations enable consensus documents to be created with 
addressing protocols for molecular diagnoses, patient assessments and outcome 
measures and most important, standards of care that can be applied to all patients 
around the world (Butcher et al. 2007). 
The level of care provided around the world varies greatly and whilst some of this is 
due to financial difficulties, some is purely due to knowledge gaps in these extremely 
rare conditions. Patient registries are a useful way of filling in these knowledge gaps 
and translating these to the health care providers. Patient registries and databases 
constitute a vital role in establishing clinical research in these rare diseases. They 
provide longitudinal natural history data and benchmarks by which to design clinical 
trials. They provide demographic data when assessing the feasibility of trials and with 
orphan drugs serve as safety monitoring in place of large phase 3 studies. They serve to 
disseminate knowledge both to patient and clinician and improve the quality and 
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outcomes of treatments in these rare conditions by standardising practice and reducing 
practice variation. 
The International FKRP registry is a global patient registry that has been set up under 
the auspice of TREAT NMD. The TREAT NMD (Translational Research in Europe-
Assessment and Treatment of Neuromuscular Diseases) initiative is a pan-European 
organisation made up of 250 researchers from 11 countries and was established in 2007 
with funding from the European Union‟s sixth framework programme (FP6). TREAT 
NMD now has 22 partner organisations including academic institutions, industry and 
patient groups (Rubinstein et al. 2010).   
 9.2 The FKRP registry 
Previous neuromuscular registries have been run on a national basis feeding into a 
larger International database, the FKRP registry however has been designed to be purely 
Global, with the server being in Munich (figure 9.1). The registry is also unique in that 
it combines both a patient and a professional part with the patient initiating the 
registration. Many registries have difficulties with curation and time taken either 
entering medical data that have been sent in by patients or by editing data entered by 
patients themselves. I designed the registry to combine both the patient and professional 
involvement as this will curtail the amount of time required curating the data as 
professionals with an interest in neuromuscular conditions will be entering the data. The 
patient, on the other hand, will act as a catalyst and continue to provide prompts to the 
clinician if the data is not entered. 
Within the patient part of the FKRP registry we have included optional questionnaires 
on quality of life and pain. The quality of life is a validated neuromuscular 
questionnaire developed by Michael Rose and his group and copyright for use of this 
was obtained. The short McGill pain questionnaire is also a well validated questionnaire 
and in this setting would only take a few minutes to complete. The mandatory questions 
refer to the patients‟ demographics, diagnosis and symptoms. These symptoms refer to 
their presenting ones as well as their current symptoms and also their current motor 
ability, past best motor ability and respiratory and cardiac status.  
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After consent for their respective doctor to enter their medical data onto the registry an 
email is generated and sent to the professional chosen by the patient from a drop down 
menu of doctors who have previously consented to this. The professional, if already 
holding an account, logs on with their password and completes their patient‟s details on 
the doctor‟s form. The doctor is able to view all his patients and their data but no other 
patients looked after by other doctors. Whilst the doctors are able to view their patient‟s 
entries on the patient form, they are discouraged from altering the data.  
 
 
 
 
 
 
If the doctor has not already created an account and is not on the drop down menu, they 
will be contacted by the registry and requested to do so in order to enter their patient‟s 
medical data. The doctor‟s form includes item such as their latest respiratory function 
tests, including FVC both sitting and lying, cardiac ECHO results, molecular result, and 
motor function including timed tests if possible. The registry is also automated so that if 
a doctor fails to fill in the relevant data sets, an email is sent to prompt them and 
Figure 9.1: This figure illustrates how the FKRP registry works; patient initiation and 
completion of part one of the registry, health professional notification and completion 
of part two of the registry. All these are directed through the central server in Munich, 
with links to other relevant registries such as the CMDIR (congenital muscular 
dystrophy international registry). There is also an oversight committee and steering 
committee for the registry to deal with any enquiries and changes to the registry. 
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likewise after one year a reminder email will be sent to the patient and professional to 
re-enter their data for the longitudinal natural history study. 
Rare disease registries are essential for industry as well. More recently there has been 
interest generated around developing drug treatments for these rare conditions and 
registries, especially global, are of vital importance for assessing the feasibility of a 
clinical trial, to facilitate the planning of the trials and most importantly to assist in the 
enrolment of suitable patients. Orphan drugs can also be monitored in this fashion by 
using the register to recognise any long-term complications and side effects.  
In 1983, the Orphan Drug Act was established, this provided incentives for the 
pharmaceutical companies to develop orphan drugs for rare diseases, due to its tax 
incentives and 7 year exclusive right to treat a rare or orphan disease. The 
pharmaceutical companies are also aware that these drugs whilst they are labour 
intensive and expensive to develop are almost indefinitely used life-long in these 
patients and therefore proving profitable long-term (FDA, Haffner et al. 2006).  As well 
as patient registries, which can be used for feasibility studies pre-clinical trials, Bio-
banks and tissue repositories linked to patient registries means that more accelerated 
research into potential drug therapies can be achieved. 
9.3 Strengths and Benefits 
It has become increasing evident that patient registries are an important resource for 
patients, professionals and industry. They are an efficient, powerful tool for evaluating 
patient change over time, response to treatment and variations in the disease course as 
well as demographics and disease pockets (Watson et al. 2008). Less than a fifth of rare 
diseases have registries, and most of these are operated by patient organisations or 
researchers (Wrobel et al. 2009). 
In rare diseases, such as LGMD2I, collaboration and coordination between major 
centres means that studies and trials performed are large enough for statistical power to 
be achieved. These registries can also be interrogated when a researcher is 
contemplating a study in order to target where the main study /trial sites would be 
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suitable. These would be centred on clusters of patients with the disease, enabling easier 
enrolment.  
Registry data and the software employed, means that alteration or addition of data sets 
is achievable, especially if a new treatment becomes available and through the registry 
we would like to monitor the response. 
As with any registry, patient and clinician awareness is vital as is retention once 
registered, however with many rare conditions patients are usually motivated to 
influence the course of their disease. There is also an added incentive to help future 
generations as in the majority, these conditions are genetic. With online registries this 
retention is easier to manage, as emails can prompt re-entry of the data, when following 
up longitudinally and can easily be built into the programme.  
In the international FKRP patient registry the patient initiates the enrolment process and 
consents online. As it is the patient that initiates the registration and fills in a small 
number of key items that would need updating to monitor disease progress, this would 
hopefully keep the patient motivated. Potentially this means that on a yearly basis 
following an automated email, they would update their data. Other enticements include 
the potential to be enrolled in a clinical trial should one become available and in time 
the ability to print off personalised graphs that highlight the change with time that the 
patient may want to show their clinician.  The patient would also act as a prompt to the 
professional to enter the data as they will be keen for the dataset to be as complete as 
possible to be meaningful. With the clinician filling in the second part this means that 
the medical data should be accurate, negating the intensive curation step required in 
patient only registries. 
Incentives for the clinician may include the ability to produce a report on their patient. 
Once the clinician has entered the data, the registry can be instructed to produce a clinic 
letter/formal report for their patient. This could either be inserted into the local 
clinician‟s standard letter or act as a standalone report.  This would therefore save the 
clinician having to produce a separate one or dictate a clinic letter after their patient‟s 
appointment. 
 177 
9.4 Limitations 
Although the technology for creating massive databases is feasible, the agreement 
between professionals on the standardised dataset required for rare diseases can be more 
problematic. The registry ideally needs to be standardised in a way that is accessible to 
all users with and without translations and leaves no room for error in the recording of 
the data. Registries are only as good as the data recorded and if this is poor quality data 
then this will prove useless in the future. In a recent rare diseases workshop in the US, 
this was the concern that if a mega database made up of 7000 rare diseases with 9 
million registrants, based on 30% enrolling,  was created then it would take “a seismic 
shift” to get individuals to commit to the effort and agree on the standardised 
terminology (Rubinstein et al. 2010). 
In the FKRP registry there have certainly been delays in launching due to technical 
difficulties and standardising the questions after feedback from various specialists, and 
whilst it has been launched in all the English speaking countries and Germany the other 
European languages remain to be launched, although the registry questions are 
translated. 
9.5 The Future and discussion 
Patient registries for rare diseases are the way forward if research is to progress and be 
meaningful. It has been said that patient registries can be identified as “an organised 
system that uses observational study methods to collect uniform data (clinical and other) 
to evaluate specified outcomes for a population defined by a particular disease, 
condition or exposure, and that serves one or more predetermined scientific, clinical, or 
policy purposes” (Gliklich et al. 2010). 
Ideally these registries would be linked centrally and be identical in format, with a 
common subset of questions for all patients, and more disease specific questions 
depending on disease/gene registry. With formatting being the same, this would make 
the ease of addition and deletion of questions easier as well as curation.  
Most importantly if these registries could be linked to the government health systems, 
such as the NHS in the UK, this would mean that patient data could be transferred and 
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stored on systems that are compatible with each other, which result in a decrease in the 
manpower time required as well as eliminate the element of human error. This would 
also mean that data entry would be possible whilst the patient is in the clinical setting 
and if the two systems were compatible and able to „talk to each other‟ then this would 
negate double entry of data, both on the registry and in the doctor‟s notes/hospital 
system.  
Worldwide, this would require harmonisation to enable communication between the 
different health care systems and exchange data in a sensitive and secure manner. This 
then would enable international collaboration which is key to understanding the natural 
history of these complex and rare diseases, developing gold standards of care, defining 
patients and trials with clinically relevant outcome measures and ultimately discovering 
a cure for these rare diseases (Bushby et al. 2009b). 
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Chapter 10 – Conclusion 
This study represents the largest cohort to date of patients with LGMD2I studied 
longitudinally with functional, physical and imaging assessments. These patients 
represent a sub-group of the wider population of patients with LGMD2I. The results 
from this study could prove useful when considering future developments in the 
treatment of patients with LGMD2I and the construction of well designed trials and 
outcome measures. Definition of powerful and specific trial end-points requires a 
detailed knowledge of the natural history of the disease and ideally the muscles that are 
being imaged and analysed should have a wide dynamic range of pathology, be easy to 
delineate and sensitive enough to pick up change over the time course of a therapeutic 
trial. 
The group as a whole had similar characteristics as described in the literature regarding 
the age of presentation with almost half recognising symptoms in childhood, the 
presenting symptoms with difficulty climbing stairs, running and myalgia being the 
commonest. The percentage demonstrating respiratory and cardiac involvement were 
also similar to the figures quoted in the literature (Poppe et al. 2004, Sveen et al. 2006, 
Walter et al. 2003). 42% of our cohort had cardiac involvement with approximately 
three quarters of them male. A third had respiratory involvement with a FVC </=75%, 
with almost half demonstrating a drop in their FVC on lying, indicating diaphragmatic 
involvement. 
The standardised physical testing and functional scales did not show any significant 
difference longitudinally, however they did correlate strongly with muscle pathology 
seen on the MRI. They also provided insight into the particular difficulties these 
patients have as well as identified compensatory mechanisms that they all appear to 
adopt independently, such as supporting the weakened pelvic girdle with their hands in 
their trouser pockets or using their relatively strong neck muscles to walk themselves up 
a wall to achieve an upright position.  
Whilst it is useful to document strength and functional abilities, they only give a snap 
shot of that particular patient‟s daily level of functioning. Many patients will perform 
well in that hour of assessment as they have rested pre assessment and will be fatigued 
 180 
for days afterwards. The physical and functional tests are subjective and a number of 
factors contribute to the success or failure at assessment. These include fatigue, pain, 
illness, contractures and respiratory impairments and can all contribute to a patient‟s 
level of activity (Johnson et al 1992, Tiffreau et al 2006, McDonald et al. 1995, Feasson 
et al. 2006). Personal factors such as, emotion, motivation, cognition as well as 
environmental factors also play a role in a patient‟s level of functioning. In our patients 
this was most evident on the first round of testing when the floor surface appeared to be 
shiny and hence potentially slippery, they were therefore wary about walking too fast in 
the 10 metre test.  
Clinical trials require robust rating scales that measure the health constructs that they 
claim to (i.e. the scales are valid) and they require that the health constructs are 
clinically meaningful and can be interpreted. (Hobart et al. 2007). Rasch methods have 
the advantage over classical rating scales. This Rasch analysis was applied to the NCL 
cohort who completed a total of 48 adapted NSAA over the 12 months. Rasch can 
measure stability (Andrich 1988), testing convergent and discriminant construct 
validity, which is deemed the strongest statistical evidence of scale validity (Campbell 
and Fiske, 1959). 
The cross sectional quantitative analysis of the fat fraction using the 3 point Dixon 
technique has shown that quantitative fat imaging provides an objective measurement of 
the fat fraction that is more sensitive than the previous qualitative technique. We have 
found a similar pattern of muscle involvement as previously described in the literature 
but have also demonstrated gender differences not previously reported. These 
quantitative techniques could be used on an individual patient basis to monitor both 
disease progression and in the future, improvement in the advent of a therapeutic agent. 
The longitudinal quantitative analysis of the fat fraction changed significantly over the 
12 month period with significant increases in fat fraction seen in 9 out of the 14 muscles 
analysed. The qualitative grading did not change significantly longitudinally and this 
possibly represents the broadness of the grades. As a result of this analysis I was able to 
identify possible muscles that would be candidates for longitudinal studies in this 
cohort. These included the medial gastrocnemius muscle in the calf, the gracilis muscle, 
the rectus femoris muscle and the vastus lateralis muscle in the thigh. These muscles 
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were identified as they showed a significantly increase in pathology over time, were 
easy to delineate on the 3 point Dixon image and generally had good longitudinal ROI 
placement and did not have extensive pathology within the muscle.  
The skeletal MRS results demonstrated metabolic abnormalities at rest, while 
demonstrating no impairment in maximal mitochondrial function. This cohort of 
LGMD2I patients did have similar, albeit more modest, changes to those seen in DMD 
and BMD. There was also an increased concentration of resting inorganic phosphate 
and raised PDE levels at rest, which suggest a loss of membrane integrity and hence 
membrane breakdown, similar to those seen in BMD and DMD.  
The cardiac MR results from the small cohort of LGMD2I patients gives an insight into 
the pathogenesis of cardiac dysfunction, with early reduction in myocardial energetics 
which worsens with age, and early reductions in cardiac torsion and ejection fraction. 
Despite the small numbers, there is the suggestion that the cardiac mass increases in the 
early disease course before decreasing. These results demonstrate, for the first time, the 
power of cardiac spectroscopy and cardiac tagging to distinguish changes in cardiac 
performance in LGMD2I patients. 
In coordinating the setup of the international FKRP patient registry and the 
development of the mandatory and highly desirable questions, I was aware that 
longitudinal capture of data and preparation for clinical trials was important.  Since the 
launch earlier this year the registry has had 87 patients register from 14 countries. It is 
now increasingly evident that patient registries are an important resource for patients, 
professionals and industry. They are an efficient, powerful tool for evaluating patient 
change over time, response to treatment and variations in the disease course as well as 
demographics and disease pockets (Watson et al. 2008). 
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Limitations 
This study, whilst being the largest cohort of patients with LGMD2I involved in 
longitudinal imaging, is still small and the time period between the scans was only 12 
months. As LGMD2I is a slowly progressive disorder, unlike DMD, pathological 
changes may therefore become more obvious over a longer time period. It would 
therefore be interesting to follow these patients up over a five year period and re-image 
them as well as perform the standardised physical assessment and functional 
assessments, including the adapted NSAA. 
The quantitative MRI was only analysed at one level, mid thigh and mid calf. As I have 
identified possible candidate muscles, future work should be directed at analysing these 
particular muscles at all levels to establish the proximal and distal distribution of muscle 
pathology. 
The cardiac results, whilst providing a possible pathogenesis of cardiac dysfunction, 
was only carried out on the NCL cohort (n=10) and therefore should ideally be 
expanded to include the total cohort of 38 patients.  
The FKRP international registry was delayed in launching due to technical difficulties, 
and whilst it has been launched in all the English speaking countries and Germany the 
other European languages remain to be launched, although the registry questions are 
translated. 
Future work 
This study has provided longitudinal quantitative MRI data on a large cohort of patients 
with LGMD2I. Further work will be required to continue to define the natural history of 
this condition, which can be achieved both by interrogating the global FKRP patient 
registry as well as by the follow up of this cohort. In the future one would ideally like to 
re-image these patients at year 3 and year 5 with the standardised physical testing and 
functional assessments as well as perform the adapted NSAA across the whole cohort. It 
would be interesting to relook at this gender difference detected and monitor whether 
this does correlate with the gender differences seen in the MRI‟s, particularly in the 
anterior thigh muscles. Expanding the cohort to include paediatric patients as well as 
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those who are asymptomatic would also provide further insight into the 
pathomechanisms of the muscle pathology in LGMD2I.  
It is the patients that are mildly affected and asymptomatic that will probably benefit 
most from therapeutic interventions, rather than the severely affected patients who have 
little to no muscle left to preserve. Therefore it is vitally important to detect sensitive 
biomarkers that will highlight these changes and progression. A biomarker is an 
objectively measureable parameter that indicates the pathogenic process and potentially 
serves as a surrogate endpoint in a treatment trial. Candidates for biomarkers include 
motor functional scales, serological parameters, electrophysiological data, 
histopathological findings and imaging parameters. Takeuchi et al. (2008) states that it 
is feasible to analyse combinations of biomarkers to monitor disease progression, such 
as the functional scales and the quantitative MRI.  
Functional assessments alone, may not demonstrate a change until a threshold of fat 
fraction is reached and only then is a decrease in function observed. We have 
demonstrated in this study that pre clinical changes are seen on MRI. We ideally want 
to be intervening before this point to preserve as much of the muscle tissue as we can 
whether this is by upregulating other proteins, such as LARGE (Barresi et al. 2004, 
Kanagawa et al. 2009), stem cell therapy (Benchaouir et al. 2007, Quenneville et al 
2007, Denti et al. 2008, Goyenvalle et al. 2009) or mutation specific therapies, such as 
the antisense-oligonucleotide-induced exon skipping in DMD (van Deutekom et al. 
2007, Kinali et al. 2009). 
In conclusion, this study has therefore established that quantitative MRI is a sensitive 
biomarker longitudinally, even in a slowly progressive disorder such as LGMD2I. It has 
been possible to identify potential target muscles to analyse longitudinally in LGMD2I 
patients. The MRI findings are clinically relevant and do reflect the ability of the 
patients and the MRI fat fraction correlates well with functional and strength 
assessments. MRI is also able to pick up significant changes in patients with only mild 
disease whereas the physical testing and functional assessments did not. MRS 
demonstrated that whilst there was no mitochondrial dysfunction, resting abnormalities 
were seen suggesting loss of membrane integrity and hence membrane breakdown. The 
cardiac MRI results indicate that an there is an early reduction in myocardial energetics 
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and also reductions in cardiac torsion and ejection fraction seen early in the disease 
course in patients with LGMD2I that have not been reported before. 
Further longitudinal work is required to continue to define the natural history of this 
condition both from following this cohort longitudinally as well as interrogating the 
international FKRP patient registry. This is key in designing a powerful clinical trial 
with sensitive outcome measures and biomarkers that are clinically relevant and to 
prepare these patients for “trial readiness”. 
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REC reference number:  
Committee; Newcastle and North Tyneside REC 1 
Protocol version 4, 30/04/08 
Patient identification number for this trial; 
 
   Institute of Human Genetics 
International Centre for Life 
Central Parkway 
Newcastle upon Tyne  NE1 3BZ 
 
A study using Magnetic Resonance Imaging (MRI) and 
Magnetic Resonance Spectroscopy (MRS) to assess 
muscle damage in patients with Limb girdle muscular 
dystrophy type 2I 
 
Patient Information Sheet 
 
Why have I been chosen? 
As a known patient with Limb Girdle Muscular Dystrophy 2I, we are inviting you to 
take part in this research study. Before you accept or decline the invitation, it is 
important for you to understand why the research is being done and what it will involve. 
Please read the following information and discuss it with relatives, friends and your 
General Practitioner, if you wish. If there is anything that is not clear, or you have any 
further questions, please ask us (our contact details are at the end of this information 
sheet). Take time to decide whether you would like to take part, or not. This study will 
have no direct benefit to you, but will provide important information for possible future 
therapeutic trials. 
 
Who is taking part in the study? 
We are asking all patients from our local database who have a diagnosis of LGMD2I 
and who are ambulant to take part in the study. This is part of a larger study involving 
patients from London, Paris, Denmark and Munich. All the data will be stored and 
analysed locally. The information will be anonymised with no risk of patient 
identification. 
 
What is the purpose of the study? 
The aim of the study is to assess the damage that occurs in the muscle of patients with 
LGMD2I, this is going to be achieved in two parts; 
 Firstly, we will perform standard MRI scans to assess overall muscle damage 
and, in particular, which muscles are involved and to what extent they are damaged. 
This scan will look at the muscles in your mid thigh and mid calf area. These scans are a 
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standard MRI which looks at what muscles are involved and a technique called 3 point 
Dixon which looks at the percentage of fat within your muscles. 
 Secondly, we will look at the energy levels within your muscles and how they 
respond to exercise. This is called Magnetic Resonance Spectroscopy (MRS). MRS 
allows doctors to obtain biochemical information about the tissues of the human body in 
a non-invasive way (without the need for a biopsy), whereas MRI only gives them 
information about the structure of the body (the distribution of water and fat). 
This will involve lying in the MRI scanner and flexing and extending your ankle whilst 
we take measurements with a monitor strapped to your legs. It is not painful and the 
movement required is like depressing a clutch pedal on the car. You will be required to 
do this for 3 minutes. 
 
What is a Magnetic Resonance Imaging (MRI) scan? 
MRI is a special technique that uses powerful magnets, radio waves and computers to 
produce detailed images (or scans) of the inside of your body. MRI does not use X-rays 
and doesn‟t cause pain or discomfort. 
 
The scanning session takes approximately two hours and you will be need to lie on your 
back on a moveable table, which slides inside the cylinder shaped scanner. The scanner 
is open ended and as we are only scanning your leg, you will not be completely 
enclosed at any time. 
 
A radiographer will operate the scanner from behind a window but will be able to hear 
you and see you during the scan. You will be given a call button to hold during the scan, 
which you can press to get the radiographer‟s attention, should you need to. 
 
It can take several minutes for each image to be taken, and it is important to lie still and 
breath gently during the process. The machine is noisy and will make a loud knocking 
or buzzing sound throughout the scan. However, we will provide you with earplugs or 
headphones which will help block a lot of the sound out. 
 
When the scans are complete, the table will be removed from the scanner, whilst you 
are on the table and then you will be able to get off once safely out. There will be 
someone to help you off the table if required. 
 
What happens now? 
If you are happy to participate in the study, we will ask you to sign a consent form 
indicating your willingness to take part. We will also arrange a time for you to come for 
your scan. There will be a total of 2 scans with a twelve month interval, assessing the 
extent of the muscle damage and also assessing the individual muscles which are 
affected. The scanning session will take approximately two hours and will also include 
a clinical examination of your muscle strength prior to the scan, as well as a timed walk 
for six minutes and a breathing test.  
 
You will be able to eat and drink as usual and will not need to take any special 
precautions. 
Are there any side effects to taking part in the study? 
MRI scans are commonly performed and generally safe. However you need to be aware 
of the possible side-effects.  
 188 
Some people are slightly claustrophobic in the scanner, however with the scan of your 
leg you will not be completely enclosed. The radiowaves used in the MRI can cause 
metal and tissues to heat up, you will therefore need to inform us if you have any of the 
following; 
 
Surgical clips, 
A previous history of metal fragments in your eyes. 
Any pacemakers or heart defibrillators, 
Inner ear implant (a hearing aid), 
Medicine infusion pump (insulin pump),  
Neurostimulator, 
Aneurysm clip (a metal clip on an artery), 
Shunts (tubes) in the brain, 
Joint replacements/large metal implants, 
Stents (tubes) in the heart or arteries, 
Eye, penis or breast implants, 
An intrauterine contraceptive device or coil, 
Any allergies. 
You will also need to inform us if you have any body piercing, tattoos or transdermal 
patches, metal fragments anywhere in your body or gun/shrapnel wounds. 
 
If you are pregnant or possibly pregnant please let us know, as you will not be able to be 
included in the study. 
 
You may find that teeth fillings may tingle during the scan but are safe. 
 
Please note that there will someone to help you onto and off the table if needed. 
 
Confidentiality 
 
All data collected will be anonymised – you will not be able to be identified from 
the information we collect. The results of the study will be published, but again, 
you will not be able to be identified from this information. 
 
Do I have to agree to take part in the study? 
You do not have to agree to take part in this study. If you do not wish to take part, your 
future care will not be affected in any way. You may also wish to change your mind and 
withdraw from the study at any time. Again this will not affect your care in any way. If 
you choose to withdraw from the study, we will not use any of the data already 
collected on you. 
If you have any further questions or concerns, please do not hesitate to telephone 
Professor Volker Straub on 0191 2418762, or you can write to him: 
Professor Volker Straub, 
Institute of Human Genetics 
International Centre for Life 
Newcastle upon Tyne 
NE1 3BZ. 
Thank you for reading this information sheet. 
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REC reference number: 
Committee; Newcastle and North Tyneside REC 2 
Protocol version 3, 04/06/09 
Patient identification number for this trial; 
 
 
   Institute of Human Genetics 
International Centre for Life 
Central Parkway 
Newcastle upon Tyne  NE1 3BZ 
 
Consent form - patients 
 
Title of Study: Assessment of muscle damage in patients with Limb girdle muscular dystrophy 2I using MRI and 
MRS  
 
Name of researchers:  Professor Volker Straub, 
   Institute of Human Genetics 
   International Centre for Life, 
   Newcastle upon Tyne NE1 3BZ. 
Please initial box if in agreement. 
 
1. I confirm that I have read the information sheet dated ……………..(version 5)for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that participation in this study is voluntary and that I am able to withdraw at any time, without 
the need to give reasons for withdrawal. This will not affect my future clinical care. 
 
3. I understand that my research medical notes may be reviewed by responsible individuals from the research 
team or from regulatory authorities where it is relevant to taking part in this research. I give permission for 
these individuals to have access to my records.   
 
4. I understand that the coded MRI images and MRS data obtained are stored indefinitely as DVDs or CD-
ROMs by Professor Straub. 
 
5. I agree for the MRI images and MRS data obtained to be stored indefinitely. 
 
6. I agree for any photographs to be stored indefinitely.       
 
7. I understand that there is a small possibility that the MRI research may produce unexpected results that are 
clinically important for me. In this event, I will be contacted via the research team in Newcastle and 
appropriate follow-up arranged. 
 
8. (Optional – follow up physiotherapy assessment within one month of 1st/2nd scan date)  
9. I agree to take part in this study. 
 
______________                                    __________   _________ 
Name of patient    Date    Signature 
 
_____________________  __________   _________ 
Name of person taking consent.  Date    Signature 
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Limb Girdle Muscular Dystrophy 2I Study 
 
Draft Manual of Operations 
Clinical Evaluation 
 
Dr Michelle Eagle  
Consultant Physiotherapist 
Dr Anna Mayhew 
Research Physiotherapist 
 
Newcastle Muscle Centre 
UK 
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INTRODUCTION 
 
Clinical evaluation will include myometry, functional assessment (which includes timed 
up and go, timed 10 metre walk and rise from the floor and stairs), 6 minute walk test 
and activity monitoring.  
 
General Testing Guidelines 
 Tests should be performed at approximately the same time of day and after similar 
pre-test activities and routines. 
 Tests should be performed in the order provided in this manual. 
 If any test must be repeated, a 30-second rest period is allowed. 
 To avoid bias, the clinical evaluator (CE) should not review any previous testing 
results. 
 The testing environment should be standardized.  It is recommended that family 
members or friends not be present in the room during testing, unless test compliance 
is affected by the absence of the parent/caregiver.  A second CE or staff member 
may be in the room during testing. 
 The subject should wear loose clothing.  It is preferable for the subject to wear a 
short-sleeved shirt and shorts. 
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Equipment Required 
Myometry 
 
Hand held myometer: CITEC   
A weight of ~5 lbs or 2.5 kg for calibration testing 
Range of Movement  
 
Examination table with a firm testing surface that is accessible 
to the CE from both sides 
Functional and 
timed tests  
 
Digital stopwatch 
A quiet hallway with at least 12 meters of straight, 
uninterrupted walking space, with a starting line and finish 
line exactly 10 meters (32 feet and 9 and 10/16th inches) apart 
A sturdy chair for use in the Gowers maneuver, if required.  
The same chair must be used for all evaluations. 
Floor mat.  It is recommended that the floor be used, but if a 
floor mat is required to obtain the cooperation of the subject, 
then the same floor mat should be used throughout the study. 
A box step of approximately15 cms height 
Six Minute Walk 
Test 
 
Small orange cones (12 inch or 20 cm): 2 
 Two 25 metre tape measures 
Stop watch: 2 
Soft cloth surgical tape:  
Marking pens:  
Wide 3M vinyl tape:  
Clip board:  
A chair or wheelchair that can be easily moved along the 
walking course 
6MWT worksheet with checklist. 
Step Activity 
Monitoring 
To be provided by Orthocare or company providing activity 
monitors 
 
Recommended Sequence of study procedures 
 
Study procedures should be performed in the same order and at approximately the same 
time of day for each subject.  All procedures should be conducted by a trained 
physiotherapist.  
Order of evaluations 
1. Myometry 
2. Ankle Range of Movement 
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3. Functional and Timed Tests 
4. 6 minute walk test 
5. Step activity monitoring calibration and placement (when required, according to 
protocol).  
 
 
1; Myometry 
 
1.1; Testing Guidelines 
 
 Tests should be performed in the order listed on the myometry worksheet. 
 The myometer is a very sensitive measuring tool therefore care must be taken to be 
consistent with test method. 
 Allow at least 5 seconds of rest between trials. 
 Repeat the test if the subject moves out of the testing position during a trial.   
 The subject should be vigorously coached to push or pull in the desired direction 
while the myometer is held stable by the CE (“make” test).   
 If the CE encounters problems during a trial, the trial must be repeated.  Three 
“valid” trials will be performed, and the value from the myometer will be recorded 
after each trial.  The unit of measurement should be the pound, and values should 
be recorded with 1 decimal place (eg, 1.0 lbs). 
 Calibration dependent on myometer The test is explained to the patient in a way 
that they understand. The intent is to build a maximum isometric hold, so the 
command is effectively „HOLD‟ or „Keep still/don‟t let me move you‟. The 
words push or pull should not be used. 
 The patient will be encouraged verbally to build to and maintain a maximum hold 
over a period of approximately 5 seconds, to allow for full physiological 
recruitment of muscle. 
 Following one „trial‟ test to allow for learning, the best of 3 tests shall be noted. 
Test results should be fairly closely grouped – a 10% variation is not unusual, e.g.  
30N +/- 3 
 Any discomfort will limit the patient‟s ability to offer maximum resistance. As 
much as is possible, ensure comfort when applying the myometer. The applicator 
can be padded to allow for comfort. 
 If the evaluator does not feel that they have been able to gain compliance from the 
patient for any reason (e.g. understanding or poor concentration), this should be 
noted. 
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1.2; Order of Tests 
 
A „make‟ test will be used unilaterally (dominant side) for the following muscle groups: 
 
1. Hip flexors 
2. Hip abductors 
3. Hip adductors 
4. Knee extensors 
5. Knee flexors 
6. Ankle dorsiflexion 
Hip Flexors 
Patient position Supine with hip and knee at 90º. Femur in neutral rotation. 
Patient is asked to concentrate on keeping knee steady, not to 
move foot, as this discourages hamstring involvement 
Stabilisation Under knee and calf to support weight of leg and prevent 
unwanted hip movement 
 
Myometer Position Anterior aspect of lower thigh, just proximal to condyles 
 
 
Therapist Position At side of, or kneeling on, plinth.  Facing the patient 
 
Figure 2a: Hip 
Flexors - Option 1 
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Figure 2b: Hip 
Flexors - Option 2 
 
 
 
 
 
 
 
 
Hip Abductors 
Patient position Supine, arms by side, leg straight, knee caps pointing towards 
the ceiling. Patient is asked to concentrate on keeping knee 
steady, not to move foot.  
Stabilisation Around heel if necessary 
Myometer Position  
10 cm above lateral maleolus of ankle 
 
Therapist Position Either at end of plinth or standing at edge of plinth on side 
which is to be tested 
Figure  
 
 
 
 
Not available 
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Hip Adductors 
Patient position Supine, arms by side, leg straight, knee caps pointing towards 
the ceiling. Patient is asked to concentrate on keeping knee 
steady, not to move foot.  
Stabilisation Around heel if necessary 
Myometer Position 10 cm above medial maleolus of ankle 
Therapist Position Either at end of plinth or standing at edge of plinth on side 
which is to be tested 
Figure  Not available 
 
 Knee Extensors  
Patient position Patient sitting with thigh supported and hip and knee at 90º, on 
plinth, chair or in wheelchair. Feet must be clear of the floor. 
Femur in neutral rotation. Patient can hold onto front of plinth or 
chair to stabilise himself 
Stabilisation If needed, given by therapist over lower third of thigh, just above 
knee 
Myometer Position Anterior surface of tibia, at junction between middle and lower 
third of tibia 
Therapist Position Sitting in front of patient, on a chair or on floor 
Figure 1: Knee 
extensors 
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Knee Flexors 
Patient position Patient sitting with thigh supported and hip and knee at 90º, on 
plinth, chair or in wheelchair. Feet must be clear of the floor. 
Femur in neutral rotation. Patient can hold onto front of plinth 
or chair to stabilise himself 
Stabilisation If needed, given by therapist over lower third of thigh, just 
above knee Watch for: hip external rotation, trunk flexion 
Myometer Position  
 
Therapist Position Sitting in front of patient, on a chair or on floor 
Figure  Not available 
 
 
Ankle Dorsiflexors 
Patient position Patient sitting with thigh supported and hip and knee at 90º, on 
plinth, chair or in wheelchair. Feet must be clear of the floor. 
Femur in neutral rotation. Patient can hold onto front of plinth 
or chair to stabilise himself 
Supine? 
Stabilisation If needed, given by therapist over lower third of thigh, just 
above knee Watch for: hip external rotation, trunk flexion, 
ankle eversion and inversion 
Myometer Position  
Anterior surface of foot, just in front of the ankle joint 
 
Therapist Position Sitting in front of the patient, on a chair or on floor 
Figure  Not available 
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Ankle Dorsiflexion Range of Movement 
 
1.3; Testing Procedure 
 
Patient position: Supine. As we are interested in the effects of gastrocnemius 
shortening on ankle dorsiflexion, this test is undertaken with the knee in full extension. 
The calcaneum is held in neutral alignment whilst pressure is applied over the mid-
section of the foot to dorsiflex the ankle as much as possible, preventing inversion. 
 
Goniometer position: Axis of the goniometer over the lateral malleolus. Stationary arm 
aligned with the fibular head, along the lateral aspect of the lower leg. “Moving arm” 
held parallel to the lateral aspect of the 5
th
 metatarsal, aligned with the posterior third of 
the foot (this is to ensure that gastrocnemius range is being monitored and not that of 
the planter structures of the foot). Note range of dorsiflexion past plantergrade as +xº‟s, 
range lacking from plantergrade as -xº‟s 
 
 
Normal range: 20º dorsiflexion to 50º planterflexion. 
 
End feel: firm due to joint capsule, Achilles tendon and ligaments 
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1; Functional and Timed Tests 
 
1.1; Order of Tests 
 Timed up and go 
 10 metre walk / run 
 Stair Ascend 
 Stair Descend 
 Timed rise from the chair 
 
Testing procedure 
 
Timed up and go „TUG‟ test 
 
Preparation Place a piece of tape or other marker on the floor 3 meters away from 
the chair so that it is easily seen by the subject. The chair should be 
stable and positioned such that it will not move when the subject 
moves from sitting to standing. 
 
The subject wears their regular footwear, may use any gait aid that 
they normally use during ambulation, but may not be assisted by 
another person. There is no time limit. They may stop and rest (but 
not sit down) if they need to.  
 
Normal healthy elderly usually complete the task in ten seconds or 
less. Very frail or weak elderly with poor mobility may take 2 minutes 
or more. 
 
The subject should be given a practice trial that is not timed before 
testing 
Starting 
position 
Subject sitting in a chair with arms. The subject‟s back should resting 
on the back of the chair.  
 
Instructions On the word “GO” you will stand up, walk to the line on the floor, 
turn around and walk back to the chair and sit down. Walk at your 
regular pace 
Timing Start timing on the word “GO” and stop timing when the subject is 
seated again correctly in the chair with their back resting on the back 
of the chair. 
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10 metre walk/run 
 
Preparation Orthoses should not be worn for this assessment. However if the 
person regularly uses them the test could be repeated with orthoses for 
comparison 
 
Mark out 10m distance in quiet area if possible 
 
Starting 
position 
Standing at start of marked distance 
 
Instructions On the word “GO” go as fast as you can to “x”. Define point x. 
 
Timing Start timing on the word go and stop when the first foot passes the 10 
metre mark. 
 
Grading 1 Unable to walk even with aids 
2 Able to walk with a walking aid (sticks, Frames) 
3 Walk but cannot pick up speed 
4 Walking but able to pick up speed 
5 Picking up speed, nearly running but still using double stance phase 
6 Running - no double stance phase, no excessive trunk and upper 
limb movement 
 
 
Stair Climb 
 
Preparation Use standard steps four steps with handrail where possible 
 
Starting 
position 
Standing upright at bottom of steps. Arms by side 
 
Instructions When I say “GO” climb the stairs as quickly as you can, safely and 
stand up straight with your arms by your side when you get to the top 
Timing  
Start the watch on the word go and stop it when they are standing 
straight with their arms by their side. 
 
Grading 1.   Unable to climb 4 standard stairs 
2. Climbs 4 standard stairs “marking time” (climbs one foot at a 
time, with both feet on a step before moving to next step), uses 
both arms on one or both handrails 
3. Climbs 4 standard stairs “marking time” (climbs one foot at a 
time, with both feet on a step before moving to next step), 
using one arm on one handrail  
4. climbs 4 standard stairs “marking time” (climbs one foot at a 
time, with both feet on a step before moving to next step), not 
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needing handrail 
5. Climbs 4 standard stairs alternating feet, needs handrail for 
support  
6. Climbs 4 standard stairs alternating feet, not needing handrail 
support 
 
 
 
Stair Descend 
Preparation As stair ascend 
Starting 
position 
Standing at the top of the stairs with arms by side 
Instructions When I say “GO” go as fast as you can down the stairs safely and at 
the bottom stand up straight with your arms by your side 
Timing Start the watch on the word go and stop it when they are standing 
straight with their arms by their side. 
Grading 1. 1.Unable to descend 4 standard stairs 
2. Descends 4 standard stairs “marking time” (descends one foot 
at a time, with both feet on a step before moving to next step), 
requires both arms on one or both handrails. 
3. Descends 4 standard stairs “marking time” (descends one foot 
at a time, with both feet on a step before moving to next step), 
requires one arm on a handrail 
 
4. Descends 4 standard stairs “marking time” (descends one foot 
at a time, with both feet on a step before moving to next step), 
not needing handrail 
 
5. Descends 4 standard stairs alternating feet in both directions, 
needs handrail for support 
 
6. Descends 4 standard stairs alternating feet, not needing 
handrail support. 
 
 
 
Timed rise from a chair 
Preparation Chair 
 
Starting 
position 
Hips and knees at 90 degrees with arms folded 
Instructions When I say “GO” stand up as fast as you can, stand up straight with 
your arms by your side 
 
Timing Start the watch on the word “GO” and stop it when they are standing 
up straight with their arms by their side 
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Grading 1.  Unable to stand up even with the use of furniture 
2.  Can stand up using additional furniture or turms to face chair 
3.  Uses two arms to stand up on leg or on chair 
4.  Uses one arm to stand up on leg or on chair 
5.  Adapt starting position to a wide base and use more flexion to rise 
from chair 
6.  Gets up normally without using arms 
 
 
6-MINUTE WALK TEST 
This evaluation is a modified version of the 6MWT adapted from the protocol 
specifically designed for DMD in the PTC 124 2b trial [ATS, 2002, Ref Henriksen, Mc 
Donald). 
Testing Guidelines 
 Subjects should wear comfortable clothing and appropriate shoes for walking (ie, 
trainers, tennis shoes, etc).  Since subjects will be tested at multiple time points, they 
should make an effort to wear the same type of shoes each time. 
 A light meal or snack is permissible at least 1 hour before testing.   
Set up of course 
 The test should be performed indoors, along a flat, straight, enclosed, and seldom 
traveled corridor at least 6 feet wide with a hard surface.  The test area will be 
marked with a 25-meter tape line.  The tape line should be placed in the middle of 
the corridor.  Arrows indicating the counterclockwise direction and path of 
movement should be placed in a half-circle at the ends of the course. Note that due 
to the possibility of subject falls, the course should be within easy access of 
appropriate medical assistance. 
Testing Directions 
 Set the stopwatch to zero. 
 Ask the subject to stand quietly with his toes at the starting line, immediately 
adjacent to axis of the “home” cone.   
 “Remember, you will be walking back and forth around these cones 
without crossing the line in the middle.  You will walk around the cone in 
a half circle without slowing down.  Then you will go back the other way.  
START
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Remember that the object of this test is to walk as fast and as far as you can for 
six minutes without running.” 
 The clinical evaluator should follow the subject whilst he is walking around the 
course. 
 When the subject is ready, say “Ready, set, go!”, and start the stopwatch. 
 Every time the subject reaches the each end of the course, mark the worksheet to 
record the time at each 25 metres completed. 
 Give positive verbal encouragement at approximately 15-second intervals.  
Encouragement should be similar to any of the following phrases: 
 “You‟re doing great (subject name)!  Keep it up!” 
 “Remember, walk as fast as you can!” 
 “Fantastic job (subject name)!  Keep Going!” 
 “Keep up the good work!” 
 let the subject know how long he has been walking. For example “three minutes 
done, only three to go, you are half way there, one minute left” 
 If the subject stops to rest, say: 
 “You can lean on the wall to rest.  Just start walking again as soon as you feel 
like you can.” 
 If the subject falls:  
 Record the time of fall 
o The evaluator should ensure that the subject is OK, and then should assist him 
back to a standing position as soon as it is safe to do so. 
o If the subject is injured or cannot rise from the floor, the test is over.  Total time 
and distance should be recorded, and any necessary medical attention should be 
given to the subject. 
o If the subject is uninjured, he should resume walking as soon as he is able.  Say:  
“If you are alright, you should start walking again as soon as you feel like 
you can.” 
 At the final seconds of the test count down, the timer will announce: 
 “Five fifty seven, five fifty-eight, five fifty-nine, six minutes!  Great job, you 
can stop now.” 
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 Bring a chair or wheelchair for him to sit and rest. Offer the subject a drink of water. 
 Measure the distance from the marker to the point at which the subject stopped at 6 
minutes. Multiply by 25 the number of completed 25 metre laps and add to the 
distance reached on the final lap. This is recorded as the total distance walked in 6 
minutes.  
 Document the number of falls during the 6 minute walk test 
Safety Considerations and Additional Information 
 Subjects should have medical clearance from the study investigator prior to testing. 
 Testing staff should know the location of the nearest resuscitation cart and 
institutional emergency care procedures.  Emergency contact numbers should be 
immediately accessible. 
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                                                       Adapted North Star Scale for LGMD 2I  (NSAA for LGMD 2I)                                            
09/06/09 
Name                                                                                                                    DOB 
Date of assessment                                                                                            Assessor 
Time test took to complete 
 
Test  Instruction 2 1 0 Comments 
1 Stand 
unsupported 
Can you stand 
without 
holding onto 
anything for 
the count of 3? 
Stands upright and 
symmetrically, 
without 
compensation (with 
heels flat and legs in 
neutral) for minimum 
count of 3 
Stands but with 
some degree of 
compensation  
 
Cannot stand  
independently, 
needs support  
 
2 Walk 10 m 
 
Can you walk 
as far as 
…..(give 10 m 
marker) 
Able to complete the 
distance with no 
aids 
Able to complete 
the distance with 
aids 
Specify aids 
Unable to walk 
10 m  
Aids = 
………… 
 
3 Stand up 
from chair 
Stand up from 
the chair 
keeping your 
arms folded if 
you can 
Able to stand up not 
using arms 
With help from 
thighs or push on 
chair or prone turn 
Unable  
 
4 Stand on 
one leg - 
Right 
Can you stand 
on your right 
leg for as long 
as you can? 
Able to stand in a 
relaxed manner (no 
fixation) for count of 
3 
Stands but either 
momentarily or 
needs a lot of 
fixation e.g. by 
knees tightly 
adducted or other 
trick 
Unable  
5 Stand on 
one leg - Left 
Can you stand 
on your left leg 
for as long as 
you can? 
Able to stand in a 
relaxed manner (no 
fixation) for count of 
3 
Stands but either 
momentarily or 
needs a lot of 
fixation e.g. by 
knees tightly 
adducted or other 
trick 
Unable  
6 Climb box 
steps – Right  
Can you step 
onto the top of 
the box using 
your right leg 
first? 
Faces forwards, 
climbs up– no 
support needed 
Goes up sideways 
or needs support 
Unable  
7 Climb box 
steps – Left  
Can you step 
onto the top of 
the box using 
your left leg 
first? 
Faces forwards, 
climbs up– no 
support needed 
Goes up sideways 
or needs support 
Unable  
8 Descends 
box step - 
Right 
Can you step 
down from the 
box using your 
right leg first? 
Faces forward, 
climbs down 
controlling weight 
bearing leg. No 
support needed 
Goes down 
sideways or skips 
down or needs 
support 
Unable  
9 Descends 
box step - 
Left 
Can you step 
down from the 
box using your 
left leg first? 
Faces forward, 
climbs down 
controlling weight 
bearing leg. No 
support needed 
Goes down 
sideways or skips 
down or needs 
support 
Unable  
10 Lying to 
sitting 
Can you get 
from lying to 
sitting? 
Able - may use one 
hand to push 
Self assistance 
e.g. pulls on legs 
or turns into prone 
/ towards floor 
Unable  
12 Lifts head 
from supine 
Lift your head 
to look at your 
toes keeping 
your arms 
folded 
In supine, head 
must be lifted in mid-
line. Chin reaches 
chest 
Head must be lifted 
in mid-line. Chin 
moves towards 
chest 
Head is lifted but 
through side 
flexion or with no 
neck flexion 
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13 
Standing 
on heels 
 
Can you stand on 
your heels? 
 
Both feet at the same 
time, clearly standing 
on heels only for 
count of 3 
 
 
Flexes hip and 
only raises 
forefoot 
 
Unable  
 
 
14 Jumps How high can you 
jump? 
Both feet at the same 
time, clear the 
ground 
simultaneously 
 
One foot after 
the other (skip) 
Unable  
15 Hops –
Right leg 
 
 
16 Hops – 
Left leg 
Can you hop on your 
right leg? 
 
 
Can you hop on your 
left leg? 
 
 
Clears forefoot and 
heel off floor. 
 
 
Clears forefoot and 
heel off the floor. 
Able to bend 
knee and raise 
heel, no floor 
clearance. 
 
Able to bend 
knee and raise 
heel, no floor 
clearance 
Unable 
 
 
 
Unable 
 
 
 
 
 
 
17 Runs 
10m 
 
 
 
 
S1 Squat 
 
 
 
 
 
 
Score 
 
 
 
18 Step 
ups  
TT 
Go as fast as you can 
to……….(give point) 
 
 
 
Can you squat? 
Pretend you are going 
to sit in a very low 
seat. 
 
 
 
 
 
 
 
How many step ups 
can you do in 30 
seconds from when I 
say “go” to when I say 
“stop” 
 
Can run – both feet 
off the ground – no 
double stance phase 
during running 
 
Squats with arms 
free (at least 90 
degrees of hip and 
knee flexion) 
 
 
 
No. of 1’s =  
 
 
 
Number = ……….. 
Speeds up 
walk but 
maintains 
double stance 
phase 
 
 
Initiates squat 
(more than 10 
degrees), uses 
arm support. 
 
 
 
 
No. of 2’s 
Walks with no 
extra speed. 
 
 
 
Unable/ 
Unable to 
initiate 
 
 
 
 
 
 
 
 
 
One step up 
= floor to both 
feet on step 
to both feet 
back down  
Time 
…………secs 
 
 
 
 
 
Total =  
   /34 
Comments 
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Institute of Human Genetics 
International Centre for Life 
Central Parkway  
Newcastle upon Tyne   
NE1 3BZ 
 
Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy 
(MRS) in patients with Limb girdle muscular dystrophy 2I: Assessment of muscle 
damage 
Respiratory Function 
Name Date ddmmyy and time of test 24 hour clock 
_ _ / _ _ / _ _                         Time _ _ . _ _ 
Date of Birth ddmmyy Examiner  
Study Number  Signature of examiner 
Contractures Yes         No   
Details of contractures  
 
Height (cm) ………………… Weight (kg) ……………………….. 
FVC Sitting  
% predicted FVC in sitting  
FVC Lying  
% predicted FVC in  lying  
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Institute of Human Genetics 
International Centre for Life 
Newcastle upon Tyne 
NE1 3BZ 
Myometry and Range of Movement Worksheet                                                                                  
                      
Name Date ddmmyy and time of test 24 hour clock 
_ _ / _ _ / _ _                         Time _ _ . _ _ 
Date of Birth ddmmyy Examiner  
Study Number  Signature of examiner 
Test dominant side.  
Dominant side             Right        Left  
 
If unable to test a muscle/muscle group, record 
“ND”.  To convert pounds to kilograms, use the 
following: 1 pound = 0.4536 kilograms  
 
Tested in supine Muscle / Muscle Group  Result (Maximum Force) 
Myometry 
 
 Kilograms 
 Newtons 
 Pounds 
 
Hip Flexors               __ __ . 
__ 
                                 __ __ . 
__ 
                                 __ __ . 
__ 
Highest    
__ __ . __  
 
Hip Abductors           __ __ . 
__ 
                                  __ __ . 
__ 
                                  __ __ . 
__ 
Highest    
__ __ . __  
 
Hip Adductors             __ __ 
. __ 
                                   __ __ 
. __ 
                                   __ __ 
. __ 
Highest    
__ __ . __  
    
  
 
Ankle dorsiflexion       __ __ 
. __ 
                                   __ __ 
. __ 
                                   __ __ 
. __ 
Highest    
__ __ . __  
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Ankle Dorsiflexion ROM 
(Range 20° + to 50° -) 
 
 
 
 
 
 
 
Right ° Left ° 
 
 
 
Tested in sitting Muscle / Muscle Group  Result (Maximum Force) 
Myometry Knee extensors          __ __ 
. __ 
                                   __ __ 
. __ 
                                   __ __ 
. __ 
Highest    
__ __ . __  
    
Knee flexors               __ __ 
. __ 
                                   __ __ 
. __ 
                                   __ __ 
. __          
Highest    
__ __ . __  
    
Comments: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 213 
 
Functional and Timed Tests                                                                                                                        
Name Date ddmmyy and time of test 24 hour clock 
_ _ / _ _ / _ _                         Time _ _ . _ _ 
Date of Birth ddmmyy Examiner  
Study Number  Signature of examiner 
 
Timed up and go Comments Time 
(seconds) 
_ _ . _ _ 
 
 
Grade 1 2 3 4 5 6 Time 
(seconds) 
10 metre 
walk / 
run 
Please 
circle 
Unable Walk with 
aids 
Walk No 
extra 
speed 
Walk 
extra 
speed 
Nearly 
running 
Double 
stance 
Running  
_ _ . _ _ 
Comments 
 
 
Stair Climb Record Height of Hand rail from floor to top of rail …………..cm 
Stair 
Climb 
Please 
circle 
Unable Marking 
time 
Using two 
hands 
Marking 
time 
Using 
one 
hand 
Marking 
time 
No 
handrail 
Alternating 
feet 
Needs 
handrail 
Alternating 
feet 
No 
handrail 
_ _ . _ _ 
Comments 
 
 
Stair 
Descend 
Please 
circle 
Unable Marking 
time 
Using two 
hands 
Marking 
time 
Using 
one 
hand 
Marking 
time 
No 
handrail 
Alternating 
feet 
Needs 
handrail 
Alternating 
feet 
No 
handrail 
_ _ . _ _ 
Comments 
 
 
Rise form Chair  Record height of chair from floor to middle of cushion or pad  ……………..cm 
Timed 
rise from 
chair 
Please 
circle 
Standard 
chair with 
no arms 
Unable Stand up 
using 
additional 
furniture 
or person 
Uses 
two 
hands to 
stand up 
Uses 
one 
hand to 
stand up 
Adapts 
standing 
position to 
stand 
Gets up 
normally 
_ _ . _ _ 
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Institute of Human Genetics 
International Centre for Life 
Central Parkway 
Newcastle upon Tyne   
Six minute Walk Test                                                                                                                         
 
Name Date ddmmyy and time of test 24 hour clock 
_ _ / _ _ / _ _                         Time _ _ . _ _ 
Date of Birth ddmmyy Examiner  
Study Number  Signature of examiner 
BP and HR before test         
      _ _ _ /_ _ _mmHg.       _ _ _ bpm 
BP and HR after test 
                 _ _ _ /_ _ _mmHg.       _ _ _ bpm 
See manual for details 
Distance Time  
minutes . 
seconds 
Distance Time Falls 
25 _ _._ _ 325 _ _._ _  Time 
50 _ _._ _ 350 _ _._ _ 1 _ _._ _ 
75 _ _._ _ 375 _ _._ _ 2 _ _._ _ 
100 _ _._ _ 400 _ _._ _ 3 _ _._ _ 
125 _ _._ _ 425 _ _._ _ Comments 
150 _ _._ _ 450 _ _._ _ 
175 _ _._ _ 475 _ _._ _ 
200 _ _._ _ 500 _ _._ _ 
225 _ _._ _ 525 _ _._ _ 
250 _ _._ _ 550 _ _._ _ 
275 _ _._ _ 575 _ _._ _ 
300 _ _._ _ 600 _ _._ _ 
Distance at six minutes 
Measure the distance from the marker to the point at which the subject stopped at 6 minutes. 
Multiply by 25 the number of completed 25 metre laps and add to the distance reached on the 
final lap. This is recorded as the total distance walked in 6 minutes 
 
 
Distance from 
marker  (a) 
 
 
    _ _ metres 
 
Number of 
completed 
laps (n) 
 
 
_ _ 
 
(25 x n) + a = Total distance 
 
25 x _ _ + _ _ = 
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Institute of Human Genetics 
International Centre for Life 
Central Parkway 
 
Activity Monitor given (number)  
 
Information sheet given Yes   
Functional sheet (NSAA for LGMD) 
IPAQ 
Yes   
Yes   
Activity Monitor returned and data 
downloaded 
Yes   
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   Institute of Human Genetics 
International Centre for Life 
Central Parkway 
Newcastle upon Tyne  
 NE1 3BZ 
Medical Information Sheet 
A study using Magnetic Resonance Imaging (MRI) and Magnetic Resonance 
Spectroscopy (MRS) in patients with Limb girdle muscular dystrophy 2I; an 
assessment of muscle damage. 
Name Date ddmmyy and time of test 24 hour clock 
_ _ / _ _ / _ _                         Time _ _ . _ _ 
Date of Birth ddmmyy Examiner  
Study Number  Signature of examiner 
 First Appointment      Yes 
Address 
 
 
Telephone: 
Mobile number: 
GP 
 
 
Telephone: 
 
Age at first symptoms ………years 
First symptoms were  
Age at diagnosis ……….years 
Best motor function 
Including participation in sports, 
ability on stairs walking distance 
etc. 
 
Family history Yes 
Family History details  
Genetic Mutation  
Highest recorded CPK  
Date of highest CPK  
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test 
Most recent CPK Level  
Date of recent CPK 
test 
 
 
Current motor function/symptoms 
Walk Distance  ………………..metres 
Able to run Yes    No   
Able to climb stairs Yes    No   
Arm involvement Yes    No   
Participates in sports Yes    No   
Details of sports   
 
Myalgia Yes    No   
 
Respiratory involvement 
Respiratory Involvement Yes    No   
Details of respiratory 
involvement 
 
 
 
Ventilated at night Yes BiPAP             Yes CPAP                    No   
Number of hours 
ventilated each night 
……………………hours 
Last FVC in sitting  
 
% predicted in sitting  
 
Last FVC in lying  
 
% predicted in lying  
Diagnosed with sleep Yes    No   
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apnoea 
Latest oximetry if known 
Amount of minutes below 
90% and lowest SaO2. 
 
 
Other Medical 
Echo results. Ejection 
fraction (%) 
 
Details of any cardiac 
involvement 
 
 
 
Any other medical 
conditions 
Renal, vision, diabetes, 
peripheral vascular disease 
etc. 
 
 
 
 
 
 
 
Medications  
 
 
 
 
 
 
Additional Comments  
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FKRP website July 2011 – http://www.fkrp-registry.org  
Information for patients 
General information 
Background and purpose 
TREAT-NMD aims to improve treatment and find cures for patients with 
neuromuscular disorders. For the treatment of LGMD2I, MDC1C and other 
conditions caused by FKRP, promising new therapeutic strategies are currently 
being developed which need to be tested in clinical trials/research studies. This 
international registry will make the recruitment of FKRP patients for trials or studies 
easier by helping to identify suitable patients for particular trials or studies and by 
enabling them to be contacted and informed quickly when there is a trial or study 
they might be interested in. More information  
Target group 
The registry is for patients affected by LGMD2I (Limb girdle muscular dystrophy 
2I), MDC1C (congenital muscular dystrophy 1C) and other conditions caused by a 
mutation in the FKRP gene. There have been two registries launched which are 
collecting data, preparing for trial readiness. These are in patients with Duchenne 
Muscular Dystrophy and Spinal Muscular Atrophy. Because this registry, as with 
the other two, is primarily designed to register patients who might be suitable for 
participation in future clinical trials of new therapies, and to help the researchers 
find the best way of caring for patients with LGMD2I/MDC1C and other FKRP-
related conditions, this registry is intended for patients currently living with the 
condition and not a record for those who have already died.  
Advantages for patients 
If you are a patient affected by LGMD2I, MDC1C or an other FKRP-related 
condition and register here, we can direct you to clinical trials and research results 
(such as new treatments) that might be of specific interest to you. In addition, by 
registering you are helping researchers obtain precise data about the prevalence of 
LGMD2I, MDC1C and other FKRP-related conditions, which could be of benefit to 
all affected patients. You are also helping achieve equal care for all patients. More 
information  
Required data 
The required data will be asked for in a two-part questionnaire.  
Part 1  
This part is to be completed by the patient or carer / guardian / parent of the patient.  
You can view all the questions in advance:  
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Questionnaire FKRP Registry  
Part 2  
This part is to be completed by the professional involved either geneticist or 
neurologist/neuromuscular specialist. The information required will be related to 
test results such as respiratory function, cardiac status, mutation analysis and 
outcome scores such as the 6 minute walk distance which would not be readily 
available to the patient.  
Registration process 
Patients can register on their own by clicking “Registration”, which leads them to 
the web application for the international FKRP patient registry, which is an online 
(internet-based) self-report registry. A self-report registry is one where patients enter 
their details themselves, which is often quicker and easier for everybody concerned, 
but you can of course talk to your own doctor or to the registry staff at any time if 
you have any questions.  
Roughly speaking, the registration process contains the following steps. After 
reading the patient information, you agree to the online consent form and enter your 
personal and contact details.Then you fill in Part 1 of the questionnaire.  
If necessary, you can save and interrupt your registration any time, for instance in 
order to consult a doctor to discuss questions. More information  
Data access 
Staff in charge of the registry might need to gain access to your medical records to 
obtain information necessary to the project (for example we will need to ask your 
geneticist/physician for a copy of your genetic report and also information on your 
respiratory and cardiac function). More information about data protection  
Data updates 
To make sure that the data in the registry are correct and up to date, it is essential 
that we update them regularly. To do this, we will send you emails once a year 
asking you to tell us about any changes in your medical condition. If there are any 
major changes in your details that might occur in the period between updates, for 
example change of address or loss of ambulation, you can easily update them 
yourself by logging into the registry and changing your data.  
Data protection 
Your data is stored on a specially secured computer in the University of Munich, 
which can be accessed only by selected people. Information that you enter online via 
the Internet is encrypted while being transferred, so that it cannot be intercepted. 
More information about data protection  
Help 
Here you will find answers to some questions that you might have when using the 
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registry.  
I had to temporarily interrupt my registration. When I wanted to continue, I 
had to type in my password. Why? 
For security reasons you are logged out automatically if you have been idle for two 
hours, i.e. not clicked on a link or button or typed in any text. After you type in your 
password as requested, in most cases you should be back on the page you were on 
before you were logged out. If not, you can click through to the desired page via the 
navigation bar on the left. If at the time you were automatically logged out you had 
made changes in a form without clicking the “Save” button, you will have to make 
these changes again.  
I have forgotten my password. What should I do? 
If you forget your password, please follow the instructions on the “Forgot 
password” page.  
I have forgotten my username. What should I do? 
You can find your username on the list of backup passwords you should have 
received by mail after registration. Please also see the page “Forgot password”.  
 
If you have any more general questions about TREAT-NMD patient registries, you 
may like to view the “Patient Registries - Questions and Answers” section of the 
main TREAT-NMD website.  
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Background and purpose 
Background and purpose 
What is the patient registry and why do we want to create one? 
Scientific advances over recent years have led to substantial changes in the 
treatment of many disorders. New therapeutic strategies are being developed and, 
for some of these treatments, plans for large studies involving patients from more 
than one country are already in place.  
Several new therapeutic strategies for neuromuscular disorders like LGMD2I target 
specific gene defects. When a clinical trial is being planned, it is very important that 
patients suitable for that trial can be found and contacted quickly. The best way to 
insure that this happens, is to make sure that patients‟ details are all collected in a 
single database or “registry” that contains all the information that researchers will 
need, including each patient‟s particular genetic defect and other key information 
about that disorder.  
The Treat-NMD network is creating this kind of global registry, which means that 
all patients who register will be contacted if their profile fits the requirements for the 
clinical trial. In addition, the registry will help researchers answer questions such as 
how common disorders like LGMD2I are internationally, and will support other 
activities to improve patient care, and establish a standard of care worldwide.  
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Advantages for patients 
Advantages for patients 
How will I benefit from registering? 
The registry is intended as a public service for the benefit of patients living with 
LGMD2I or MDC1C. You will not receive any payment or any other financial benefit 
as a result of submitting your data to the registry. The results of research facilitated by 
the registry may be patentable or may have commercial potential. However, you will 
not receive patent rights and will not receive financial benefits from future commercial 
development.  
Nevertheless, there may be other benefits from participating, including the following: 
We will inform you if (on the basis of the information that you and your doctor provide) 
you might be a suitable candidate for a certain clinical trial. We will also inform you if 
we receive any new information on your disorder which might be of interest to you - for 
example if we find better ways for caring for patients with LGMD2I or MDC1C. The 
data collected might also provide benefits for other patients with your disorder, for 
example by revealing statistics on how many people worldwide have the same 
condition, or providing information for researchers interested in the best standards of 
care for your disorder.  
I want to take part in a clinical trial. If I register, is this guaranteed? 
Although one of the main aims of this registry is to make it easier for patients to be 
recruited for trials, there is no guarantee that registering your details will ensure that you 
will be involved in a clinical trial. If you are interested in receiving details of trials that 
you may be eligible for, please tick the box at the end of the online consent form.  
However, it is important that you understand that even if the coordinators of a clinical 
trial believe that you might be eligible for that trial, based on your data about you stored 
in the registry, it is possible that at a later date it will turn out that you do not meet the 
inclusion criteria for the trial after all.  
I do not want to take part in a clinical trial. Should I still register? 
We hope that you will be interested in registering even if you do not want to take part in 
a clinical trial. Your information will still be useful to researchers who are trying to find 
out more information about patients living with LGMD2I and MDC1C, and we will still 
provide you with other information that might be relevant to your disorder. If you do 
not want to receive any information about clinical trials that you might be eligible for, 
please tick “no” at the end of the online consent form.  
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Questionnaire 
Questionnaire 
Here you can find a preview of the questions you will be asked if you sign up as patient 
with LGMD2I, MDC1C or an other condition caused by a mutation in the FKRP gene. 
When filling in the real questionnaire online, you can click on the answers and enter 
your details in text boxes.  
Part 1 (to be completed by the patient or carer / guardian / parent of the patient) 
Please answer all the questions, as this information is necessary for including you in the 
international registry. But if there is a question that you can not answer right away, just 
leave the option „not specified‟ checked and continue with the other questions. You can 
enter the missing data at a later date.  
1. What is your diagnosis according to your doctor?  
LGMD2I (Limb Girdle Muscular Dystrophy 2I)  
MDC1C (Congenital Muscular Dystrophy 1C)  
Other FKRP-related condition (please specify below)  
Other diagnosis (please specifiy below)  
Not specified  
Other diagnosis : _________________________  
2. What is your current best motor function?  
Motor function describes a person‟s ability to move his or her body. Sitting 
independently means that you can stay in the sitting position for several minutes, 
without being supported by either another position or stabilizing device (chair back, 
corset or brace).  
I am able to run  
I am currently able to climb stairs without assistance  
I am currently able to climb stairs with the use of hand rails  
I am currently able to walk without support  
I am currently able to walk with support  
I am currently not able to walk, but I am able to sit independently (without support)  
I am currently neither able to walk nor to sit independently  
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Not specified  
3. What was the best motor function you achieved?  
This question is not about the current situation, but about the time when your ability to 
move was the best. What was your best motor function ever? Please also state the age at 
which you were able to perform this motor function.  
I was able to run  
I was able to climb stairs without assistance  
I was able to climb stairs with the use of hand rails  
I was able to walk without support  
I was able to walk with support  
I was not able to walk, but I was able to sit independently (without support)  
I was neither able to walk nor to sit independently  
Not specified  
This was possible from the age of ___ years and ___ months up to the age of ___ years 
and ___ months (leave the last two fields blank if this is your current motor ability).  
4. Do you currently use a wheelchair?  
I always use a wheelchair  
I sometimes use a wheelchair, but I am able to walk  
I never use a wheelchair  
Not specified  
5. Do you have muscle aches or pains (myalgia)?  
I don‟t have muscle aches or pains  
I have muscle aches or pains at rest  
I have muscle aches or pains during exercise  
I have muscle aches or pains after exercise  
Not specified  
6. Do you regularly use a non-invasive ventilation device?  
Some patients with LGMD2I or MDC1C have trouble with their breathing. To support 
their breathing, they get a ventilation device that they either use full-time, i.e. 24 hours a 
day, or only for several hours a day or at night. “Non-invasive” means that they use this 
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device without having had an operation. Usually this means they wear a mask that can 
be removed at any time.  
I do not regularly use a non-invasive ventilation device  
I regularly use a non-invasive ventilation device for several hours a day or at night  
I regularly use a non-invasive ventilation device full-time, i.e. 24 hours a day  
Not specified  
This has been the case since the age of ___ years and ___ months.  
7. Do you regularly use invasive ventilation?  
“Invasive ventilation” means that the patient had to have an operation (an incision in the 
wind-pipe, also known as tracheotomy) to use the ventilation device. Again, this 
ventilatory support system can be used either all day or a few hours per day.  
I do not regularly use invasive ventilation  
I regularly use invasive ventilation for several hours day or at night  
I regularly use invasive ventilation full-time, i.e. 24 hours a day  
Not specified  
This has been the case since the age of ___ years and ___ months.  
8. Do you know of any family members who have similar symptoms, or a diagnosis 
of LGMD2I, MDC1C or a different condition caused by a mutation in the FKRP 
gene?  
FRKP is a a gene that when mutated (faulty) can cause LGMD2I or a more severe 
congenital muscular dystrophy (MDC1C). It is important to know if any other family 
members have similar conditions, or raised creatine kinase (muscle enzyme) levels, or 
the same diagnosis.  
Yes  
No  
Not specified  
9. Would you like to be contacted if you might be suitable for a clinical 
trial/research study?  
If you do not want us to inform you if there is a clinical trial/research study that you 
might be eligible for, please turn off the following option. But note that by leaving this 
option on, you are not placing yourself at any risk or under any obligation to take part in 
a trial or a study. This option only means you will be informed about trials/studies. In 
order to take part in any trial/study, you would be given precise details about that 
trial/study and you would have to sign a separate consent form. Also note that we will 
never give away your contact data to anybody, whether you are interested in clinical 
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trials/research studies or not. You can switch this option off or on at any time.  
Yes  
No  
Part 2 is to be completed by the professional involved either geneticist or 
neurologist/neuromuscular specialist and is available for viewing by the patient 
1. When were the first presenting symptoms?  
At the age of: ___ years ___ months  
What were the presenting symptoms?  
Weakness in upper limb  
Weakness in lower limb  
Proximal weakness  
Distal weakness  
Myalgia  
Respiratory problems  
Myoglobinuria  
HyperCKaemia  
Cramps  
Stiffness  
Other: _______________  
2. What is the result of the last pulmonary function test?  
Forced vital capacity (FVC)  
__________ litres  
__________ %  
Type  
In sittting position  
In lying position  
Not specified  
Date of the test: year-month-day  
3. What was the result of the last cardiac check (ultrasound examination)?  
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Normal  
Impaired function, no treatment  
Impaired function and started treatment  
Deterioration and medication changed  
Not specified  
Results:  
Fractional shortening (FS) ______ %  
Ejection fraction (EF) ______ %  
Further results: _________________________  
4. What medication are you currently on?  
ACE inhibitors  
Beta blockers  
Steroids  
Other medication: _________________________  
5. Has a brain MRI been performed?  
Yes, it showed normal results  
Yes, it showed structural brain abnormalities (please specify below)  
No brain MRI has been performed  
Not specified  
Structural brain abnormalities: _________________________  
6. Is your cognitive function normal?  
Yes  
No  
Not specified  
7. Has a muscle MRI been performed?  
Yes, it showed normal results  
Yes, it showed abnormal results (please specify below)  
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No, a muscle MRI has not been performed  
Not specified  
The MRI showed abnormal results in the following muscle groups:  
Biceps femoris and/or internal adductors  
Rest of the hamstring muscles involved  
Vastus medialis and/or lateralis muscles  
Other: _________________________  
8. Do you have contractures?  
Yes (please specify below)  
No  
Not specified  
Elbow  
Wrist  
Fingers  
Knee  
Ankle  
Hip  
Other joints : _________________________  
9. Are there any other medical problems?  
Yes (please specify below)  
No  
Not specified  
Vision  
Hearing  
CNS  
Vascular  
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Endocrine  
Renal  
Others: _________________________  
10. What is your current 6 minute walk distance?  
___________ metres  
This is a validated test that is easy to perform and can be accurately and reproducibly 
assessed. Standard procedures for conduct of the test and for analysis of the data in 
adults and children have been developed (ATS 2002, Geiger 2007). Space and 
equipment are minimal (stop watch, hallway and traffic cones) and physiotherapists will 
be easily able to perform this.  
11. What are your current MRC scores?  
Hip flexor ___ /5  
Hip extensor ___ /5  
Hip adductors ___ /5  
Hip abductors ___ /5  
Shoulder flexion ___ /5  
Shoulder abduction ___ /5  
Ankle dorsiflexion ___ /5  
Ankle plantar flexion ___ /5  
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Registration process 
Registration process 
Creating a user account 
In the first step of the registration process, you create your user account. This means 
that you enter your name, date of birth and gender and choose a user name and 
password. You only need to create your user account once; using the user name and 
password you create now, you can log in again later at any time in order to continue an 
incomplete registration, update your clinical details and/or contact information or 
simply view your data at any time, whether your registration is complete or not.  
Note that a parent/guardian can have one or more patients added to his/her account (e.g., 
siblings with FKRP can be added to the same parent‟s account). When creating a user 
account, the following situations are possible:  
If you are a patient aged 18 or over, then please create a user account in your own name.  
If you are a patient aged under 18, please ask your parent or guardian to create a user 
account under their name and add you as a patient to their account.  
If you are a parent or guardian of a patient aged 18 or over, then please ask the patient to 
create a user account under their own name.  
If you are a parent or guardian of a patient aged under 18, please create a user account 
under your own name and add the patient to your account.  
Whenever we have any new information for a patient, we will get in touch with the 
owner of the respective user account.  
In a later registration step we will ask not only the patient (if old enough), but also the 
account owner (if different from the patient) to sign the informed consent form, which is 
a form that asks you to confirm that you are happy to have your data stored in the 
registry and whether or not you want to be contacted if we have information e.g. about a 
clinical trial that might be relevant to you.  
 
Entering contact details 
In the next step, you as the user account owner will enter your contact details. We need 
your postal address, a telephone number and an e-mail address. You are encouraged to 
enter more than one postal/e-mail address and/or phone number; this makes it easier for 
us to contact you if you move house but forget to update your data.  
Adding patient(s) 
Now you can add patients to your user account. You can only add either yourself or a 
child of whom you are a parent or guardian. (If you know someone else in your family 
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who might benefit from being added to the registry, you might want to suggest that they 
register themselves, as you cannot register on their behalf.) If you are entering a patient 
who is not yourself, you will need to provide some further personal and contact details.  
Informed Consent 
Next, an informed consent form is automatically created for each patient. The consent 
forms are personalised, containing the name of the respective patient as well as of the 
user account owner (if different from the patient). You will be able to agree online. The 
informed consent is a PDF document, which you can download and print for your own 
documentation.  
Filling in the questionnaire 
Finally, the questionnaire appears. You can complete it directly on-screen. Where 
possible, automatic checks are performed to make sure your data entries make sense and 
do not contradict each other. For example, if you by mistake enter an impossible date of 
birth, you are alerted to this immediately. The questionnaire asks questions about each 
patient‟s genetic and clinical state. You can view the questionnaire in advance.  
Updating your details 
You can return to each registration step at any time, for instance to complete, update or 
simply view your/the patient‟s data. In this way you can also check whether we have 
received your informed consent form and/or genetic report. Once a year we send out a 
letter asking for a clinical data update but you are encouraged to inform us about major 
changes whenever they occur (including any change in your contact details) by logging 
into the registry and changing your data. We also send out a letter when a patient turns 
18, asking them whether they would like to move to their own user account.  
It is possible to withdraw your data from the FKRP registry at any time - please contact 
us if you wish this to be done.  
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Data protection 
Data protection 
Where will my data be stored? 
In the questionnaire we ask you for some personal data and some information about 
your condition. The information that you enter will be entered into an international 
registry which is supervised by TREAT-NMD. Your data will be stored securely and no 
unauthorized people will be able to gain any information about you. When planning 
clinical trials, researchers can search the registry for participants eligible for the trial, 
based on the patients‟ clinical and genetic data. Only researchers who have been 
approved by their local ethics committee and by the TREAT-NMD governing board and 
ethics are allowed access to the registry.  
In the registry, your data will only be identified by an anonymous code, not by your 
name. This means that when researchers search the registry they will not be able to find 
out your personal information (name, address, etc.), but only the information they need 
to know about your condition that will help them decide whether you might be suitable 
for the trial. If they think that you meet the criteria and might benefit from the trial, they 
will contact the person in charge of the registry. Staff working for the registry will “de-
code” the data to find out the personal details and will contact you to give you 
information about the trial or about any other issues relevant to your condition. They 
will not give your name or personal information to the researchers.  
If you are interested in the information that you receive about a particular clinical trial, 
you will be given information about how you can contact the researchers running the 
trial. If you decide to take part in the trial, you will need to review and sign a separate 
consent form. You are completely free to make your own decision about any trial we 
inform you about. If you decide not to take part in a particular trial, your data will still 
be kept in the registry and we will continue to inform you about other trials unless you 
tell us not to. Please note that if we tell you about the existence of a trial, this does not 
imply that we endorse it.  
 
Who will have access to my medical records? 
Staff in charge of the registry might need to gain access to your medical records to 
obtain information necessary to the project (for example we will need to ask your 
geneticist/physician for a copy of your genetic report and also information on your 
respiratory and cardiac function).  
How will I be identified in the registry? 
Your personal details (name, address etc.) have to be stored in the registry so that we 
can contact you if we need to inform you about possible clinical trials or anything else 
that might be relevant to your disorder.  
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This data will be stored in a secure manner and your records will be assigned a unique 
code. Your records will only be identified by this unique code. Researchers searching in 
the registry therefore cannot identify you personally from the information you have 
access to. Only the person in charge of the registry (Priv.- Doz. Dr. M. Walter M.A.) 
and persons explicitly appointed by her will be able to “de-code” the data to get access 
to your personal details.  
Will my data be kept confidential? 
Your data will be kept for an indefinite period at Munich, under the responsibility of 
Priv.- Doz. Dr. M. Walter M.A..  
Creating a registry requires the existence of a file containing a patient‟s personal and 
medical data. This file will be subject to the regulations on data protection (national 
laws related to EU directive 95/46). All information we receive from you will be treated 
confidentially. The information will be encrypted and stored on a secure server.  
Third parties wishing to have access to the data in the registry (such as researchers or 
companies planning clinical trials or conducting research on new therapies) will only 
have access to anonymous information identifiable by a code. Before they are granted 
access even to this anonymous information, they have to have permission from the 
ethics committee. Your data will not be made available to employers, government 
organisations, insurance companies or educational institutions, nor to your spouse, other 
members of your family or your doctor!  
Can I withdraw and have my data erased if I change my mind? 
Your participation in this project is completely voluntary. The data protection act grants 
you the right to access your own data and to rectify them or withdraw them completely 
at any time. Should you wish to withdraw your data from the registry you will be free to 
do so without having to provide any explanation. If you wish to withdraw, you should 
get in touch with the staff in charge of the registry.  
 
  
 237 
Information for Doctors 
Information for doctors 
The global registry for patients affected with FKRP mutations collects genetic and 
clinical data about patients either affected with a (Limb Girdle Muscular Dystrophy) 
LGMD, (Congenital Muscular Dystrophy) MDC1C or any other condition caused by a 
mutation in the FKRP gene. For research into treatments for LGMD2I, MDC1C and 
other FKRP-related conditions, it is important that the researchers have precise 
information about the genetic mutation that causes the condition. This information will 
be validated by experts. In anonymous form, the valuable medical data will be available 
to selective researchers around the world, thereby accelerating the research into 
LGMD2I and MDC1C and other conditions caused by mutations involving the FKRP 
gene.  
Additionally with the advent of clinical trials and research studies for some of the 
neuromuscular conditions, patient registries mean that patients who are eligible for 
certain clinical trials and research studies are readily identifiable. The registries contain 
accurate and updated information about the patients‟ genetic mutations and clinical 
conditions. Without a patient registry for these conditions it means that finding enough 
patients for a meaningful trial can take years to recruit and therefore delay potential 
therapies.  
In the global FKRP patient registry this information is both provided by the patient and 
the professionals involved in the patient‟s care after full consent by the patient.  
 
  
 238 
Genetics 
Useful information on reporting the mutation for the registry 
Most mutations in the FKRP gene are substitutions, the common mutation being 
c.826C>A, p.Leu276Ile, denoting a change from cytosine to adenine at position 826. 
There is however many other mutations detected in the FKRP gene however 
substitutions remain the more commonly reported abnormality.  
In recording the mutation, there are a few guidelines so that all reporting is universal 
across the registry.  
Firstly,  
Identify the method used for testing:  
Sequence analysis  
quantitative methods [MLPA (Multiplex ligation-dependent probe amplification), Real 
time PCR]  
RFLP (Restriction fragment length polymorphisms)  
Other methods  
Secondly,  
Describe the mutation (see www.hgvs.org)  
Indicate the level of description of mutation:  
c. coding sequence  
g. genomic DNA  
r. RNA  
p. protein: use the three-letter amino acid code  
To discriminate between different levels, DNA, RNA or protein, descriptions are 
unique:  
At DNA level, in capitals starting with a number referring to the first nucleotide 
affected (eg c.76A>T)  
At RNA level, in lower case starting with a number referring to the first nucleotide 
affected (eg r.76a>c)  
At protein level, in capitals, starting with a letter referring to the first amino acid (one 
letter code) affected (eg p.thr26pro)  
Two sequence variations in the same allele are listed between brackets, separated by a 
“,” , whereas in recessive conditions when there are sequence changes in different 
alleles, the characters are separated by a “+”.  
Use the correct symbols:  
“>” for substitutions  
Eg: c.826C>A (p.Leu276Ile) denotes a change cytosine to adenine at nucleotide 
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position 826.  
“_” for small deletions, duplications or insertions.  
Eg; c.918_929del, c.242_244del.  
Eg; c.1234dupC , denotes a duplication of nucleotide C at 1234  
Or c.154_158dup, p.(Val53_Arg54ins).  
Insertions/deletions(indels) are described as a deletion followed by an insertion after the 
nucleotides affected; eg. 112_117delinsTG (alternatively 112_117delAGGT-CAinsTG 
or 112_117>TG denotes the replacement of nucleotides 112 to 117 (AGGTCA) by TG  
“+” and “-“ for intronic mutations  
The current recommendations for the description of intronic mutations suggest 
identifying them relative to the coding DNA reference sequence (c.889+6T>G or 
c.1603-…) rather than relative to the intron number (IVS3+……or IVS14-.)The coding 
DNA reference sequence position used is either the first or last nucleotide of a given 
exon, as follows;  
“+” beginning of the intron: the number of the last nucleotide of the preceding exon, a 
plus sign and the position in the intron.  
“-“ end of the intron. : the number of the first nucleotide of the following exon, a minus 
sign and the position in the intron.  
At the RNA level, changes are basically the same as those described at the DNA level 
with the following modifications;  
An “r” is used to indicate that this is at the RNA level  
Nucleotides are designated by the bases (in the lower case); a (adenine), c (cytosine), g 
(guanine) and u (uracil).  
When one change affects RNA processing, yielding two or more transcripts, these are 
described between square brackets, separated by a “,” character.  
In summary  
Identify the technique use.  
Identify the exact exons tested:  
Was the entire gene directly sequenced, or screened by another technique?  
Was the entire gene sequenced, or just one exon?  
Collect all available data:  
Mutation class (substitutions, insertion/deletion, missense)  
Exon or Intron number  
Nucleotide position (DNA level)  
Amino acid position (protein level)  
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Confirm the correct mutation nomenclature using International Mutation Nomenclature.  
Determine if the mutation has already been described in the literature.  
Determine if the testing was conclusive.  
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Contact us 
Contact us 
If you have a question that we have not answered to your satisfaction on our 
information pages or if you want to give us any feedback, you can contact us directly by 
sending us an e-mail to the following address:  
uk@fkrp-registry.org  
If the question you are contacting us about concerns a particular patient, please give us 
the full name and date of birth of the patient.  
It is also possible to contact the following e-mail-addresses according to your country or 
language:  
australia@fkrp-registry.org  
belgium@fkrp-registry.org  
canada@fkrp-registry.org  
catalan@fkrp-registry.org  
croatia@fkrp-registry.org  
denmark@fkrp-registry.org  
germany@fkrp-registry.org  
italy@fkrp-registry.org  
netherlands@fkrp-registry.org  
nz@fkrp-registry.org  
spain@fkrp-registry.org  
switzerland@fkrp-registry.org  
usa@fkrp-registry.org  
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The team 
The Team 
Steering Committee 
The committee is responsible for reviewing all requests for data from the global 
database. It is composed of four neuromuscular specialists plus a representative from 
CureCMD. Read more about the steering committee.  
Operator 
The global FKRP registry is operated by the Friedrich-Baur-Institut of Munich 
University. Read more about the operator.  
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The steering committee 
The FKRP Registry Steering Committee 
About the Global FKRP Database Steering Committee 
The FKRP Global Database Steering Committee is composed of four neuromuscular 
specialists plus a representative from Cure CMD. The committee is chaired by Volker 
Straub, from TREAT-NMD.  
The committee is responsible for reviewing all requests for data from the global 
database. This is intended to be a streamlined and rapid procedure in order not to delay 
approval. Requests will be discussed with the TREAT NMD Global Oversight 
Committee.  
The members 
 
Dr. Katherine Dianne Mathews 
Katherine Dianne Mathews is Professor of Paediatrics and Neurology at the University 
of Iowa. She has served as Director of the Division of Pediatric Neurology since 2001 
(expanded to the division of Neurology, Behavior and Development in 2008). She was 
involved in the early efforts to map the gene for FSHD, and was instrumental in setting 
up FSHD genetic testing at the University of Iowa. Her research activities are focused 
on clinical aspects of muscular dystrophies, with the goal of improving outcomes. Dr. 
Mathews runs an active clinical service, and has been director of the MDA clinic for the 
past 14 years. She is on the MDA Medical Advisory Committee and the FSH Society‟s 
Scientific Advisory Board.  
katherine-mathews@uiowa.edu  
Profile Dr. Katherine Dianne Mathews  
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Dr. Anne Rutkowski 
Dr. Anne Rutkowski, MD is co-founder and Chairman of Cure CMD. Dr. Rutkowski is 
a practicing board certified emergency medicine physician in Los Angeles. Dr. 
Rutkowski‟s daughter has congenital muscular dystrophy, subtype, dystroglycanopathy. 
Dr. Rutkowski graduated from the University of California Irvine Medical School, 
elected to Alpha Omega Alpha Honor Medical Society. She attended Bryn Mawr 
College as an undergraduate, graduating Magna cum laude with Honors in Biology. 
Prior to attending medical school, Dr. Rutkowski taught for 3 years in an inner city 
elementary school in Los Angeles, as part of Teach for America. She would like to 
shrink the diagnostic odyssey, see improvements and standardization of guidelines in 
medical care for all patients with CMD and a focused approach to identifying 
therapeutic targets. As a former educator, education and improved disease awareness 
are two further areas of focus for Cure CMD.  
info@curecmd.com  
Profile Dr. Anne Rutkowski  
 
Dr. Volker Straub 
Professor Volker Straub is joint co-ordinator of TREAT-NMD, executive board 
member of the World Muscle Society and executive board member of the Institute of 
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Human Genetics at Newcastle University. Together with Hanns Lochmüller, Volker 
was responsible for setting up the German muscular dystrophy network, MD-NET, of 
which he was joint coordinator until 2008. Within the neuromuscular research group at 
Newcastle, Volker has a long-standing interest in the pathogenesis of muscular 
dystrophies, with research using zebrafish and mouse models. His current research also 
involves the application of contrast enhanced MRI.  
volker.straub@ncl.ac.uk  
Profile Dr. Volker Straub  
 
Dr. John Vissing 
John Vissing is Professor of Neurology at the University of Copenhagen, Denmark. 
John has been director of the Neuromuscular clinic and research unit since 2000. His 
main research interest is in exercise and the effect of training in muscle conditions such 
as Becker Muscular dystrophy and Limb Girdle Muscular dystrophy 2I. His other main 
interest is metabolic muscle disease such as McArdle disease and mitochondrial 
myopathies.  
vissing@rh.regionh.dk  
Profile Dr. John Vissing  
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Dr. Maggie C. Walter 
Maggie Walter is Assistant Professor of Neurology at the Ludwig-Maximilians-
University of Munich. She has trained as a neurologist at the LMU Munich, and is 
working at the Friedrich-Baur-Institute, the neuromuscular department of the LMU, in 
leading position. Furthermore, she graduated with a master degree in management of 
social and health institutions.  
Her main research interest are neuromuscular diseases, mainly muscular dystrophies, 
myofibrillar myopathies, inflammatory myopathies and clinical trials in neuromuscular 
patients. She is coordinator of the German Muscular Dystrophy Network (MD-NET), 
funded by the Federal Ministry of Education and Research (BMBF) since 2003, and 
member of TREAT-NMD, an European Network of Excellence in the 6th EU frame 
program for translational research in neuromuscular diseases. Since 1997, she is 
member of the Scientific Advisory Board of the Muscular Dystrophy Association of 
Germany (DGM), and ad hoc reviewer for several peer-reviewed journals.  
maggie.walter@lrz.uni-muenchen.de  
Profile Dr. Maggie C. Walter  
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Operator 
Operator 
This registry is operated by the Friedrich-Baur-Institut, Klinikum der Universität 
München (University of Munich hospital).  
Head of the FKRP registry 
 
Priv.-Doz. Dr. med. Maggie C. Walter M.A. 
Maggie Walter is Assistant Professor of Neurology at the Ludwig-Maximilians-
University of Munich. She is working at the Friedrich-Baur-Institute, the neuromuscular 
department of the LMU, in leading position. Her main research interests are 
neuromuscular diseases, mainly muscular dystrophies, myofibrillar myopathies, 
inflammatory myopathies and clinical trials in neuromuscular patients. She is 
coordinator of the German Muscular Dystrophy Network (MD-NET), funded by the 
Federal Ministry of Education and Research (BMBF) since 2003, and member of 
TREAT-NMD, an European Network of Excellence in the 6th EU frame program for 
translational research in neuromuscular diseases. Since 1997, she is member of the 
Scientific Advisory Board of the Muscular Dystrophy Association of Germany (DGM), 
and ad hoc reviewer for several peer-reviewed journals.  
Profile Priv.-Doz. Dr. med. Maggie C. Walter M.A.  
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Prof. Volker Straub 
Professor Volker Straub is joint co-ordinator of TREAT-NMD, executive board 
member of the World Muscle Society and executive board member of the Institute of 
Human Genetics at Newcastle University. Together with Hanns Lochmüller, Volker 
was responsible for setting up the German muscular dystrophy network, MD-NET, of 
which he was joint coordinator until 2008. Within the neuromuscular research group at 
Newcastle, Volker has a long-standing interest in the pathogenesis of muscular 
dystrophies, with research using zebrafish and mouse models. His current research also 
involves the application of contrast enhanced MRI.  
Profile Prof. Dr. med. Volker Straub  
Medical contact person 
 
Dr. Olivia Schreiber 
Olivia Schreiber is currently working as MD at the Friedrich-Baur-Institute, the 
Neuromuscular Department of the Ludwig-Maximilians-Universtity of Munich, where 
she specializes in the field of neurology and neuromuscular diseases. Her research 
interest focuses on inherited neuromuscular disorders and clinical trials in order to 
improve diagnosis, health care and therapeutic options in patients with neuromuscular 
diseases. Within the European Network TREAT-NMD and the German Network MD-
NET she is concerned with the patient registries for Duchenne Muscular Dystrophy, 
Spinal Muscular Atrophy as well as the FKRP registry.  
Profile Dr. Olivia Schreiber  
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Dr Tracey Willis 
Dr Tracey Willis is a Paediatric Neurologist with an interest in neuromuscular diseases. 
She completed her paediatric neurology training in Birmingham, UK and since then has 
worked as a paediatric neurologist in Birmingham, UK and Auckland, New Zealand. In 
2008 she became the Muscular Dystrophy Campaign (MDC) fellow at the Institute of 
Genetic Medicine in Newcastle with Professor Straub and is studying for her doctorate 
which has involved coordinating a multicentre MRI/MRS study in LGMD2I. At the 
MRC Centre for Neuromuscular Diseases in Newcastle, which is the national referral 
centre for patients with limb girdle muscular dystrophy, she is involved in the diagnosis 
and care of a broad spectrum of patients with neuromuscular diseases.  
Profile Dr Tracey Willis  
 
Curator 
 
Simone Thiele 
Simone Thiele is a member of the European Network TREAT-NMD as well as the 
German Network MD-NET and Curator of the FKRP registry. Besides, she is involved 
with the patient registries for Duchenne Muscular Dystrophy and Spinal Muscular 
Atrophy which are organised by the Friedrich-Baur-Institute in Munich. Her other focus 
lies on the coordination of clinical trials.  
Profile Simone Thiele  
IT 
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Marcel Kiel 
Marcel Kiel is the software engineer for this and the other patient registries for rare 
neuromuscular diseases which are organised by the Friedrich-Baur-Institute in Munich. 
Please contact him if you have any technical questions or interest in this software.  
Profile Marcel Kiel  
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Registration 
Registration 
Please complete this form and click on the “Continue” button to start the 
registration. 
If you have already registered and would like to update your data or add another patient, 
you don't have to fill in this form again. Just go to the login page and login with the e-
mail address and password you previously registered with. 
Personal data 
Please enter your own details here, even if you are not the patient yourself. If you are 
registering a child as a patient, you will be able to enter his or her details in a later step. 
Please note that you must be the patient‟s parent or guardian to enter a patient other than 
yourself. 
First name(s) 
Surname 
Date of birth as year-month-day, e.g. 1967-03-19 
Sex 
Male 
Female 
User account 
With your e-mail address and the password you choose here, you can login at any time 
to view or edit your data. In order to protect your personal data against unauthorised 
access, please choose a password which is hard to guess and write it down in a safe 
place. Note that the password is case-sensitive. Your password must be at least 6 
characters long. 
E-mail address e.g. joe_bloggs@example.com 
Password 
Repeat Password 
Continue    Cancel 
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Login 
Login 
Please enter your e-mail address and the password you chose when you registered. If 
you haven't got a user account yet, you can create one on the registration page. 
If you have forgotten your password, please see the page Forgot password. 
Email address 
Password 
Continue 
 
 
Forgot password 
Forgot password 
If you have forgotten your password, please enter the e-mail address with which you 
registered. You will then receive an e-mail containing a link with which you can reset 
your password. 
Email address 
Continue 
 
 
 
 
 
 
Legal notice 
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Legal notice 
Operator 
The global FKRP Registry, accessible on the web at www.fkrp-registry.org, is operated 
by the Friedrich-Baur-Institut, Klinikum der Universität München.  
Friedrich-Baur-Institut  
Klinikum der Universität München  
Ziemssenstr. 1a  
80336 München  
Germany  
Tel. +49 (0) 89 5160-7400  
Fax +49 (0) 89 5160-7402  
E-Mail: info@fkrp-registry.org  
Credits 
Patient registry software architecture and programming by Marcel Kiel  
Webdesign, application design and illustrations by Ricarda Kiel / Butter&Fische 
Webdesign  
Icons by Mark James / famfamfam  
Disclaimer 
All the information and advice on the global FKRP Registry website has been 
assembled to the best of our knowledge. However, in any individual case consultation 
with the attending doctor or other qualified health professional is strongly 
recommended. The registry website contents are for informational purposes only and 
not intended to be a substitute for independent professional medical advice, diagnosis or 
treatment. All users of the registry website are responsible for their own medical care, 
treatment and oversight.  
Although the greatest possible care has been taken in compiling the registry website, we 
cannot guarantee that all the information provided on these pages is accurate. Friedrich-
Baur-Institut assumes no liability for the accuracy of the registry website contents and 
will not be held responsible for any loss, damage or inconvenience caused as a result of 
any inaccuracy or error within these pages.  
Friedrich-Baur-Institut also assumes no liability for the contents and their accuracy on 
any third party websites that are accessible through links via the international FKRP 
Registry website. These links are provided purely for your convenience, and do not 
imply that Friedrich-Baur-Institut supports the information given on those pages.  
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